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11Introduction and aim of the thesis
The central theme of this thesis is the concept that it is possible to improve the 
nutritional state of patients with chronic renal failure undergoing peritoneal 
dialysis by adding nutrients to the dialysis fluid. 
Peritoneal dialysis
In 1923 Ganter performed the first peritoneal dialysis (PD) in a woman with renal 
failure.1  It was only in the 1960s that PD became an accepted renal replacement 
treatment in end-stage renal failure.2  Following the introduction of continuous 
ambulatory PD (CAPD) in 1975 by Popovich and Monrief, and the introduction 
of automated PD (APD) in 1980,3-5 the number of PD patients increased rapidly 
worldwide. In the Netherlands, 25.7% of dialysis patients were on PD in 2005.6  In 
CAPD 2 liters of fresh dialysis fluid are usually infused into the abdomen via a 
peritoneal catheter. After a dwell time of 4 to 8 h, during which retained body fluid 
and metabolites diffuse from the blood into the peritoneal cavity and vice versa, the 
dialysis fluid is drained. After drainage, fresh dialysis fluid is infused. A common 
prescription for CAPD is three to four exchanges during daytime and one long 
(usually 6 to 12 h) overnight exchange. In contrast, in APD an automated cycler 
regulates the infusions of the dialysis solutions (usually 2 liters) into the abdominal 
cavity. The cycler is programmed to perform three to four (or more) exchanges 
during the night. In the morning, 2 to 2.5 liters of fluid is left in the abdomen for 
12 to 16 h. There is usually no additional exchange during the daytime, but in some 
patients one or two additional exchanges are performed during the day to improve 
clearance or ultrafiltration.
Ideally, a peritoneal dialysis solution should have a maximal and sustained 
ultrafiltration capacity and a predictable solute clearance, with minimal absorption 
of the osmotic agents, and deliver a minimal caloric load; it should have no systemic 
toxicity, it should not accumulate in the body or in body compartments, it should 
be non-toxic to the peritoneum, non-immunogenic, and it should be easy and 
inexpensive to manufacture.7  The first solute in PD fluid to be used commercially 
on a large scale was glucose. However, it did not fulfill all requirements. After the 
first commercial dialysis solution became available in 1959, several substances 
including glycerol, amino acids, and various mixtures of low molecular weight 
osmotic agents as well as the high molecular weight icodextrin have been studied 
as alternatives to glucose.7, 8  Despite the long-term disadvantages of glucose such as 
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obesity, hyperglycemia, hypertriglyceridemia and bioincompatibility, it is still the 
most widely used osmotic agent for PD. The standard peritoneal dialysis solutions 
contain 1.36%, 2.27% or 3.86% of anhydrous dextrose/glucose as an osmotic 
agent in an aqueous solution of electrolytes similar to blood, which also contains 
a buffer, usually either lactate or a combination of lactate and bicarbonate. In 
spite of improvements in the composition of PD fluids and in the care of dialysis 
patients, however, the morbidity and mortality rates remain high.9  Atherosclerotic 
cardiovascular disease is a major cause of morbidity and mortality in patients with 
chronic renal failure, including those treated with dialysis.10,11  Among the many 
factors that affect outcome in the PD population, malnutrition plays an important 
role.12-14  Since insufficient intake of protein and calories due to a poor appetite 
and protein loss into the dialysate are major risk factors for the development of 
malnutrition in PD patients, intraperitoneal provision of amino acids (AA) and 
glucose (calories) is a logical approach to improve the nutritional state of these 
patients. This will be outlined in the next sections.
Malnutrition in peritoneal dialysis patients
Protein and energy malnutrition (PEM) is common in patients with chronic 
renal failure, including those undergoing peritoneal dialysis.15 The reported 
prevalence of PEM in PD patients varies from 18% to 56%, depending on the 
characteristics of the included patients, the time on dialysis treatment, and 
the nutritional assessment tools and nutritional markers used.16-18  There is 
abundant evidence in patients with chronic renal failure for a strong association 
between malnutrition, inflammation, and atherosclerosis (known as MIA 
syndrome), but how these factors interact to cause malnutrition is not clear.19 
Although PEM is rarely the direct cause of death, it is an important risk factor 
for morbidity and mortality in PD patients.20,21  Prevention and treatment of 
malnutrition have been advocated to reduce malnutrition-related complications 
and to improve the quality of life and life expectancy. Although it seems self-
evident, the beneficial effect of improving nutritional status on the prognosis 
of PD patients still needs to be confirmed. Effective strategies to prevent and 
treat malnutrition in PD patients should be based on an understanding of the 
pathogenesis. In the past decade two types of PEM in dialysis patients have 
been identified. Type-1 malnutrition is mainly caused by inadequate nutrient 
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intake. This type of malnutrition should benefit from nutritional supplements. 
In contrast, type-2 malnutrition is thought to be induced by a catabolic state 
due to inflammation and coexisting illnesses, rather than only a low nutrient 
intake.22  The terms wasting or malnutrition-inflammation complex syndrome or 
malnutrition-inflammation-cachexia syndrome (MICS) have been proposed for 
this latter condition.23  In type-2 malnutrition, in addition to sufficient nutrient 
intake, treatment of the underlying illnesses and inflammation is essential. Most 
malnourished dialysis patients probably suffer from a combination of the two 
types of malnutrition. Factors thought to be involved in the pathogenesis of PEM 
in PD patients24  will be summarized in the next paragraphs.
Low dietary nutrient intake 
A large proportion of chronic renal failure patients, including patients on PD, 
suffer from anorexia.25,26  Factors involved in the suppression of appetite in 
PD patients include uremic toxicity, metabolic acidosis, inflammation, fluid 
overload, dialysis procedures, hormonal and gastrointestinal disturbances, 
and complicating illnesses. The mechanisms of appetite suppression are poorly 
understood.27  A relationship between the progression of renal failure and 
spontaneous dietary protein intake, especially below a creatinine clearance 
of 25 ml/min, has been documented.28,29  In the Modification of Diet in Renal 
disease (MDRD) study group, patients with a GFR of 24 ml/min/1.73 m2 or lower 
tended to lose body mass.29  It has been shown that the protein requirements for 
CAPD patients are considerably higher than those for normal individuals.30,31 
After about one year after commencing dialysis therapy, the protein intake of a 
substantial proportion of PD patients remains far below an intake of 1.2 to 1.3 
g/kg body weight per day that is recommended for clinically stable chronic PD 
patients by the National Kidney Foundation Dialysis Outcome Quality Initiative 
(NKF/DOQI) guidelines.32,33  In spite of the additional energy supplied by glucose 
absorbed from the dialysis fluid, the actual energy intake is lower than the 
recommended total (diet and dialysate) energy intake of 35 kcal/kg body weight 
per day.34  In the few studies reporting resting energy expenditure (REE) in PD 
patients, no difference in REE was found compared with healthy subjects.35,36
Dialysis procedure
The number of dialysate exchanges per day, the glucose concentration of each 
exchange and plasma glucose concentration, the dwell time, and patient’s membrane 
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characteristics determine the amount of glucose absorbed from the dialysate. 
Generally, CAPD patients absorb on average 100 to 200 g glucose per day from 
dialysate, accounting for 12% to 34% of the total daily energy intake.37  Continuous 
glucose absorption from the dialysate may lead to hyperinsulinemia, hyperglycemia 
and hypertriglyceridemia, and may also suppress appetite.37,38  When oral intake is 
not reduced, in some patients glucose absorption may lead to obesity.39,40
A total daily loss of 3.4 ± 1.2 (SD) g of amino acids and 5 to 15 g of protein 
through peritoneal clearance has been reported in various studies.41-43  Factors 
which are involved in the quantity of the protein lost into the dialysate include 
the composition of the infused dialysis fluid, the peritoneal membrane transport 
characteristics, the serum protein concentration, and the patient’s clinical state. 
An early washout phenomenon due to residual peritoneal fluid may explain why 
in intermittent peritoneal dialysis the protein concentration is usually highest in 
the first exchange.44  The protein and amino acid losses can be compensated by 
an adequate protein intake.41  A poor appetite, however, prevents a considerable 
proportion of PD patients from consuming sufficient protein, resulting in protein 
deficiency and a decrease in lean body mass. Various factors may play a role in 
the development of PEM including loss of residual renal function, fluid overload, 
underdialysis with accumulation of poorly defined uremic toxins, such as 
middle molecular weight waste products of proteins.45-48  A relationship between 
peritoneal membrane permeability characteristics and nutritional state has also 
been suggested. A high permeability state may be a risk factor for PEM in PD 
patients.49,50
Metabolic acidosis
Metabolic acidosis is often overlooked in patients on PD, but may reduce appetite. 
Another major consequence of chronic metabolic acidosis is activation of the 
ATP-dependent ubiquitin-proteasome pathway and increased branched-chain 
keto-acid dehydrogenase activity, which results in breakdown of muscle protein 
and inhibition of protein synthesis.51,52  Several studies have shown that correction 
of metabolic acidosis in maintenance dialysis prevents the up-regulation of 
the ubiquitin-proteasome pathway and reduces protein degradation, and is 
associated with an improvement in nutritional status.53,54  The optimal level of 
serum bicarbonate for correcting acidemia has not been established. The NKF/
DOQI guidelines for maintenance dialysis recommend a serum bicarbonate level 
of 22 meq/L or higher.
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Inflammation and hypoalbuminemia
Inflammation is a common feature of end-stage renal failure as a cause of 
PEM.55,56  Infectious peritonitis and low-grade inflammation of the peritoneum 
induced by the presence of glucose in the dialysis fluid are likely to contribute to 
the increased levels of pro-inflammatory cytokines such as tumor necrosis factor 
alpha (TNFα), interleukins 1β (IL-1β), and 6 (IL-6) in dialysate of PD patients.57- 59 
Pro-inflammatory cytokines may suppress appetite, cause muscle wasting, 
hypoalbuminemia, and increased C-reactive protein (CRP) concentrations.60,61  As 
mentioned above, a pathophysiologic link between malnutrition, inflammation, 
and atherosclerosis has been proposed in this patient population.19,62
Inflammation, alone or in combination with a low protein intake or 
transperitoneal losses of albumin, plays a significant role in causing hypo-
albuminemia in PD patients.63  A strong association between hypoalbuminemia 
and a high mortality rate has also been reported in PD patients.64,65 
Hypoalbuminemia, however, reflects the presence of systemic disease rather 
than malnutrition, and serum albumin is a poor nutritional parameter in PD 
patients.66
Gastrointestinal disturbances
An increase in abdominal pressure due to the presence of dialysis fluid, sometimes 
combined with impaired gastric emptying, has inconsistently been reported as 
a factor contributing to anorexia and malnutrition in PD patients.67,68  There is 
evidence for impaired small intestinal protein assimilation in end-stage renal 
disease, which seems to correlate with the severity of the MIA syndrome.69 
Finally, an association between infection with Helicobacter pylori and anorexia 
and malnutrition has been recently reported.70 
Hormonal disturbances
Chronic renal failure of any cause is associated with insulin resistance of 
peripheral tissues with hyperinsulinemia and glucose intolerance.71  Resistance 
to the anabolic effects of other hormones such as insulin-like growth factor 
(IGF- 1) may also contribute to PEM in maintenance dialysis patients.72,73 
A reduced serum IGF-1 has been found in malnourished uremic patients, and 
it has been suggested to be an early indicator of malnutrition in end-stage renal 
disease.74,75  Another hormone that may play a role in the development of PEM is 
leptin. However, whether leptin contributes to malnutrition in uremic patients 
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has not yet been clarified. An association between an elevated serum leptin with 
inflammation and a decrease in lean body mass during PD has been recently 
reported.76 
Comorbidity
Pre-existing illnesses such as diabetes mellitus are highly prevalent in the 
PD population and may be the most important determinant of morbidity 
and mortality.77  There is a strong association between co-morbidity and poor 
nutrition with a lower dietary protein and calorie intake.78
Methods to assess nutritional state in peritoneal dialysis 
patients
Nutritional assessment is essential for the early recognition and treatment of 
protein and calorie malnutrition (PEM) in PD patients. Unfortunately there 
is no single perfect tool for evaluating the nutritional status of PD patients, 
and in clinical practice we have to make do with a combination of objective 
and subjective methods. These methods should preferably being simple and 
inexpensive. The original subjective global assessment (SGA) is such a simple 
and inexpensive method, initially validated as a screening tool for surgical 
patients.79  The SGA has been repeatedly modified and tailored to the needs of 
the PD patients, as recently reviewed.80,81  However, the best version of the SGA as 
a screening tool of the nutritional state of PD patients has still to be defined. In 
our studies we used the original SGA. Other approaches such as the body mass 
index (BMI), four-site skinfold anthropometry (FSA), bioelectrical impedance 
analysis (BIA), and total body dual energy x-ray absorptiometry (DEXA) have 
been used to measure body composition in PD patients. These methods will be 
discussed in chapter 2.
Protein homeostasis 
Protein homeostasis is a continuous process in which proteins are synthesized 
from amino acids and degraded back to them, a process of protein turnover. A 
‘nitrogen or amino acids pool’ is considered to exist in the body that is in dynamic 
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equilibrium with tissue proteins (Figure 1). Amino acids (AA) are continually 
taken from the pool for protein synthesis and replaced by dietary and tissue AA 
through proteolysis. In a healthy adult, the total amount of protein in the body 
is rather constant, so that the long-term rate of protein synthesis is equal to the 
long-term rate of protein breakdown. In an average 70 kg person, about 300 g of 
protein is synthesized each day and 300 g is degraded.82  About 80% of the amino 
acids from degraded protein are reutilized for protein synthesis. Individual 
proteins turn over at different rates. For example, some liver and plasma proteins 
have a half-life of 180 days or more, while enzymes and hormones may be recycled 
in a matter of minutes or hours. All cellular and tissue protein has a biological 
function. Since surplus non-functional protein cannot be stored, any amino acids 
that are not immediately used are oxidized and their nitrogen converted to urea, 
which is excreted from the body. There is a diurnal pattern of protein and energy 
metabolism in the human body due to the cyclic pattern of food intake.83  The 
discontinuous pattern of nutrition consists of a post-absorptive phase (fasting 
state) of negative net protein balance (i.e. protein synthesis minus breakdown), 
while in a post-prandial phase (fed state) repletion of the post-absorptive losses 
occurs, resulting in a positive balance after ingestion of food. Various studies 
of the effects of administration of insulin and amino acids (AA) on protein 
metabolism have been published.84- 89  In healthy human subjects, insulin and 
AA have different effects on protein dynamics in the splanchnic bed and skeletal 
muscle.90,91 After an overnight fast (post-absorptive state), muscle is in a catabolic 
state and provides AA for synthesis of essential proteins in other parts of the 
body, e.g. the splanchnic bed. Insulin has been shown to have an inhibitory 
effect on protein breakdown (PB) in skeletal muscle and supplying AA did not 
enhance this inhibitory effect. In contrast, in the splanchnic bed insulin had 
no inhibitory effect on PB, while AA had a profound inhibitory effect on PB. In 
muscle, insulin and AA had an additive effect on protein synthesis (PS), whereas 
no such additive effect was found in the splanchnic bed. After a mixed meal a 
net positive AA balance is achieved mainly by the insulin-induced inhibition 
on muscle PB and the AA-induced stimulation of muscle PS. The net positive 
AA balance in splanchnic bed was a consequence of an AA-induced inhibition 
of PB and an AA-induced stimulation of PS. This effect of AA is independent of 
insulin, as studies of subjects with type 1 diabetes have shown that in the insulin 
deficiency state, high circulating AA are associated with increased AA uptake in 
the splanchnic bed and an increase in PS rate.92  Taken together, these findings 
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indicate that AA are predominant stimulants of splanchnic PS.91  It is likely that 
the increase in splanchnic PS results from an increase in gut PS, as infusion of AA 
together with insulin did not stimulate PS in the liver.93  Thus, protein anabolism 
in muscle is mostly due to the insulin effect on muscle protein breakdown; 
insulin alone plays little or no role in stimulating muscle protein synthesis. By 
contrast, protein anabolism in the splanchnic bed is largely determined by amino 
acids through stimulating protein synthesis and inhibiting protein breakdown. 
A differential effect of insulin on the synthesis rates of various liver proteins has 
also been reported.93  The results, however, are conflicting.94,95  In human studies, 
insulin infusion decreased splanchnic protein synthesis in non-diabetic and type 
1 diabetic subjects.90,92  Although insulin may stimulate the synthesis of some liver 
proteins95 like albumin, the synthesis of other liver proteins, such as fibrinogen, is 
suppressed.96  To maintain the synthesis rate of albumin, insulin together with a 
supply of amino acid is necessary. 93, 95,97 
Insulin resistance is common in patients with CRF, including those on PD.71  In 
CRF patients, the insulin-mediated suppression of muscle protein breakdown is 
normal,98  but the ability of amino acids and insulin to augment protein synthesis 
during AA-infusion seems to be impaired.99 Conversely, in CAPD patients the 
post-absorptive reduction of protein synthesis is reversed by supplying amino 
acids, which suggests a normal anabolic response to protein feeding.100
Methods of measuring whole-body protein metabolism
Overall protein metabolism in an organism can be studied by techniques that 
enable quantification of biological pathways (of amino acids) involved in protein 
synthesis and breakdown.
Nitrogen balance
The classical nitrogen balance (N-balance) is the oldest method and is the 
traditional reference technique for assessing nutritional efficacy in protein 
metabolism, despite its limitations.101  It measures the net change in total body 
protein, i.e. the difference between the amount of nitrogen entering the body and 
the amount leaving the body. It is calculated using measured nitrogen intake, 
measured fecal and urinary nitrogen losses, while fixed values of 1.5 and 0.5 g/d 
for nitrogen losses via feces and via the skin respectively are usually assumed. 
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When applied to patients with renal failure, nitrogen balance must be adjusted 
for changes in the body nitrogen pool, because of a large urea N pool.101,102  Such 
changes are detected by daily measurement of serum urea nitrogen. 
Whole-body protein turnover
Since stable isotopes became available in 1939, they have been extensively used in 
diagnostic tests and in clinical research.103  In 1949, Sprinson and Rittenberg were 
the first to publish the end-product method using a single oral dose of [15N]glycine 
and measuring 15N enrichment of urinary urea as end product to estimate 
whole-body protein turnover (WBPT).104  This method has subsequently been 
modified several times. Waterlow introduced the single oral [15N]glycine method 
with ammonia as end product.105,106  Fern et al made a correction by measuring 
the body urea pool during WBPT assessment.107  The various modifications of 
the end-product methods of measuring WBPT have been reviewed recently by 
Duggleby and Waterlow.108  A technique that developed after the single-dose 
method makes use of continuous infusion of stable isotopic tracers of amino 
acids and is known as the precursor method. The precursor method with 
continuous infusion of L-[1-14C]leucine has previously been compared with the 
end-product method using [15N]glycine. It was concluded that the results of 
both methods were comparable.109  The precursor method,110  however, provided 
more appropriate results than those obtained with the end-product method. 
In this thesis, the precursor method with L-[1-13C]leucine, administered as a 
primed continuous intravenous infusion, is used as the reference tracer method 
for measuring WBPT. To our knowledge there is no study comparing the two 
methods in PD patients. In this thesis, the end-product method with [15N]glycine 
given as a single oral dose is compared with the precursor method using a primed 
continuously intravenous infusion of L-[1-13C]leucine for measuring WBPT to 
have a methological comparison in PD patients. The precursor method will be 
described in chapters 3 and 4, and the comparison between both methods will 
be discussed in chapter 6.
Principles of the whole-body protein turnover-methods
A model consisting of simple homogeneous pools as shown in Figure 1, restricted 
by some assumptions, represents the human whole body.
In this model there is one amino acid pool and one protein pool. It is 
considered that each of these pools is mixed homogeneously. The following 
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assumption is that there is equilibrium between these pools during the time of 
sampling for measurements. Amino acids are continuously entering the pool 
via diet and/or dialysate (I) and as a consequence of tissue protein breakdown 
(B). At the same time, amino acids are leaving the pool for new protein 
synthesis (S) and are susceptible to oxidation (O). The total flow through 
this system is called the flux (Q). The ideal situation to be reached during 
measurements for protein turnover is that there is a steady state for the system 
during which the pools do not change in size. In this steady state, the total 
rate of AA appearance in the pool is equal to the total rate of disappearance. 
In this situation the total flux Q can be represented as Q = S + O. But at the 
same time, the flux can be represented with the formula: Q = I + B. Because 
there is only one flux per definition, the formula can be written as Q = S + 
O = I + B. When known variables are substituted, the unknown processes as 
synthesis and breakdown can be calculated by this method. This simple model 
can be used in two different ways to find synthesis and breakdown of protein: 
the precursor method using continuous infusion of L-[1-13C]leucine or the 
end-product method using a single oral dose of [15N]glycine. Both methods are 
shortly explained hereafter.
In the precursor method L-[1-13C]leucine is infused after a priming dose, which 
leads to an equilibrium (plateau concentration) of the infused material. Instead 
of L-[1-13C]leucine itself the measurements are based on [13C]ketoisocaproic 
acid (KICA) which is a metabolite representing closely the L-[1-13C]leucine 
value inside the tissue cells where protein synthesis actually takes place.111  The 
rate of oxidation of amino acid is calculated from the 13CO
2
 in expired air. The 
flux, protein synthesis, and breakdown rates are calculated from these results. 
Since part of the absorbed amino acid is taken up by the splanchnic tissues 
(i.e. first pass uptake), the splanchnic retention has to be taken into account as 
reported,112,113 and as will be discussed in chapters 3 and 4.
The end-product method uses [15N]glycine as a tracer, which is orally 
ingested as one single dose. In the period following, this amino acid is diluted 
in the pool and is subject to metabolism along with the other amino acids. 
After this ‘pulse label’ is metabolized (usually 9 h), the end products urea and 
ammonia can be analyzed for [15N] and lead to a prediction of the amounts of N 
used for synthesis (S) or breakdown (B) of protein. Both methods are based on 
different assumptions and calculation procedures, which are reviewed in detail 
elsewhere.108
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Dialytic approach to nutritional intervention
Intraperitoneal nutrition has been proposed as an alternative approach to 
overcome protein deficiency in PD patients, and dialysis solutions, which contain 
amino acids, have become commercially available.
Amino acid-based dialysate
Gjessing (1968) was the first to evaluate the effects of adding amino acids (AA) to 
the dialysis fluid in patients under regular PD regimens for chronic renal failure. 
He noticed considerable absorption of AA by the peritoneum and a diminished 
reduction of serum protein.114  Oreopoulos et al (1979) was the first to use AA-
based dialysate in CAPD patients.115  The use of AA-based peritoneal dialysis 
solutions has been extensively reviewed.116-118  To summarize, peritoneal solute 
transport and ultrafiltration during dialysis with solutions containing 1% AA 
and containing 1.36% glucose are similar. The average molecular weight of AA 
included in the AA-containing PD solutions is about 140 daltons. In short-term 
studies it has been found that AA-based PD solutions are capable of providing 
sufficient ultrafiltration, although the period of effective ultrafiltration is rather 
Figure 1. A general model of protein metabolism used in the whole-body turnover method82  
                              Dietary protein intake 
                                
Labeled AA 
           Breakdown 
Synthesis
  Breakdown 
Protein
synthesis
N-excretion (urine)  
 (NH3 and urea) 
   CO 2
(expired air) 
  AA pool 
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short due to the more rapid absorption of AA  than that of glucose. The amount 
of absorbed AA depends on the AA concentration in the PD solutions, dwell time 
and dwell volume, and a patient’s membrane transport characteristics. In CAPD 
an absorption ranging from 60 to 90% is reported during a 4 to 6 h dwell. Plasma 
AA concentrations rise significantly during the use of AA-containing solutions. 
After peritoneal delivery, peak plasma levels of most AA were comparable with 
the levels that are normally found after ingestion of a large protein meal or after 
mixed meals with a protein ingestion similar to that observed after a protein-
only meal. An increased peritoneal protein loss with AA solutions has been 
reported in studies with 1% and 2.7% AA-based solutions respectively.119,120  The 
composition of the AA-PD solutions and the buffer component have been changed 
over time and adjusted to the needs of CRF patients. In the earlier studies an AA-
PD solution (Travasol, Baxter Healthcare, Deerfield, Il, USA) was used. The pH 
of the solution was 6.0 to 6.5 and the buffer was lactate at a concentration of 33 
mmol/liter either alone or combined with acetate at 7 mmol/liter. Studies with 
a small number of patients showed a wide discrepancy in nutritional effects, 
in part due to a great diversity in the nutritional parameters examined, while 
there was a little overall nutritional benefit. Uremic symptoms and metabolic 
acidosis were reported. In subsequent studies performed with RenAmin (Baxter 
Healthcare), the AA composition was changed, with an increase in the essential 
AA. The total AA concentration remained at 1%, the lactate concentration was 
increased to 35 mmol/liter and the pH maintained at 6.0 to 6.5. These studies in 
a small number of patients demonstrated an overall positive nutritional benefit, 
but an increase in BUN and mild metabolic acidosis persisted. The solution was 
well tolerated. The current 1.1% AA-PD solution (Nutrineal, Baxter Healthcare) 
approaches the assumed optimal balance between essential and non-essential 
AA required for a CRF patient. It contains all nine essential AA, six non-essential 
AA, and the buffer component is lactate at a level of 40 mmol/liter (Table 1). 
Studies conducted with the 1.1% AA-based PD solutions encompass a larger 
number of patients. The gain of amino acids exceeds the losses of amino acids, 
i.e. there is a net gain.121   An increase in serum urea and, with the use of more 
than one bag of 1.1% AA dialysis solutions per day, mild metabolic acidosis has 
been found. Generally one bag of 1.1% AA dialysis solutions is well tolerated.
The beneficial nutritional effects of the AA-based solutions have not been 
consistently found, which may due in part to differences in study design, 
patient characteristics such as the presence or absence of malnutrition and the 
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nutritional parameters being used.122-130  An important factor underlying the 
lack of conclusive positive results, however, might be that the use of the AA-
containing solution was not accompanied by an adequate supply of calories. 
Moreover, it has been reported recently that 1.1% AA-containing dialysate 
produced an increased glucose transport from blood to dialysate, which 
may contribute to loss of glucose from the body.131  It has been shown that 
simultaneous administration of sufficient oral calories is essential to achieve an 
optimal utilization of intraperitoneally administered AA.132  Since a poor appetite 
prevents PD patients from taking sufficient proteins and calories, PD solutions 
containing a mixture of AA plus glucose as a source of food would be a practical 
approach to circumvent the insufficient nutrient intake in these patients.
Table 1. The composition of 1.1% amino acid-peritoneal dialysis solution (Nutrineal) 
 Amino acids 
Essential  amino acids 
(g/L)
Histidine
Isoleucine
Leucine
Lysine-HCL
Methionine
Phenylalanine
Threonine
Tryptophane
Valine
0.714
0.850
1.020
0.955
0.850
0.570
0.646
0.270
1.393
Non-essential amino acids 
(g/L)
Arginine
Alanine
Proline
Glycine
Serine
Tyrosine
1.071
0.951
0.595
0.510
0.510
0.300
Electrolytes and buffer 
(mmol/L)
pH
Osmolality
Sodium
Chloride
Calcium
Magnesium
Lactate
365 mOsmol
132
105
1.25
0.25
40
6.7
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Aim of the thesis
Patients treated with peritoneal dialysis (PD) often develop protein and 
calorie malnutrition (PEM), which is an important risk factor for morbidity 
and mortality. This thesis examines the potential of a specific approach to the 
prevention and treatment of PEM, the administration of protein and calories via 
dialysis fluid. The underlying idea is to circumvent a number of factors, such as 
the loss of appetite and the gastrointestinal problems that reduce food intake. 
The amounts of food administered via the dialysis fluid are simple to quantify 
and, in contrast to parenteral nutrition, direct access to the bloodstream is not 
needed. Dialysis solutions containing amino acids (AA) plus glucose are expected 
to compensate for the low dietary protein and calorie intake in these patients.
In chapter 2 we assessed the nutritional state of patients with chronic renal 
failure who were being treated in the Erasmus MC using the original subjective 
global assessment (SGA).
In chapter 3 we investigate the metabolic effects of dialysis solutions 
containing AA plus glucose in patients treated with automated PD (APD) in the 
fasting state overnight.
A substantial part of PD patients, however, are still treated by continuous 
ambulatory PD (CAPD) during the day while they consume their meals. These 
patients might also benefit from the use of AA-containing solutions in addition 
to their dietary food intake.  In chapter 4 we investigate whether dialysis solution 
containing AA plus glucose may also contribute to an improvement in protein 
metabolism in CAPD patients.
In chapter 5 we examine whether dialysis solution containing AA plus glucose 
combined with food intake is capable of increasing the fractional synthesis rate of 
albumin (FSR-albumin) in parallel to an improvement of the whole-body protein 
synthesis in PD patients in the fasting (APD) and the fed state (CAPD). 
There is a need for a validated method to measure whole-body protein 
metabolism, which can be applied repeatedly in different patient populations 
and in an outpatient setting. In chapter 6 we examine whether the end-product 
method with a single oral dose of [15N]glycine is such a method and whether it can 
replace the precursor method with primed continuous infusion of [13C] leucine.
Little is known about the protein and AA losses into dialysis effluent in 
APD patients, and as AA-based dialysis solutions could conceivably induce 
inflammation of the peritoneum, resulting in increased peritoneal protein 
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losses, in chapter 7 we describe the measurements of peritoneal protein losses 
and cytokines in plasma and dialysate with the use of combined AA plus glucose 
dialysis solutions, and additionally the amino acid losses into the dialysis 
effluents with standard (glucose) dialysis solution in APD patients. 
In the final chapter the results are discussed and summarized.
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Abstract
Early detection of malnutrition in uremic patients is essential as malnutrition 
is associated with high morbidity and mortality. We compared the results of 
subjective global assessment (SGA) of nutrition state of peritoneal dialysis (PD) 
patients with other nutritional parameters.
An observational cross-sectional study was performed in 30 adults (20 males) 
on PD. Nutritional state was assessed by SGA, and related to body mass index 
(BMI), four skin-fold anthropometry (FSA), bioelectrical impedance analysis 
(BIA), and dual energy x-ray absorptiometry (DEXA).
Using SGA 37% of all patients were malnourished (CI: 20 % to 56 %), with 27% 
in SGA-B (moderate) and 10% in SGA-C (severe). High correlations were found 
between the graded SGA on one hand and BMI (r = - 0.75, P < 0.001), fat mass (FM) 
index using FSA (r = - 0.75, P < 0.001), BIA (r = - 0.71, P < 0.001), DEXA (r = - 0.76, 
P < 0.001) on the other hand. In conclusion, a high prevalence of malnutrition 
was found in PD patients, using SGA as a screening tool. SGA correlated well 
with body composition measurements.
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Introduction
Malnutrition is a risk factor for morbidity and mortality in PD patients.1,2 
Early detection of malnutrition in PD patients is crucial if effective nutritional 
strategies are to be initiated. Reliable methods to assess the nutritional status 
such as underwater weighing to estimate body composition, prompt neutron 
activation analysis to measure total body nitrogen, and total body potassium 
counting to measure fat free mass (FFM) are only available in a few centers 
and require costly equipment.3-5  Alternative methods for the assessment of the 
body composition have been proposed, including anthropometry, bioelectrical 
impedance analysis (BIA), and dual energy x-ray absorptiometry (DEXA).3,6- 9 
The subjective global assessment (SGA) has a fundamentally different 
approach. It is a simple method, which is easy to apply in routine clinical 
practice. It is a reproducible and inexpensive tool, which has been shown to 
be a valid method for nutritional assessment in different populations.10-13  SGA 
takes clinical findings into account and reflects changes in the nutritional 
state in the preceding months (i.e. change in body weight), whether it is 
compromised at the present time (edema), or whether it affects function 
(muscular weakness). The other methods give information about the actual 
nutritional state by measuring body composition. Initially, SGA was used to 
assess nutritional state in preoperative surgical patients to predict risk of 
postoperative complications.14  The original SGA was subsequently modified 
in an attempt to increase its predictive value and reproducibility for dialysis 
patients.15-18  Up to now, however, none of these modifications for PD patients 
have been validated in a large study.19,20
The primary purpose of this study was to assess the nutritional state of PD 
patient by using the original SGA. Secondly we analyzed relationships between 
the SGA and measurements of body composition.
Subjects and Methods
Patients
Patients were recruited from the Peritoneal Dialysis Unit of the Erasmus MC, 
Rotterdam, the Netherlands. The enrollment period was from July to September 
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2005. Thirty out of thirty-three consecutive PD patients were included in this 
study. Three patients did not participate in the evaluation because of non-medical 
reasons (refusal and non-compliance). The study was performed according to 
the guidelines of the local medical ethical committee. All participating patients 
gave informed consent.
Study design
We performed an observational cross-sectional study to assess nutritional state. 
In each patient all measurements were carried out on a single day. On the study 
day all patients came to the hospital at least two hours after their last meal and 
before the next exchange of dialysate. One observer performed the SGA, the 
anthropometric measurements, the BIA, and the DEXA in all patients. Weighing, 
BIA and DEXA measurements were carried out with an empty peritoneal cavity. 
The daily intake of protein and calories was based on food records and a dietary 
interview by a renal dietician.
Measurements
Subjective global assessment (SGA): the SGA method was used as described by 
Detsky et al.21  Using data from the history (anorexia, nausea, vomiting, diarrhea 
and weight loss in the preceding 6 months) and physical examination (loss of 
subcutaneous fat over the triceps and mid-axillary line on lateral chest wall, 
muscle wasting in the deltoids and quadriceps, and the presence of ankle edema), 
the patients were classified into three categories: category A = good nutritional 
state, category B = moderate malnutrition, category C = severe malnutrition. 
The SGA was performed in all patients by one single observer.
Anthropometric measurements: body height was measured to the nearest 
0.5 cm with the patient standing against a fixed stadiometer. Body weight was 
measured to the nearest 0.1 kg, in light clothing without shoes using a weight 
scale (Seca Corp. Scale, USA). Body mass index (BMI) was calculated as weight 
(kg) divided by height square (m2).
Four-site skinfold anthropometry (FSA): skinfold measurements were 
performed to estimate total body fat mass using a Harpenden calliper (British 
Indicators Ltd, West Sussex, UK). Skinfold thickness was measured at four 
sites (biceps, triceps, subscapular and suprailiac) on the non-dominant arm 
to the nearest 0.1 mm. Three measurements were performed at each site and 
the averaged value is presented. Body fat mass (FM) and fat free mass (FFM) 
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were estimated from the sum of the four skinfold thickness and body density 
according to the method of Durnin and Wormersley.22 
Bioelectrical impedance analysis (BIA): measurements were performed 
using a bioelectrical impedance analyser (model BIA-101 RJL/Akern Systems, 
Detroit, MI, USA). After five minutes in supine position, a low-amplitude, single-
frequency, imperceptible current of 800 mA at 50 kHz was introduced at the 
distal electrodes. Resistance and reactance were measured as parameters of 
impedance. Software supplied by LeanBody RJL Systems (Detroit, MI, USA) 
was used to provide data of the FM and FFM derived from the impedance 
parameters.
Total body dual energy x-ray absorptiometry (DEXA): the DEXA was 
performed using a Lunar Prodigy system (General Electric Corporation, 
Madison, WI, USA). The data were calculated using software version 7.53. For 
clarity the LBM measured with DEXA is presented as FFM.
Residual renal function (RRF): the RRF was defined as the mean of renal 
urea and creatinine clearances (ml/min) and derived from PD adequest 2.0, 
software Baxter. 
Calculations
The following formulas were used to calculate the fat free mass index (FFMI) 
and the fat mass index (FMI): FFM divided by the square of the height (kg/m2) 
and FM divided by the square of the height (kg/m2), respectively.
Statistical analysis
Data are expressed as mean ± SD or range and median. Correlations between 
the SGA classifications and the RRF and the body composition measurements 
were evaluated using Spearman’s rank correlation. The two-independent 
sample t test was used to compare differences regarding the RRF as well as 
body composition measurements between both nutritional states. Differences 
were considered statistically significant when the two-sided P value was < 0.05. 
Receiver operating characteristic (ROC) curve of BMI, with SGA as reference, 
was constructed.
To assess the agreement between different methods of measuring body 
compositions intraclass correlation coefficients (ICC) were calculated.
Data were analyzed using the statistical program SPSS version 11.0, for 
Windows (SPSS Inc., Chicago, IL, USA).
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Results
Table 1 shows the baseline characteristics of the patients. Hypertensive 
nephropathy was the most prevalent cause of renal failure. There was only one 
patient with diabetic nephropathy. Six patients (4 males, 2 females) were anuric, 
four patients had a urine production between 50 and 320 ml per day. In 5 patients 
RRF was not determined as they were less than 3 months on PD. 
We found that nineteen patients (11 men, 8 women) were well-nourished, 
classified as SGA-A (63%), eight patients (6 men, 2 women) were moderately 
malnourished, classified as SGA-B (27%) and three patients (all men) were 
severely malnourished, classified as SGA-C (10%). For the whole group 
significant correlations were found between the SGA classifications (A, B, C) and 
the following parameters: BMI (r = 0.75, P < 0.001), FMI measured using FSA (r = 
- 0.75, P  < 0.001), using BIA (r = - 0.71, P  < 0.001), and using DEXA (r = - 0.76, P < 
0.001). Regarding the FFMI, only BIA showed a significant correlation between 
the SGA and the FFMI-values (r = - 0.47, P = 0.009). In men: FFMI measured with 
all three methods correlated significantly with SGA (FSA: r = - 0.51, P = 0.027; 
BIA: r = - 0.79, P < 0.001; DEXA: r = - 0.62, P = 0.004). Table 2 presented the results 
Table 1. Baseline characteristics of the study patients (N = 30)a
Gender (M/F) 20 /10
Age (yr ± SD) 54 ± 16.2
Cause of ESRD 10 hypertension
5 unknown
5 glomerulopathy
3 obstructive nephropathy
2 chronic pyelonephritis
2 reflux nephropathy
1 diabetic nephropathy
1 hyperoxaluria
1 APKD 
Time on PD (mo median with range) 17.5, 1-91
PET 8 H, 19 HA, 2 LA
Protein intake (g/kg/d) 1.0 ± 0.3
Energy intake (kcal/kg/d) 23 ± 7.0
aM, male; F, female; ESRD, end-stage renal disease; PD, peritoneal dialysis; mo, month; APKD, adult 
polycystic disease; PET, peritoneal equilibrium test, H, high; HA, high average; LA, low average. 
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of the comparison between nutritional state and the objective measurements 
for both gender. FMI measured with all three body composition methods was 
significantly higher in female patients than in male patients: using FSA 10.2 ± 
2.8 kg/m2 versus 6.8 ± 3.0 kg/m2, P = 0.006, using BIA 10.6 ± 3.1 kg/m2  versus 
7.1 ± 2.7 kg/m2, P = 0.004, using DEXA 9.6 ± 3.4 kg/m2 versus 6.3 ± 2.9 kg/m2, 
P = 0.011. Malnourished patients showed approximately 50% lower FMI and 
10% lower FFMI. The percentage of cases with SGA equal to B or C did not 
significantly differ between both genders, 45% (9/20) for men versus 20% (2/10) 
for women (Fisher exact test, P = 0.25). None of the differences between SGA-A 
(well-nourished) and SGA-B+C (malnourished) with regard to the nutritional 
variables (BMI, FSA-FMI or FFMI, BIA-FMI or FFMI, DEXA-FMI or FFMI) 
depended on gender (effect modification: all P > 0.09 using Anova). 
Using the ROC curve and the SGA as reference standard, we found a good 
discriminating value between SGA-A versus SGA-B+C for BMI (AUC > 0.90). A 
cut-off level of BMI of < 23.7 kg/m2 was able to predict malnourishment with a 
sensitivity of 90% and a specificity of 91% for the whole group. There was a very 
good agreement between FSA and BIA (ICC = 0.90), FSA and DEXA (ICC = 0.93) 
and between BIA and DEXA (ICC = 0.91).
Furthermore we found that the SGA-classification A, B, C was significantly 
correlated with the RRF (r = - 0.51, P = 0.009). Mean RRF varied between 0 and 
8.53 ml/min/1.73m2 (median 3.7 ml/min/1.73m2) in the well-nourished patients 
(n = 17) and between 0 and 5.10 ml/min/1.73m2 (median 0 ml/min/1.73m2) in the 
malnourished patients (n = 8). 
Discussion
We assessed the nutritional state of patients with chronic renal failure who 
were being treated with PD in our center using the three-point SGA scale 
as originally described to identify malnourished PD patients. A generally 
accepted standard clinical method to assess nutritional status of PD patients 
is not available at present. The SGA has been used in many populations 
including dialysis patients.10-13  The SGA is reproducible and easy to perform 
in daily practice. In addition, evidence that the SGA has the potential to guide 
nutritional intervention resulting in a better clinical outcome has recently 
been reported.15 
22321_tjong_V7.indd   43 19-12-2007   11:12:28
44 Chapter 2
Using the SGA, malnutrition was observed in 37% of our study population 
while 10% were even severely malnourished. This is in accordance with the 
literature, which reports a prevalence of malnutrition of up to 40% in PD 
patients.11
We compared the SGA with the results of the body composition measurements 
using anthropometry, BIA, and DEXA. There is no consensus in the literature on 
which method is the best to assess body composition in PD patients. We found 
a high ICC between the different methods in our study (0.90-0.94), in line with 
what has been reported previously by others.23
FSA is another simple and inexpensive method to assess nutritional state. 
It has been reported that with trained observers the estimation of FM and FFM 
using FSA correlated reasonably well with results from DEXA.23,24  Unfortunately, 
FSA does not work as well in routine clinical practice as in research, since this 
method is subject to a high intra-observer and inter-observer variability and is 
not easy to perform in obese subjects.3 BIA is considered a valid method to assess 
the nutritional state of stable dialysis patients.7 It has been reported that BIA 
measurements are influenced by the presence of peritoneal dialysis fluid.25  We 
have also found a statistically significant, albeit very small difference, between 
the BIA measurements before and after drainage of dialysis fluid (data not 
shown). These findings suggest that BIA measurements in PD patients should 
be taken under well-defined and standardized conditions. The same goes for the 
DEXA measurements. DEXA is an expensive method and not widely available. 
BIA and DEXA give information only about the actual body composition. SGA 
differs from the other methods discussed above in that it takes clinical and 
functional findings into account and moreover, it reflects the nutritional state as 
it developed in the preceding months, since it includes changes in body weight. 
In our study we found that in male patients the SGA was strongly correlated 
with all measured objective parameters and discriminated the malnourished 
from the well-nourished patients as defined by body composition techniques. 
In female patients there were no significant correlations between SGA and 
FFM index. The reason for this discrepancy is not well understood. In line 
with the literature we found a significantly higher FM in women than in men.24 
Furthermore we observed an approximately 50% lower FM and 10% lower FFM 
in malnourished patients than in well-nourished patients. This suggests that in 
malnourished PD patients lean body mass is preferentially conserved relative to 
body fat similar to patients undergoing bariatic surgery.26
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For malnutrition we showed a cut-off value for BMI of < 23 kg/m2. This 
finding indicates that a BMI that falls within the normal range does not exclude 
malnutrition. Measurement of BMI fails to take into account the separate 
contributions of fat mass and fat free mass to body weight. A high BMI can be 
due to either an excess of adipose tissue or an increase in FFM or a combination 
of both. Similarly, a low BMI may be due to a decrease in FFM or adipose tissue 
or both.27 Generally a BMI < 18.5 kg/m2 is considered to reflect malnutrition 
in the normal population (World Health Organization, 1995). However, the 
use of currently available normal anthropometric values in PD patients are of 
questionable value, since age-, sex-, and race- or ethnicity-specific reference data 
are not available for the PD population.28  Recently Deurenberg et al reported that 
the relationship between the body fat percentage and BMI is different between 
Asians and Caucasians, and that body fat in relation to BMI is higher in Asians 
than in Caucasians.29  PD patients have higher visceral fat for a given BMI when 
compared with the normal population.30
Interestingly, we found a strong correlation between the SGA and the RRF, 
in particular in male patients. This may indicate that a decline in residual 
renal clearance may play a role in the development of malnutrition in PD 
patients.11,31,32
In conclusion, based on the SGA we observed a high prevalence of 
malnutrition in PD patients. This cross-sectional study shows that conventional 
SGA is a practical screening tool to assess malnutrition in PD patients, and that 
BMI, FSA, BIA, or DEXA have a high correlation with the SGA. BIA and DEXA do, 
however, provide additional information on body composition and may be used 
to follow up changes in lean body or fat mass. Although several modifications of 
the SGA have been proposed, none has convincingly been shown to be superior 
to the original three-point SGA scale. In the absence of further studies to define 
the best SGA for PD patients, clinicians should probably continue to use the 
version of SGA with which they are familiar.
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Abstract
Protein-energy malnutrition as a result of anorexia frequently occurs in dialysis 
patients. In patients who are on peritoneal dialysis (PD), dialysate that contains 
amino acids (AA) improves protein anabolism when combined with a sufficient 
oral intake of calories. It was investigated whether protein anabolism can be 
obtained with a mixture of AA and glucose (G) as a source of proteins and calories 
during nocturnal automated PD (APD). A random-order crossover study was 
performed in eight APD patients to compare in two periods of 7 d each AA and G 
dialysate obtained by cycler-assisted mixing of one bag of 2.5 L of AA (Nutrineal 
1.1%, 27 g of AA) and four bags of 2.5 L of G (Physioneal 1.36 to 3.86%) versus 
G as control dialysate. Whole-body protein turnover was determined using a 
primed continuous infusion of L-[1-13C]leucine, and 24 h nitrogen balance studies 
were performed. During AA and G dialysis when compared with control, rates of 
protein synthesis were 1.20 ± 0.4 and 1.10 ± 0.2 µmol/kg per min leucine (mean 
± SD), respectively (NS), and protein breakdown rates were 1.60 ± 0.5 and 1.72 ± 
0.3 µmol/kg per min (NS). Net protein balance (protein synthesis minus protein 
breakdown) increased on AA and G in all patients (mean 0.21 ± 0.12 µmol leucine/
kg per min; P < 0.001). The 24 h nitrogen balance changed by 0.96 ± 1.21 g/d, 
from - 0.60 ± 2.38 to 0.35 ± 3.25 g/d (P = 0.061, NS), improving in six patients. In 
conclusion, APD with AA and G dialysate improves protein kinetics. This dialysis 
procedure may improve the nutritional status in malnourished PD patients.
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Introduction
Protein-energy malnutrition (PEM) is frequently found in patients with chronic 
renal failure, including those who are on dialysis.1-3  There is increasing evidence 
of a strong association among malnutrition, inflammatory processes, and 
cardiovascular mortality.4-7  Many factors are involved in the development of PEM, 
in particular inadequate intake of proteins and calories through anorexia. Although 
many strategies have been proposed to improve dietary nutrient intake in peritoneal 
dialysis (PD) patients, actual protein intake is frequently below the recommended 
amount of 1.2 g/kg body wt.8,9  In continuous ambulatory PD (CAPD) patients, amino 
acids (AA)-containing dialysate has been used to compensate for a low dietary 
protein intake and loss of AA and proteins through peritoneal clearance.10  Until now, 
however, no convincing clinical benefits have been demonstrated.11-19  AA dialysate 
may lead to significant increase in serum urea levels11-14  and metabolic acidosis,11,12,15 
a protein catabolic stimulus.20,21  To date, AA dialysates are not routinely used in 
PD. Recently, it was shown convincingly that simultaneous ingestion of calories is 
essential to obtain an optimal anabolic effect of intraperitoneal AA.22-24  However, 
anorexia may impede patients from taking enough calories with intraperitoneally 
supplied AA. Giving AA intraperitoneally during nightly dialysis without calories 
had not shown beneficial nutritional effects.14
Because the utilization of intraperitoneally supplied AA can be optimized 
by giving them simultaneously with glucose (G), we put forward the hypothesis 
that in patients who are on nightly automated peritoneal dialysis (APD), a 
dialysis solution that contains a mixture of AA and G (AAG), as part of a 
regular dialysis schedule, could improve protein metabolism. We conducted a 
randomized crossover study in APD patients to compare AAG dialysis with G 
dialysis as control. To assess the effects on protein metabolism, we measured 
whole-body protein turnover and nitrogen balance as endpoints.
Materials and Methods
Patients
Eight APD patients (Table 1) were recruited from the Peritoneal Dialysis Unit 
of the Erasmus MC. Inclusion criteria called for stable patients who were on 
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PD >3 mo and had weekly Kt/V >1.7. Exclusion criteria were peritonitis, other 
infectious or inflammatory diseases in the previous 6 weeks, malignancy, and life 
expectancy <6 mo. The study was approved by the Medical Ethics Committee, 
and written informed consent was obtained from all patients.
Study Design 
The study is a single-center, open-label, randomized, crossover study of 14 d 
duration (Figure 1). In two consecutive periods of 7 d each, a dialysis scheme 
using dialysate-containing AAG (Nutrineal 1.1% and Physioneal 1.36% to 3.86%, 
Baxter BV, Utrecht, the Netherlands) was compared with a control scheme that 
contained G (Physioneal 1.36% to 3.86%). Before the study, all patients used G-
based dialysis fluid (Dianeal or Physioneal; Baxter BV).
The study was performed on an outpatient basis, except for the whole-body 
turnover study. Patients were randomized to start with AAG or G as the first 
dialysis scheme by drawing one of eight sealed envelopes. 
Primary end points of the study were whole-body protein turnover (WBPT) 
and 24-h nitrogen balance (NB). Secondary end points were changes in acid-
base homeostasis and blood chemistry.
Before the study and at the end of the first and second week (day 7 and day 
14), venous blood samples were taken for chemistry and an acid-base profile. On 
PTO N-balance
first study period controlled diet
either AAG or G dialysate
day 1 2 3 4 5 6 7
8 9 10 11 12 13 14
PTO N-balance
second study period controlled diet
either G or AAG dialysate
day
Figure 1. The study design was a randomized, crossover study that consisted of two consecutive 
study periods of 7 d each. During these periods (days 1 to 7 and 8 to 14), dialysis with amino acids 
plus glucose (AAG) or with glucose (G) was performed. A controlled hospital-supplied diet was 
prescribed during 5 d (days 3 to 7 and 10 to 14). Collection of materials for nitrogen balance took 
place during days 5 to 7 and 12 to 14. Protein turnover study (PTO) was carried out on day 3.
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the third day of each period, patients were admitted to the metabolic ward, where 
WBPT was determined during an overnight stay. The NB study was carried out 
on an outpatient basis.
Dialysis Procedures
Six nighttimes exchanges were performed automatically using a cycler (HomeChoice; 
Baxter BV). In the daytime, there were one or two exchanges with G (Dianeal or 
Physioneal) and / or polyglucose-containing (Extraneal, Baxter BV) dialysate.
During the study, the APD schedule for each patient was similar to that used 
before the study to meet adequacy and ultrafiltration targets. The cycler regulated 
mixing of AA and G. The AAG dialysate was obtained after mixing one bag of 2.5 
L of Nutrineal 1.1%, which contained 27 g AA, and four bags of 2.5 L of Physioneal, 
1.36 % to 3.86 % G, depending on ultrafiltration targets. In one patient (patient 8), 
only bags with 2.0 L were used. The AA and G solutions need to be mixed such that 
at each cycle, AA are given together with a sufficient amount of energy. To obtain 
an AAG mixture from the first cycle onward, we applied an ’empty bag procedure,’ 
while all bags were hung with the undersides on the same level. For the first cycle, 
a weighed amount of AA solution was mixed in the so-called heater bag (the bag 
where the solutions are mixed) with the G solutions to a final ratio of 1:4. For the NB 
studies, when the patients were dialyzed at home, mixing during the other cycles 
was regulated automatically by the cycler. This mixing procedure was tested in 
an in vitro experiment by labeling the AA solution with methylene blue. A proper 
mixing for each cycle was found (interbag coefficient of variation for methylene blue 
concentrations, 7%). During the WBPT studies, in each cycle, the heater bag first 
was filled by the research nurse with the AA solution in an exactly weighed amount, 
whereupon the cycler filled the bag with the required amount of G solution so that 
exactly the same amount of AA was supplied and the steady-state conditions could 
be met in each cycle. During the G period, five bags of 2.5 L of Physioneal 1.36% to 
3.86% were infused, individualized per patient depending on ultrafiltration targets.
The composition of the AA 1.1% dialysis solution (g/L) was 0.714 histidine, 0.850 
isoleucine, 1.020 leucine, 0.955 lysine-HCl, 0.850 methionine, 0.570 phenylalanine, 
0.646 threonine, 0.270 tryptophane, 1.393 valine, 1.071 arginine, 0.951 alanine, 0.595 
proline, 0.510 glycine, 0.510 serine, and 0.300 tyrosine. The electrolyte and buffer 
concentrations (mmol/L) were 132 Na, 105 Cl, 1.25 Ca, 0.25 Mg, and 40 lactate. The 
electrolyte and buffer composition (mmol/L) of the 1.36%, 2.27%, or 3.86% G was 
132 Na, 95 Cl, 1.25 Ca, 0.25 Mg, 25 bicarbonate, and 15 lactate.
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WBPT Studies
In the two study periods, rates of WBPT during nocturnal dialysis were 
determined with a primed continuous intravenous infusion of 13C-leucine.25 
WBPT was studied on day 3, at the end of the dialysis between 2.30 and 5.00 
a.m. (Figure 2). To create baseline conditions, patients were instructed to drain 
all dialysate 12 h before starting the APD, leaving the abdomen empty. Thus, 
only during day 3, when WBPT was performed, the patients had a dry day. At 
5:00 p.m., two catheters were inserted into superficial veins on both arms, 
one for continuous infusion of the tracer solution and the other for repeated 
blood sampling. Dialysis started at 8.30 p.m. (T
0
). Baseline blood samples and 
expiratory breath samples were collected in duplicate at 2.30 a.m.(6 h
 
from the 
start of the dialysis, T
360
),
 
and priming doses of L-[1-13C] leucine (3.8 µmol/kg) 
and of NaH13CO
3 
(1.7 μmol/kg) were given to label the leucine and CO
2
 pools. 
Then, a continuous infusion of L-[1-13C] leucine (infusion rate 0.063 µmol/
kg per min) was started and continued for 150 minutes until the end of the 
nocturnal dialysis at T
510
. For measuring plateau plasma keto-isocaproic acid 
(KIC) and CO
2  
13C enrichment, blood and expired air samples were collected 
simultaneously in duplicate at T
480
, T
495
 and T
510
 min. i.e. at 120, 135, and 150 
min, after priming and starting the tracer infusion. Indirect calorimetry 
(Deltatrac metabolic monitor; Datex, Helsinki, Finland) was performed to 
measure CO
2
 production. Patients were not allowed to eat during the isotope 
studies, but noncaloric beverages were permitted.
Figure 2. Schematic diagram of the PTO study protocol. Arrowheads denote time points of 
blood and breath sampling during automated  peritoneal dialysis (0 to 510 min)
0 360
Dialysis AAG or G
Primed constant infusion of
L-[1-13 C]leucine
510 min
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Diet
A renal dietician instructed the patients on how to complete a 4 d food diary. 
On these food records and a subsequent dietary interview, the patient’s habitual 
dietary intake was determined. A balanced diet was designed, isonitrogenous 
and isocaloric to the prestudy habitual diet. Meals were prepared and deep-
frozen in the Erasmus MC according to the prescription of the dietitian. The 
patients took nothing but this food during days 3 through 7 of each period. The 
patients recorded all food intake in the diaries.
NB Studies
On day 3 of each week, patients started the individually tailored diets and 
continued them until the end of day 7. During day 5, 6, and 7, all dialysate and 
all urine produced per 24 h period were collected. On the daily patients visits, 
the research nurse delivered the hospital-prepared food, supervised the study 
procedures, checked for changes in body weight, and returned to the hospital all 
collected materials (urine, spent dialysate) and the remaining food of the previous 
day. The dietitian weighed the remaining food to calculate its protein and energy 
content. An aliquot of every collection was stored at -20 °C until later analysis.
Analytical Determination
Dialysate and urine nitrogen content were determined by a continuous 
flow elemental analyzer (Carlo Erba NC-1500; Interscience BV, Breda, the 
Netherlands). In brief, triplicate samples are weighed in tin containers, freeze-
dried, and combusted at 1020°C; the resulting nitrogen gas is measured. This is 
an automation of the Dumas combustion method.26
Leucine carbon flux was calculated from the 13C enrichment of KIC.27  In brief, 
the sample was deproteinized with sulfosalicylic acid and the supernatant was put 
on a cation exchange column to isolate the AA. The effluent that contained the KIC 
was reacted with phenylene-diamine to form quinoxalinols. These derivatives were 
extracted with a mixture of dichloromethane/hexane, dried, and silylated with 
N-methyl-N-(tert-butyldimethylsilyl)-trifluoracetamide. The 13C enrichment was 
determined by gas chromatography-mass spectrometry by measuring the fragments 
259 and 260 of natural and 13C KIC, respectively. Gas chromatography-mass 
spectrometry analyses were carried out on a Carlo Erba GC8000 gas chromatograph 
coupled to a Fisons MD800 mass spectrometer (Interscience BV) by injecting 1 μl 
of test material with a split ratio of 50:1 on a 25-m x 0.22-mm fused silica capillary 
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column, coated with 0.11μm of HT5 (SGE, Victoria, Australia). Oxidation of L-[1-
13C]leucine was determined by measuring breath CO
2  
13C- enrichment (Automatic 
Breath Carbon Analyser; Europa Scientific, Crewe, Great Britain).
Blood Chemistries
Fasting blood samples were taken before the morning exchange, before the 
study, at the end of each study period, and at the start of WBPT studies. Serum 
urea, creatinine, phosphate, albumin, G, bicarbonate (standardized at 40 mm 
Hg), insulin, glucagon, as well as 24 h dialysate contents of urea and protein 
were measured by routine laboratory procedures. Insulin was measured by 
a chemiluminescent immunometric assay (Immulite 2000 Insulin; DPC, Los 
Angeles, CA). Glucagon was measured by means of a radioimmunochemical 
method (Eurodiagnostics, Apeldoorn, the Netherlands).
Calculations of NB
The classical NB was calculated, with the equation N
bal
 = N
in
 – N
out
. Then, the 
mean of the 3 study days was calculated. The supply of nitrogen (N
in
) consisted 
of the sum of the calculated daily dietary nitrogen intake and the dialysate 
nitrogen content (i.e., nitrogen in the infused dialysate). The loss of nitrogen 
(N
out
) included the measured nitrogen content of all peritoneal drainage fluid 
and the urinary nitrogen losses. For fecal and integumental nitrogen losses, fixed 
values of 1.5 and 0.5 g/d, respectively, were assumed. The differences between 
the study periods were evaluated by subtracting the NB on G from that on AAG. 
No correction was made of the NB for potential changes in the body urea-N pool. 
To convert the results of the NB (g of N/24 h) to its protein equivalent (g protein 
/24 h), it was assumed that 1 g of N corresponds to 6.25 g of protein.
Calculations of Whole-Body Protein Turnover
Leucine carbon flux was calculated as described previously.25  Leucine carbon 
flux (Q) is equal to the sum of endogenous leucine appearance from protein 
breakdown (B) plus exogenous leucine appearance via oral intake and via dialysate 
(I). At metabolic equilibrium (steady state), Q is also equal to the sum of leucine 
disappearance into body proteins (S) plus leucine oxidation (O). Therefore, Q = S 
+ O = B + I. Leucine flux in μmol/ kg per hr is calculated as Q = Inf (E
i
/E
plasma KIC 
-1), 
where Inf is the leucine infusion rate (μmol/ kg per hr), E
i
 is the 13C enrichment of the 
L-[1-13 C]leucine infused, and E
KIC
 is the 13C enrichment of plasma KIC as measured 
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at isotopic equilibrium. Isotopic steady state (plateau plasma 13KIC enrichment) 
was assumed between T
480 
and T
510 min
. Leucine oxidation (O, in μmol/kg per hr) is 
calculated as O = F13CO
2
 (1/E
KIC
-1/E
i
) x 100, where F13CO
2
 (in µmol 13C/kg per hr) is 
the rate of expired 13CO
2
 calculated from CO
2 
13C enrichment in expired air and from 
CO
2  
production. Leucine absorption from dialysate was calculated by subtracting 
the amount of leucine in spent dialysate from that in fresh dialysate.
Statistical analysis
Data were analyzed using the statistical program SPSS, version 10.0, for Windows 
(SPSS Inc., Chicago, IL). Data are expressed as mean ± SD. The paired t test was 
used to compare differences between the two treatment regimens (AAG versus 
G dialysis) after verifying that there were no significant carryover or period 
effects. All tests of significance were two sided, and differences were considered 
statistically significant at P < 0.05.
Results
Table 1 shows the baseline characteristics of the eight patients, three of whom 
were anuric. Apart from the use of medications that are taken regularly by PD 
patients, patient 4, 5, and 7 used prednisone in a dose of 5, 7.5, and 2.5 mg/d, 
respectively. The treatment protocol was performed easily and well tolerated by 
all patients. There were no complaints of loss of appetite or nausea, and there 
were no other adverse reactions reported during the use of AA-containing 
dialysis fluid. None of the patients dropped out of the study.
WBPT
During dialysis with AAG, protein synthesis increased (1.20 ± 0.4 versus 1.10 ± 0.2 
µmol leucine/ kg per min; mean difference 0.10 ± 0.31 µmol leucine/kg per min; 
NS) and protein breakdown decreased (1.60 ± 0.5 versus 1.72 ± 0.3 µmol leucine/
kg per min; mean difference 0.11 ± 0.30 µmol leucine/kg per min; NS) compared 
with the use of G. Net protein balance (S minus B) was negative in all patients 
(fasting state conditions). With the use of the AAG mixture, net protein balance 
was invariably less negative by a mean of 0.21 ± 0.12 µmol leucine/kg per min (P = 
0.001) compared with G dialysis in all patients. The oxidation of leucine remained 
unchanged also during the supply of AA (Table 2). Net peritoneal absorption of 
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AA was approximately 47% of infused AA. The amount of [13C]leucine lost into the 
dialysate was not significantly different between AAG and G (<1 % of the dose).
As shown in Figure 3, isotopic steady state was reached in the time frame 
in which sampling was done (T
480 
- T
510
). The gain through change in net protein 
balance (0.21 µmol leucine / kg per min) during the 8.5 h of dialysis can be 
expressed as grams of protein by taking a molecular weight of 131 for leucine, and 
assuming a leucine content of muscle protein of 7.8%. There was no significant 
treatment period interaction for the WBPT studies (P = 0.71)
0
2
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8
10
time (minutes) a fter p rimin g
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C -
M
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.  
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.  
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Figure 3. Plateau in plasma 13C-keto-isocaproic acid (KIC) enrichment during PTO study. 13C-KIC 
values (mean ± SD) in eight patients in moles percent excess(MPE).  , AAG;  , G dialysis.
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Energy and Protein Intake
The pre-study (i.e., habitual) dietary protein intake was 0.9 ± 0.2 g/kg per d; 
only one of the eight patients had an intake of 1.2 g protein/kg per d. Also, 
dietary energy intake was low 21.1 ± 6.2 kcal /kg per d. The pre-study calorie 
supply via peritoneal dialysate was estimated to be approximately 5.6 ± 3.0 
kcal/kg per d. The prescribed diet contained on average 0.9 ± 0.2 g protein/kg 
per d and 22.1 ± 5.5 kcal/kg per d. During the NB energy intake, including G 
absorbed from dialysate was 25.4 ± 7.0 kcal/kg per d with the AAG dialysate 
versus 27.0 ± 6.7 kcal/kg per d with the G dialysate (P = 0.10, NS) . Protein intake 
calculated as the sum of protein from diet and AA absorbed from dialysate (on 
average 47%) was 1.0 ± 0.2 g/kg per d on AAG and 0.85 ± 0.2.g/kg per d on G 
dialysis (P = 0.002).
NB
 Mean values of nitrogen balance were + 0.35 ± 3.25 and - 0.60 ± 2.38 gN/24h 
(mean ± SD) for AAG and G, respectively (Table 3). The strongly negative values 
in both series in one patient (nr 6) are primarily responsible for the large SD. 
In six patients, NB improved with the AAG compared with G solution, whereas 
in two patients NB showed a slight decline with AA-based dialysis. Overall, 
the difference in NB with AAG compared to G dialysis was 0.96 ± 1.2 g of 
N/24 h (P = 0.061, NS), corresponding to 6.0 ± 7.6 g of protein/d. There were no 
appreciable changes in body weight in any patient. There was no significant 
treatment period interaction for NB measurements (P = 0.36).
Biochemical Parameters
As shown in Table 4, mean serum concentrations of creatinine and urea did 
not show a statistically significant difference at the end of either study period. 
Phosphate levels were significantly lower after treatment with AAG compared 
with G dialysate. Mean serum venous bicarbonate concentrations before to 
the study were in the (low) normal range. After treatment with AAG dialysate, 
serum bicarbonate concentrations showed a slight and statistically significant 
decreased compared with G dialysate. Mean serum levels of albumin and glucose 
remained unchanged. Mean fasting insulin and glucagon were not significant 
different at the end of both study periods. The total excretion of urea in dialysate 
and urine during AAG dialysis did not show a significant difference compared 
with G dialysis. Losses of protein via dialysate were not different.
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Discussion
Our results show that combined intraperitoneal administration of AA and 
G improves protein anabolism in APD patients. Recently, the importance of 
supplying calories simultaneously with intraperitoneal AA to stimulate protein 
metabolism, was demonstrated in CAPD patients.22  In that daytime study, 
calories were taken orally. However, poor appetite may restrain patients from 
ingesting enough food including calories. Giving AAG as dialysate during 
regular APD would be a practical approach.
We found that protein synthesis increased and breakdown decreased during 
AAG dialysis. Although neither component attained statistical significance, net 
protein balance (i.e., synthesis minus breakdown) during AAG dialysis improved 
in all APD patients.
This is the first study to measure WBPT during AAG dialysis. A previous 
daytime study that involved CAPD patients and used an automated cycler 
showed an increase in muscle protein turnover,24  whereas a similar study 
performed during one night in children, showed an increase in AA levels without 
concomitant rise in blood urea nitrogen levels.23
Table 4. Serum biochemistry before study and at the end of each study perioda
Prestudy
End AAG
Dialysis Period
End G
Dialysis Period
Bicarbonate (mmol/L) 22.8 ± 2.2b 24.5  ± 1.7c 26.3 ± 1.0
Urea (mmol/L) 22.7 ± 7.1 21.1  ± 4.1 21.1 ± 5.1
Creatinine (µmol/L) 915 ± 251 878  ± 242 770 ± 237
Phosphate (mmol/L) 2.0 ± 0.4 1.9 ± 0.6d 2.1 ± 0.4
Albumin (g/L) 38  ± 3.0 38  ± 3.0 39 ± 3.0
Glucose (mmol/L) 4.4  ± 0.6 4.2  ± 0.5 4.6 ± 1.0
Insulin (mU/L) 32.1 ± 9.9 37.0  ± 10.9 37.8 ± 11.6
Glucagon (ng/L) 67.9 ± 21.7 71.4  ± 46.5 72.3 ± 31.4
Dialysate urea (mmol/24h) ND 264  ± 85 247 ± 71
Dialysate protein (g/24h) ND 7.5  ± 3.2 6.8 ± 2.6
aData are mean ± SD. ND, not determined.
bP = 0.022 versus G
cP = 0.005 versus G.
dP = 0.04 versus G.
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Anorexia is an important factor in the development of malnutrition.28  In 
our patients,  we noticed a low habitual dietary energy intake and a mean daily 
protein intake below the Kidney Disease Outcomes Quality Initiative-advised 
1.2 g of N/kg per d. In only one patient were Kidney Disease Outcomes Quality 
Initiative standards actually met. We did not notice any interference of the AA 
dialysis with appetite or daily food intake. The clinical relevance of the increase 
in net protein balance (0.21 µmol / kg per min) can be appreciated when one 
calculates that during 8.5 h of dialysis with AAG mixture, a 70 kg person would 
gain an average of 13 g of body protein. We supplied 27 g of AA during the 
night, approximately 47% of which was absorbed. This suggests that virtually 
all of the absorbed AA were utilized for protein synthesis. This gain in protein 
exceeds the usual 24 h protein and AA losses via dialysate.10  A stimulatory effect 
of intraperitoneal AA on protein synthesis was also found previously.22  The 
slow rate of AA supply in our study (27 g during 8.5 h) might explain the small 
increase in protein synthesis rate. In Delarue’s study, the additional supply of 
oral calories simultaneously with AA dialysate induced a decrease in protein 
breakdown, probably mediated through insulin secretion.16,22,23,29
Our study suggests, that combining AA with the G solution inhibits protein 
breakdown and stimulates protein synthesis. Human feeding experiments have 
shown that AA augment the insulin-mediated inhibition of protein degradation 
in addition to stimulating protein synthesis. Such an inhibitory effect of AA levels 
on endogenous AA appearance minimizes oxidation and maximizes protein 
utilization.30,31 Our study does not take into account retention of peritoneally 
absorbed leucine in the splanchnic bed during AA dialysis. Ignoring splanchnic 
retention may have resulted in overestimation of the entry rate of absorbed 
leucine in the plasma pool (i.e., exogenous leucine appearance) and thereby in 
underestimation of protein breakdown (i.e., endogenous leucine appearance) 
as the latter is calculated as flux (Q) minus exogenous appearance. A reliable 
assessment of splanchnic sequestration of AA (leucine) is difficult, and values 
of 10 to 40% have been reported.22,30 However, even if a value as high as 40% for 
splanchnic retention had been present with AA dialysis, the net protein balance 
observed in our study would still have improved in all patients.
The improvements in protein anabolism during nocturnal APD are 
acute effects in the fasting state. The results of the 24 h NB studies suggest an 
improvement in nitrogen retention with the AAG mixture; however, this change 
was not statistically significant (P = 0.061). We performed the classical NB (N
bal
 = 
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N
in 
- N
out
), which describes changes over time in body nitrogen content. Whether 
a positive balance indicates a gain in body protein, or an increase in another 
nitrogenous compound, such as urea, cannot be judged from this method, as any 
change in urea N pool are not taken into account. However, that body weight did 
not change appreciably and plasma urea at the end of each study week was not 
different from the values at the start tends to suggest that there was no increase 
in the body urea pool. Nevertheless, our results do not provide conclusive evidence 
of a gain in body protein over 24 h. Improvement in NB was reported previously in 
malnourished CAPD patients who were treated with an AA-based dialysis fluid.11
In our study, the proportion of energy and protein given via dialysate varied 
between 160 and 340 kcal/g N overnight. This suggests that some patients 
received a considerable surplus of energy in proportion to protein than is present 
in the normal West-European diet (approximately 150 to 200 kcal/g N). AA were 
given in a fixed amount of 27 gram. The variation in calorie supply resulted from 
the G concentrations in the dialysate, which were chosen to meet ultrafiltration 
targets. The best energy-to-protein ratio for optimal protein accretion is 
unknown and remains to be determined.
Various studies have reported increased urea levels with AA dialysis in CAPD 
patients.11-14  In contrast, our study showed similar plasma urea levels and urea 
excretion into dialysate in both study periods. This is in line with an effective 
utilization of the intraperitoneally administered AA. We also found a decrease in 
serum phosphate levels, suggesting a shift of phosphate toward the intracellular 
space, which is another indication that AAG dialysis induced an anabolic response.11,17 
With the use of the AAG, serum bicarbonate levels were slightly lower than on 
G dialysis but remained within the normal range. In six out of eight patients, the 
levels of serum bicarbonate were even higher than the pre-study levels; this may be 
attributable to the use of dialysis fluids that contained lower buffer concentrations 
(35 instead of 40 mmol/L) in some patients in the prestudy period. Furthermore, in 
the prestudy period, some patients performed fewer than six cycles during nightly 
dialysis. This suggests that when AA are given in a dose of 27 g in which sufficient 
amounts of buffer are also present, acidosis can be prevented.
In summary, APD with dialysate composed of a mixture of AAG improves 
protein anabolism. This finding promises an improvement of nutritional status 
of PD patients with inadequate protein intake. Studies in larger groups, especially 
in those with malnourishment, inflammation and anorexia, are needed to 
evaluate the long-term clinical relevance of this concept.
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Abstract
Inadequate food intake plays an important role in the development of 
malnutrition. Recently, an increased rate of protein anabolism was shown 
in fasting state in patients who were on automated peritoneal dialysis with 
combined amino acids (AA) and glucose (G) dialysate serving as a source of 
both proteins and calories. This study investigated the effects of such a dialysis 
procedure in the daytime in fed state in patients who were on continuous 
ambulatory peritoneal dialysis (CAPD). A crossover study was performed in 12 
CAPD patients to compare, at 7 d intervals, a mixture of AA (Nutrineal 1.1%) 
plus G (Physioneal l.36 to 3.86 %) versus G only as control dialysate. Whole-body 
protein turnover was studied by primed constant intravenous infusion of 13 C-
leucine during the 9 h dialysis. For meeting steady-state conditions during whole-
body protein turnover, frequent exchanges with a mixture of AA plus G were 
done using an automated cycler. Fed-state conditions were created by identical 
liquid hourly meals. Using AA plus G dialysate, as compared with the control, 
rates of protein synthesis increased significantly (2.02 ± 0.08 versus 1.94 ± 0.07 
µmol leucine/kg per min (mean ± SEM); P = 0.039). Rates of protein breakdown 
and net protein balance did not differ significantly between AA plus G and G. In 
conclusion, dialysate that contains AA plus G also improves protein synthesis 
in fed CAPD patients. The use of such a mixture may contribute to long-term 
improvement of the nutritional status in malnourished CAPD patients with 
deficient food intake.
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Introduction
Many patients who are on peritoneal dialysis (PD) develop protein-energy 
malnutrition.1,2  Inflammation, acidosis, insulin resistance, insufficient intake of 
proteins and calories as a result of anorexia, and peritoneal losses of proteins 
and amino acids (AA) contribute to protein-energy malnutrition.3-5  A strong 
association between malnutrition, inflammatory parameters and cardiovascular 
mortality has been reported.6-10  However, it is not understood completely how 
these factors are related causally.
Dialysate that contains AA was introduced to compensate for low protein 
intake and protein losses.11-13  The use of AA-containing dialysate was shown to 
be most effective when intraperitoneal AA were supplied simultaneously with 
sufficient oral calories.14-18  However, anorexia in continuous ambulatory PD 
(CAPD) patients prevents adequate oral intake of protein and calories. Recently, 
we showed improved protein anabolism in fasting patients who were on PD with 
dialysate that contained AA plus glucose (G).18
The daily cycle of fasting and feeding plays a key role in whole-body protein 
homeostasis. In this study, we examined the metabolic effects of AA plus G (AAG) 
dialysis in PD patients to determine whether the AAG mixture could contribute 
to protein anabolism in the fed state. This could be of clinical relevance especially 
when daily protein and calorie intake of CAPD patients is insufficient. Effects of 
AAG dialysate on protein metabolism were studied using whole-body protein 
turnover (WBPT). Because metabolic steady-state conditions are not achieved 
with a standard CAPD scheme, frequent dialysate exchanges were done using 
an automated cycler. The dialysis took place during the day while the patients 
consumed liquid food hourly in identical portions. This was a random-order 
crossover study in 12 patients to compare AAG dialysate with G dialysate as a 
control at 1 wk intervals.
Materials and Methods
Patients
Twelve CAPD patients were recruited from the PD Unit of the Erasmus Medical 
Center. Inclusion criteria called for stable patients who were on PD for >3 mo 
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and had a weekly Kt/V >1.7. Exclusion criteria were peritonitis, other infectious 
or inflammatory diseases in the previous 6 wk, malignancy, and life expectancy 
< 6 mo. The study was approved by the Medical Ethics Committee, and written 
informed consent was obtained from all patients.
Study Design 
The study was a single-center, open-label, randomized, crossover study of 
2 d with 1 wk interval to compare a dialysis scheme using either dialysate 
that contained AAG (Nutrineal 1.1% plus Physioneal 1.36% to 3.86%, Baxter 
BV, Utrecht, the Netherlands) or a control scheme that contained G only 
(Physioneal 1.36% to 3.86%). Dialysis was performed during a 9 h period 
(Figure 1). The end point of the study was WBPT. Before the study, all patients 
had a dialysis scheme of four exchanges of G-based dialysis fluid (Physioneal 
1.36% to 3.86%) in the daytime and a nighttime dwell of Physioneal1.36% to 
3.86% or Extraneal (Baxter BV). The night before the study days, all patients 
underwent dialysis with Extraneal. Patients were randomly assigned by 
drawing one of 12 sealed envelopes to determine whether patients started 
with either AAG or G on the first study day. Six patients each were allocated 
to start with AAG dialysis and G dialysis. On the 2 study days, the patients 
stayed at the Department of Nephrology of the Erasmus MC. They came at 
8.00 a.m. and they left at the end of the study after inflow of their usual nightly 
dialysate. At the end of each study day, they continued their usual dialysis 
AAG  or G dialysis
13 C Leucine infusion
  -60       0      60     240      300      360      420    180     120      540 min     480
Figure 1. Schematic diagram of the study-day protocol.  , portions of the liquid food, the first 
two portions given half-hourly and thereafter hourly;  , time points of blood sampling;  , time 
points of breath sampling.
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scheme. During the 2 study days, the patients consumed a liquid complete 
diet comparable in nitrogen and energy content to their habitual diet. In each 
patient, dietary counseling had been performed at least once per 6 mo as a 
standard practice in our department.
Subjective Global Assessment 
Subjective global assessment (SGA) as described by Detsky et al.19  is based on 
clinical parameters. Patients are classified according to their nutritional status 
into three groups: A, good nutritional status; B, moderate malnutrition; or C, 
severe malnutrition.
Dialysis Procedures
Six daytime exchanges were performed automatically using a cycler 
(HomeChoice; Baxter BV). The AAG dialysate was obtained by mixing one bag 
of 2.5 L of Nutrineal 1.1% (containing 27.5 g of AA), and four bags of 2.5 L of 
Physioneal 1.36 % to 3.86 % G. For G dialysis, five bags of 2.5 L of Physioneal 
1.36% to 3.86% were infused. G concentrations were individualized depending 
on ultrafiltration targets. The composition of the AA 1.1% dialysis solution and 
the precise mixing procedures that were required to obtain metabolic steady-
state conditions for WBPT studies were performed as described previously.18 
WBPT Studies
Rates of WBPT were determined with a primed continuous intravenous 
infusion of 13C-leucine, which was carried out at the end of the 9 h dialysis 
period between 3:30 p.m. and 6:30 p.m. At approximately 8:20 a.m., two 
catheters were inserted into superficial veins on both arms, one for continuous 
infusion of the tracer solution, the other for repeated blood sampling. 
Baseline blood samples and expiratory breath samples were collected before 
starting the oral feeding at 8:20 a.m. The dialysis started at 9:30 a.m. (T
0
). At 
3:30 p.m., priming doses of L-[1-13C] leucine (3.8 µmol/kg) and of NaH13CO
3 
(1.7 μmol/kg) were given to label the leucine and CO
2
 pools, followed by a 
continuous infusion of L-[1-13C] leucine (infusion rate 0.063 µmol/kg per 
min) and continued for 180 min until the end of the dialysis period at 6:30 
p.m. (T
540
). For measurement of plateau plasma keto-isocaproic acid (KIC) 
and CO
2 
13C enrichment, blood and expired air samples were collected 
simultaneously at T
480,
 T
510
, T
525
 and T
540
 min. (i.e., at 120, 150, 165 and 180 
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min) after priming and starting the tracer infusion. Indirect calorimetry 
(Deltatrac metabolic monitor; Datex, Helsinki, Finland) was performed 
to measure CO
2
 production. Patients were not allowed to eat except their 
liquid diet during the whole study day; however, noncaloric beverages were 
permitted.
Liquid Diet
A renal dietician instructed the patients to keep a 4 d food diary. On the basis 
of these food records and a subsequent dietary interview, the appropriate 
calorie and protein content of the study diet was calculated. The prescribed 
study diet consisted of a combination of two commercially available complete 
liquid nutritional products (Nutridrink and Fortimel; Nutricia, Zoetermeer, the 
Netherlands). The total food volume was divided into 11 equal portions. The 
first two meal portions were given at half-hourly intervals, and the remaining 
nine portions were given at hourly interval thereafter (Figure 1).
Analytical Determination
Leucine carbon flux was calculated from the 13C enrichment of KIC as 
described previously.18,20 In brief, the 13C enrichment was determined by gas 
chromatography-mass spectrometry by measuring the fragments 259 and 260 of 
natural- and 13C-KIC, respectively. Oxidation of L-[1-13C]leucine was determined 
by measurement of breath CO
2 
13C enrichment.
Blood Chemistries
Blood samples were taken before the first dialysate exchange (fasting state) 
and at the end of the study days. Insulin was measured by a chemiluminescent 
immunometric assay (Immulite 2000 Insulin; DPC, Los Angeles, CA). The other 
determinations were performed by routine laboratory procedures.
Calculations of WBPT
Metabolic leucine carbon flux was calculated as described previously.21 On the 
basis of the one-pool model at equilibrium, leucine carbon flux (Q) is equal to 
the sum of endogenous leucine appearance from protein breakdown (B) plus 
exogenous leucine appearance through oral intake (I
o
) and via dialysate (I
d
). 
At metabolic equilibrium, Q also is equal to the sum of leucine disappearance 
into body proteins (S) plus leucine oxidation (O). Thus, Q = S + O = B + I
o
 + 
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I
d
. Plasma KIC enrichment provides a better estimate of intracellular leucine 
enrichment than does plasma leucine enrichment because KIC is derived from 
intracellular leucine metabolism.20 Leucine flux in μmol/kg per hr is calculated 
as Q = Inf (E
i 
/ E
plasma KIC 
-1), where Inf is the leucine infusion rate (μmol/kg per 
hr), E
i
 is the 13C enrichment of the L-[1-13C]leucine infused, and E
KIC
 is the 13C 
enrichment of plasma KIC as measured at isotopic equilibrium. Isotopic steady 
state (plateau plasma 13KIC enrichment) was found between T
480 
and T
540 min
. 
Leucine oxidation (O; μmol/kg per hr) is calculated as O = F13CO2 (1/E
KIC
-1/E
i
) 
x 100, where F13CO
2
 (in µmol 13C/kg per hr) is the rate at which 13CO2 is expired 
as calculated from CO
2 
13C enrichment in expired air and from CO
2 
production. 
Leucine absorption from dialysate (I
d
) was calculated by subtracting the 
amount of leucine in spent dialysate from that in fresh dialysate. Loss of 
leucine (L
d
) in G dialysate was included in the total rate of disappearance of 
leucine. Thus, during G dialysis, Q = B + I
o 
= S + O + L
d
. During AAG dialysis, 
Q = B + I
o
+ I
d 
= S + O. A fraction of 0.25 of absorbed leucine was assumed for 
the retention in the splanchnicus bed.22   This correction factor was applied for 
leucine both from diet and dialysate. A fraction of 0.32 was assumed for the 
oxidation of leucine taken up by the splanchnic region.22  Therefore, leucine 
fluxes and rates of whole-body protein synthesis and breakdown corrected for 
splanchnic uptake were calculated as follows: Q
c
 = measured flux + (I
o
+ I
d
) 
x 0.25, where Q
c
 is corrected flux. The corrected oxidation (O
c
) = measured 
oxidation + [(I
o
+ I
d
) x 0.25] x 0.32. The corrected protein synthesis = Q
c
 - O
c
. 
The corrected breakdown B
c
 = Q
c
- (I
o
+ I
d
).
Statistical Analyses
Data were analyzed using the statistical program SPSS, version 11.0, for Windows 
(SPSS Inc., Chicago, IL). Data are expressed as mean ± SEM or indicated 
otherwise. The paired t test was used to compare differences between the two 
treatment regimens (AAG versus G dialysis). This comparison also was done in 
the subgroup of malnourished patients. The unpaired t test was used to compare 
differences regarding protein synthesis, protein breakdown and net protein 
balance between the present fed state study and the previous published fasting 
state study. Differences were considered statistically significant when the two-
sided P value was < 0.05.
Power-calculations, based on our previous study.18 had led to 12 patients for 
this crossover study.
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Results
The baseline characteristics of the 12 patients are shown on Table 1. Three 
patients (1, 3, and 5) were anuric, whereas most of the other patients had a 
substantial residual renal function. According to the SGA classification in this 
study, four out of the 12 patients were moderately malnourished. None of the 
patients used prednisone. The study protocol was well tolerated by all patients. 
No complaints of nausea or other adverse reactions were reported during the 
AAG dialysis. None of the patients dropped out of the study.
WBPT 
Essential conditions for measuring WBPT were met as shown in Figures 2 and 
3, showing that isotopic steady state in plasma 13C-KIC and exhaled breath 13CO
2 
was reached within the time frame of sampling (T
480 
to T
540 
). There was a slight 
increase in breath 13CO
2
 enrichment on feeding with liquid food. However, a new 
steady state was reached before sampling for analytical purposes was started 
(Figure 3). In this study, we measured that net peritoneal absorption of leucine 
was 39.3 ± SD 7.1% of the supplied amount.
Protein turnover results in Table 2 show that the leucine flux with AAG 
mixture was increased compared with G dialysis (2.90 ± 0.13 versus 2.67 ± 0.11 
µmol leucine/kg per min; mean difference 0.23 ± 0.05 µmol leucine/kg per 
min; P = 0.001). Leucine oxidation increased significantly with AAG dialysate 
compared with G dialysate (0.88 ± 0.06 versus 0.74 ± 0.06 µmol leucine/kg per 
min, mean difference 0.14 ± 0.02 µmol leucine/kg per min; P < 0.001). Protein 
synthesis increased significantly with the mixture (2.02 ± 0.08 versus 1.94 ± 
0.07 µmol leucine/kg per min; mean difference 0.08 ± 0.04 µmol leucine/kg per 
min; P = 0.039). Overall, net protein balance was not significantly increased 
using AAG dialysate compared with G dialysate (mean difference 0.03 ± 0.03 
µmol leucine/kg per min, P = 0.347). There also were no significant differences 
regarding protein breakdown (P = 0.346).
Within the subgroup of malnourished patients (Table 1, SGA classification 
B, n = 4), the net protein balance with AAG was significantly higher than with 
G dialysis (mean difference 0.13 ± 0.02 µmol leucine/kg per min; P = 0.0063). 
This difference was significantly higher (unpaired t test P = 0.0058) than the 
corresponding value in the group of eight well-nourished patients (difference 
-0.02 ± 0.03 µmol leucine/kg per min).
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Protein and Energy Intake
Table 1 shows the average prestudy (i.e., habitual) dietary protein and calorie 
intake estimates based on a dietary interview and 4 d food records. The 
proportion of dietary energy and protein varied between 107 and 157 kcal /gN 
(mean 141 kcal/gN). The liquid food contained on average 0.96 ± 0.2 g protein/kg 
per d and 22 ± 5.0 kcal/kg per d, which was consumed completely and was well 
tolerated in all patients. The proportion of dialysate energy and protein ranged 
from 124 to 243 kcal/gN (mean 161 kcal/gN).
Biochemical Parameters
As shown in Table 3, serum bicarbonate, creatinine, urea, G, and insulin 
concentrations did not show a statistically significant difference between 
AAG and G dialysis. Insulin levels significantly increased during both AAG 
and G dialysis as compared with fasting baseline conditions. During dialysis, 
serum creatinine decreased. Mean plasma leucine concentrations were 
significantly increased with AAG compared with G dialysate (P = 0.003). 
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Figure 2. Plateau 13C-ketoisocaproic acid (KIC) enrichment during whole-body protein turnover 
(WBPT) study. 13C-KIC values (mean ± SD) in 12 patients in moles percent excess (MPE). , 
amino acids plus glucose (AAG) dialysis; , glucose dialysis.
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The loss of leucine into dialysate during G dialysis was 0.65 ± 0.11 µmol/L. 
Protein loss and excretion of urea in dialysate did not differ with either type 
of dialysate.
Discussion
Recently, we reported that intraperitoneal administration of calories combined 
with AA to fasting automated peritoneal dialysis patients as part of their regular 
nightly dialysis scheme improved protein anabolism.18  In this study, we investigated 
whether AAG dialysate could serve as a useful extra supply of nutrients to CAPD 
patients in a fed state, considering that many of these patients have deficient 
Figure 3. The course of the breath 13CO
2
 levels during consumption of the liquid meals and during the 
WBPT study with AAG dialysate. Values (mean ± SD) in 12 patients are expressed in Atom % 13CO
2
1.080
1.085
1.090
1.095
1.100
1.105
time  (minute s ) afte r s tarting dialys is
At
om
 %
 1
3 C
O
2
-100 0 100 200 300 400 500 600
22321_tjong_V6.indd   83 17-12-2007   10:50:12
84 Chapter 4
intake of proteins and calories as a result of anorexia. WBPT studies were carried 
out in fed-state CAPD patients in the daytime using a primed constant infusion 
of a stable isotope. Instead of manual changes of dialysis fluids, AAG solutions 
frequently were exchanged using an automated cycler to achieve the steady-state 
conditions that were required for the WBPT studies.
Administration of AAG dialysate increased both leucine flux and leucine 
oxidation significantly compared with G dialysate. Although the amount of 
AA absorbed from the peritoneal cavity was small in comparison with dietary 
AA intake, there were significant metabolic effects. These metabolic responses 
are in line with other studies that reported that an increased protein supply 
stimulates both flux and oxidation. In contrast, in the fasting state,18  AAG 
dialysate did not stimulate oxidation, which agrees with studies that showed 
that low protein intake does not increase oxidation.23,24  Despite the increased 
oxidation, extra intraperitoneal AA stimulated protein synthesis significantly. 
Protein breakdown and net protein balance (i.e., synthesis minus breakdown) 
did not change significantly with AA dialysate.
Retention of absorbed leucine in the splanchnic bed may have influenced the 
results of the net protein balance. Splanchnic extraction cannot be measured 
directly, and a reliable assessment is difficult. Retention of 10% to 32% of 
gut-absorbed dietary leucine has been reported.22,25-28  Little is known about 
Table 3. Serum biochemistry at baseline and at the end of dialysisa
Baseline AAG 
Dialysis
End AAG 
Dialysis
Baseline G 
Dialysis
End  G
Dialysis
Bicarbonate (mmolL) 23.7 ± 3.3 25.6 ± 3.3b 24.1 ± 3.6 25.8 ± 2.8c
Urea (mmol/L) 22.0 ± 7.6 21.8 ± 6.5 20.5 ± 7.6 20.0 ± 6.9
Creatinine (µmol/L) 841 ± 225 762 ± 213b 835 ± 240 773 ± 208b
Glucose (mmol/L)  4.8  ± 1.0 6.2 ± 2.6c 4.2 ± 1.1 5.7 ± 2.1c
Insulin (pmol/L) 134 ± 76 495 ± 339b 133 ± 86 458 ± 243b
CRP (mg/L) 12.2 ± 6.9 12.2 ± 7.8 9.1 ± 10.6 10.8 ± 13.3
Plasma leucine (µmol/L) 108 ± 17.4 198 ± 40.8b 102 ± 10.3 172 ± 37b,d
Dialysate leucine (µmol/L) ND ND ND 0.65 ± 0.11
Dialysate urea (mmol/9h) ND 174 ± 59.1 ND 163 ± 61.1
Dialysate protein (g/9h) ND  3.9 ± 2.9 ND 4.0 ± 2.8
aData are mean ± SD. CRP, C-reactive protein; ND, not determined.
bP < 0.01 and cP < 0.05 versus baseline.
dP < 0.01 versus end AAG dialysis. 
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splanchnic retention of peritoneally absorbed AA.15 We assumed a value of 25% 
for both orally and peritoneally absorbed AA.22  Assuming increasing values of 
splanchnic retention brings about that the effects of protein intake shift from 
inhibition of protein breakdown to stimulation of protein synthesis.
The peritoneal absorption of leucine, calculated as the difference between 
the amounts in fresh and spent dialysate, ranged from 29 to 51% with a dwell time 
of approximately 1 h. These values are similar to those reported elsewhere.15,17  In 
the standard CAPD procedure with a dwell time of 4 to 6 h, AA absorption is 
considerably higher.15,29,30  Plasma leucine levels increased significantly with the 
AA dialysis fluid. The higher plasma leucine levels as a result of feeding may 
have caused a slightly lower absorption rate of intraperitoneal AA as a result of a 
decreased gradient compared with the fasting state.
Calories have an inhibitory effect on protein breakdown via stimulation 
of insulin secretion, whereas AA may exert a separate and additive effect.31,32 
In this study, the intake of calories was virtually the same during AAG and G 
dialysis. Intraperitoneal AA did not lead uniformly to lower protein degradation; 
neither was it associated with a different insulin response.
Comparing the results of this and previous published study18  in similar 
patients, we found that protein synthesis rates were significantly higher in the 
fed state as compared with the fasting state with both AAG and G dialysis. 
The synthesis rates (mean values in µmol leucine/kg per min) using AAG 
dialysate were 2.02 (fed state; n = 12) as compared with 1.20 (fasting state;  n 
= 8; P < 0.001) and using G only dialysate were 1.94 (fed state; n = 12) versus 
1.10 (fasting state; n = 8; P < 0.001). Protein breakdown did not significantly 
differ in response to feeding between the two studies with both AAG and G 
dialysis. This suggests that ingested protein was used mainly for stimulation 
of protein synthesis. That G-containing dialysate has been found to inhibit 
protein breakdown in fasting patients through moderate hyperinsulinemia 
may explain why feeding did not inhibit proteolysis further.16  Net protein 
balance was negative during fasting but became positive in all patients who 
were taking oral food, as also has been demonstrated in healthy people and 
hemodialysis patients. 23,33
Giving dialysis fluid that contains a mixture of AA and G guarantees 
simultaneous supply of both protein and calories when oral intake of proteins 
and calories is deficient in anorectic CAPD patients. In this study, most patients 
were not malnourished according to the SGA classification.
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In a subgroup analysis, we compared the results of WBPT in the four 
malnourished patients (SGA-B) with the eight well-nourished ones (SGA-A). 
In malnourished patients, the AAG dialysate showed a statistically significant 
increase in net protein balance compared with the G dialysate. This suggests that 
the nutritional state may play a role in the metabolic effects of AAG dialysis.
This study is the first to examine the metabolic effects of AA absorbed from 
AAG-containing dialysate on WBPT in fed CAPD patients. The results represent 
acute effects that were obtained in a relatively well-nourished and stable CAPD 
population. Further work is needed to evaluate the metabolic effects of AAG 
dialysate in the presence of inflammation or in malnourished patients.
In conclusion, even in a fed state, dialysis solutions that contain AAG 
improve protein synthesis in CAPD patients. These solutions could function as 
a nutritional supplement and may help to improve the nutritional state in CAPD 
patients with deficient intake of both proteins and calories. For assessment of 
the long-term effects on nutritional status, morbidity, and mortality in different 
subgroups, studies in a large number of patients are needed.
Acknowledgements
This study was supported by grants from Baxter Benelux. 
We thank the patients for participation and Laurens J. van Dijk, PD nurse, 
Adorée M. van der Wiel, dietitian, and Marja Belder, nurse, for cooperation in 
the study.
22321_tjong_V6.indd   86 17-12-2007   10:50:16
87Dialysate as supplementary food
References
1.  Kopple JD. McCollum Award Lecture, 1996: protein-energy malnutrition in maintenance 
dialysis patients. Am J Clin Nutr 1997; 65: 1544-1557.
2.  Young GA, Kopple JD, Lindholm B, Vonesh EF, De Vecchi A, Scalamogna A, Castelnova C, 
Oreopoulos DG, Anderson GH, Bergström J, DiChiro J, Gentile D, Nissenson A, Sakhrani 
L, Brownjohn AM, Nolph KD, Prowant BF, Algrim CE, Martis L, Serkes KD. Nutritional 
assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am 
J Kidney Dis 1991; 17: 462-471.
3.  Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW. Metabolic balance studies and dietary 
protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. 
Kidney Int 1982; 21: 849-861.
4.  Mitch WE, Maroni BJ. Factors causing malnutrition in patients with chronic uremia. Am J 
Kidney Dis 1999; 33: 176-179.
5.  Blumenkrantz MJ, Gahl GM, Kopple JD, Kambar AV, Jones MR, Kessel M, Coburn JW. Protein 
losses during peritoneal dialysis. Kidney Int 1981; 19: 593-602.
6.  Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex 
syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42: 864-881.
7.  Pupim LB, Caglar K, Hakim RM, Shyr Y, Ikizler TA. Uremic malnutrition is a predictor of 
death independent of inflammatory status. Kidney Int 2004; 66: 2054-2060.
8.  Mitch WE. Insights into the abnormalities of chronic renal disease attributed to malnutrition. 
J Am Soc Nephrol 2002; 13(Suppl): S22-S27.
9.  Stenvinkel P, Heimbürger O, Paultre F, Diczfalusy U, Wang T, Berglund L, Jogestrand T. Strong 
association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. 
Kidney Int 1999; 55: 1899-1911.
10.  Bergström J, Lindholm B. Malnutrition, cardiac disease, and mortality: an integrated point of 
view. Am J Kidney Dis 1998; 32: 834-841.
11.  Bruno M, Bagnis C, Marangella M, Rovera L, Cantaluppi A, Linari F. CAPD with an amino acid 
dialysis solution. A long-term, cross-over study. Kidney Int 1989; 35: 1189-1194.
12.  Chertow GM, Lazarus JM, Lyden ME, Caudry D, Nordberg P, Lowrie EG. Laboratory surrogates 
of nutritional status after administration of intraperitoneal amino acid-based solutions in 
ambulatory peritoneal dialysis patients. J Ren Nutr 1995; 5: 116-123.
13.  Jones M, Hagen T, Boyle CA, Vonesh E, Hamburger R, Charytan C, Sandroni S, Bernard D, 
Piraino B, Schreiber M, Gehr T, Fein P, Friedlander M, Burkart J, Ross D, Zimmerman S, Swartz 
R, Knight Th, Kraus A, McDonald L, Hartnett M, Weaver M, Martis L, Moran J. Treatment 
of malnutrition with 1.1 % amino acid peritoneal dialysis solution: results of a multicenter 
outpatient study. Am J Kidney Dis 1998; 32: 761-769.
14.  Kopple JD, Bernard D, Messana J, Swartz R, Bergström J, Lindholm B, Lim V, Brunori G, Leiserowitz M, 
Bier DM, Stegink LD, Martis L, Boyle CA, Serkes KD, Vonesh E, Jones MR. Treatment of malnourished 
CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47: 1148-1157.
15.  Delarue J, Maingourd C, Objois M, Pinault M, Cohen R, Couet C, Lamisse F. Effects of an amino 
acid dialysate on leucine metabolism in continuous ambulatory peritoneal dialysis patients. 
Kidney Int 1999; 56: 1934-1943.
16.  Garibotto G, Sofia A, Canepa A, Saffioti S, Sacco P, Sala MR, Dertenois L, Pastorino N, Deferrari 
G, Russo R. Acute effects of peritoneal dialysis with dialysates containing dextrose or dextrose 
and amino acids on muscle protein turnover in patients with chronic renal failure. J Am Soc 
Nephrol 2001: 12: 557-567.
22321_tjong_V6.indd   87 17-12-2007   10:50:17
88 Chapter 4
17.  Canepa A, Carrea A, Menoni S, Verrina E, Trivelli A, Gusmano R, Perfumo F. Acute effects of 
simultaneous intraperitoneal infusion of glucose and amino acids. Kidney Int 2001; 59: 1967-
1973.
18.  Tjiong HL, van den Berg JW, Wattimena JL, Rietveld T, van Dijk LJ, van der Wiel AM, van 
Egmond AM, Fieren MW, Swart R. Dialysate as Food: combined amino acid and glucose 
dialysate improves protein anabolism in renal failure patients on automated peritoneal 
dialysis. J Am Soc Nephrol 2005; 16: 1486-1493.
19.  Detsky AS, McLaughlin JR, Baker JP, Johnston N, Whittaker S, Mendelson RA, Jeejeeboy KN. 
What is subjective global assessment of nutritional status ? J Parenter Enteral Nutr 1987; 11: 
8-13.
20.  Schwenk WF, Beaufrere B, Haymond MW. Use of reciprocal pool specific activities to modal 
leucine metabolism in humans. Am J Physiol 1985; 249: E646-E650.
21.  Matthews DE, Motil KJ, Rohrbaugh DK, Burke JF, Young VR, Bier DM. Measurement of leucine 
metabolism in man from a primed, continuous infusion of L-[1-13C]leucine. Am J Physiol 1980; 
238: E473-E479.
22.  Forslund AH, Hambraeus L, Olsson RM, El-Khoury AE, Yu YM, Young VR. The 24-h whole- 
body leucine and urea kinetics at normal and high protein intakes with exercise in healthy 
adults. Am J Physiol 1998; 275: E310-E320.
23.  Gibson NR, Fereday A, Cox M, Halliday D, Pacy PJ, Millward DJ. Influence of dietary energy and 
protein on leucine kinetics during feeding in healthy adults. Am J Physiol 1996; 270: E282-E291.
24.  Pacy PJ, Price GM, Halliday D, Quevedo MR, Millward DJ. Nitrogen homeostasis in man: the 
diurnal responses of protein synthesis and degradation and amino acid oxidation to diets 
with increasing protein intakes. Clin Sci 1994; 86: 103-118.
25.  Hoerr RA, Matthews DE, Bier DM, Young VR. Leucine kinetics from [2H
3
]-and [13C]leucine 
infused simultaneously by gut and vein. Am J Physiol 1991; 260: E111-E117.
26.  Castillo L, Chapman TE, Yu YM, Ajami A, Burke JF, Young VR. Dietary arginine uptake by the 
splanchnic region in adult humans. Am J Physiol 1993; 265: E532-E539.
27.  Cayol M, Boirie Y, Rambourdin F, Prugnaud J, Gachon P, Beaufrère B, Obled C. Influence of 
protein intake on whole body and splanchnic leucine kinetics in humans. Am J Physiol 1997; 
272: E584-E591.
28.  Goodship TH, Mitch WE, Hoerr RA, Wagner DA, Steinman ThI, Young VR. Adaptation to low-
protein diets in renal failure: leucine turnover and nitrogen balance. J Am Soc Nephrol 1990; 1: 
66-75.
29.  Jones MR, Gehr TW, Burkart JM, Hamburger RJ, Kraus AP Jr, Piraino BM, Hagen T, Ogrinc FG, 
Wolfson M. Replacement of amino acid and protein losses with 1.1 % amino acid peritoneal 
dialysis solution. Perit Dial Int 1998; 18: 210-216.
30.  Goodship TH, Lloyd S, McKenzie PW, Earnshaw M, Smeaton I, Bartlett K, Ward MK, Wilkinson 
R. Short-term studies on the use of amino acids as an osmotic agent in continuous ambulatory 
peritoneal dialysis. Clin Sci 1987; 73: 471-478
31.  Castellino P, Luzi L, Simonson DC, Haymond M, DeFronzo RA. Effect of insulin and plasma 
amino acid concentrations on leucine metabolism in man. Role of substrate availability on 
estimates of whole body protein synthesis. J Clin Invest 1987; 80: 1784-1793.
32.  Volpi E, Lucidi P, Cruciani G, Monacchia F, Reboldi G, Brunetti P, Bolli GB, De Feo P. 
Contribution of amino acids and insulin to protein anabolism during meal absorption. 
Diabetes 1996; 45: 1245-1252.
33.  Veeneman JM, Kingma HA, Boer ThS, Stellaard F, De Jong PE, Reijngoud DJ, Huisman RM. 
Protein intake during hemodialysis maintains a positive whole body protein balance in 
chronic hemodialysis patients. Am J Physiol Endocrinol Metab 2003; 284: E954-E965.
22321_tjong_V6.indd   88 17-12-2007   10:50:17
Chapter 5
Albumin and whole body protein synthesis 
respond differently to intraperitoneal and 
oral amino acids
Hoey Lan Tjiong, Marien W. Fieren, Trinet Rietveld, Josias L. Wattimena, 
Henk Schierbeek, Jan G. Huijmans, Wim C. Hop, Roel Swart, 
and Jacobus W. van den Berg
Kidney Int 2007; 72: 364-369
22321_tjong_V6.indd   89 17-12-2007   10:50:18
22321_tjong_V6.indd   90 17-12-2007   10:50:18
91Amino acids on albumin and protein synthesis
Abstract
Patients with peritoneal dialysis are at risk for malnutrition and 
hypoalbuminemia, which are indicators of poor outcome. Recently, it was shown 
that dialysis solutions containing amino acids (AA) and glucose improve protein 
anabolism in peritoneal dialysis patients. We determined if the same solutions 
could increase the fractional synthetic rate of albumin along with whole-body 
protein synthesis. Changes in the fractional albumin synthesis rate reflect 
acute changes in hepatic albumin synthesis. A random-order cross-over study 
compared the effects of Nutrineal (AA source) plus Physioneal (glucose) dialysate 
with Physioneal alone dialysate. Eight patients in the overnight fasting state were 
compared to 12 patients in the daytime-fed state. Fractional albumin synthetic 
rate and whole-body protein synthesis were determined simultaneously using 
a primed-continuous infusion of L-[1-13C]leucine. Fractional albumin synthesis 
on AA plus glucose dialysis did not differ significantly from that on glucose 
alone in the fasting state or the fed state. Protein intake by itself (fed versus 
fasting) failed to induce a significant increase in the fractional synthetic rate 
of albumin. Conversely, the oral protein brought about a significant stimulation 
of whole-body protein synthesis. Our findings show that the supply of AA has 
different effects on whole-body protein synthesis and the fractional synthetic 
rate of albumin.
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Introduction
Hypoalbuminemia has been recognized as a strong predictor of increased 
risk of morbidity and mortality in peritoneal dialysis patients.1-3  Because in 
protein-energy malnutrition albumin synthesis is reduced, hypoalbuminemia 
traditionally has been attributed to poor nutritional intake.4  In terms of kinetics, 
plasma albumin level is determined by the synthetic rate, the catabolic rate plus 
external losses, and volume of distribution of albumin. Various clinical conditions 
apart from protein-energy malnutrition affect its concentrations including 
inflammatory states, volume expansion, and increased losses of albumin.5-9  In 
PD patients, considerable amounts of albumin are lost via dialysate. Plasma 
albumin concentration has been found to be a poor marker of protein-energy 
malnutrition.10  Most of the studies evaluating the acute effects of nutritional 
intervention in patients treated with PD, could not demonstrate appreciable 
alterations in the serum albumin concentration.11
Recently, we found a stimulation of protein synthesis in PD patients in the 
fasting and fed state with dialysate containing a mixture of amino acids (AA) 
plus glucose (G).12,13  Improvements in whole-body protein synthesis by supply of 
AA may be, partly, due to an increase in the fractional synthesis rate of albumin 
(FSR-albumin). Alterations in the FSR-albumin represent acute changes in 
hepatic albumin synthesis.
In this study, we analysed in PD patients whether combined AA plus G 
dialysate could increase FSR-albumin in PD patients both during the night in the 
fasting state as well as during the day in the fed state. Moreover, by comparing 
the fasting and fed state, we aimed to study the effects of food per se. Using stable 
isotope infusion technique, the FSR-albumin was measured simultaneously with 
the whole-body protein synthesis (WBPS).
Material and Methods
Patients
Eight patients with end-stage renal failure undergoing Automated Peritoneal 
Dialysis and 12 patients on Continuous Ambulatory Peritoneal Dialysis were 
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recruited from the Peritoneal Dialysis Unit of the Erasmus Medical Center. 
Inclusion criteria were for stable patients, undergoing PD for more than 3 months 
and who had a weekly Kt/V ≥ 1.7. Exclusion criteria included peritonitis, other 
infectious or inflammatory diseases in the previous 6 weeks, malignant disease, 
and life expectancy of less than 6 months. The local Medical Ethics Committee 
approved the study protocol, and written informed consent was obtained from 
all study patients. The baseline characteristics of the patients included in both 
studies are summarized in Table 1.
Table 1. Baseline characteristics of the patients in both studiesa
 Fasting-state study Fed-state study
Number of patients 8 12
Gender (M/F) 6/2 8/4
Age (year) 49.3 ± 9.8 54.8 ± 12.2
Time on PD (month) 24 ± 21 15.9 ± 19.2
BMI (kg/m2) 26 ± 3.1 26.4 ± 3.8
Kt/V 2.0 ± 0.2 2.41 ± 0.40
nPNA (g/kg/day) 0.8 ± 0.1 0.92 ± 0.24
BMI, body mass index; F, female; Kt/V, value per week; M, male; nPNA, normalized protein equivalent 
of nitrogen appearance (PD adequest 2.0, software Baxter); PD, peritoneal dialysis. 
aData are mean ± SD
Study Design
The plasma FSR-albumin study protocol was designed as an extension of 
our previous studies on the effects of peritoneal dialysis fluids containing 
AA and glucose on whole-body protein metabolism.12,13  This was an open-
label, randomized, cross-over single-centre study, comparing FSR-albumin 
using a dialysis scheme with dialysate containing AA plus G (Nutrineal©1.1% 
plus Physioneal© 1.36% to 3.86%; Baxter BV, Utrecht, the Netherlands) and 
a control solution containing only G (Physioneal© 1.36% to 3.86%). The study 
was conducted both in the fasting and fed state (Figure1) and was performed 
using an automated cycler (HomeChoice©, Baxter BV) to obtain steady-state 
condition. Each patient was studied on two separate days, with a 1 week interval. 
The patients were randomly assigned to start with AA plus G or G dialysis. The 
results  of WBPS were all derived from our previously published studies.12,13
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Dialysis Procedure 
In the fasting-state study, the dialysis procedure was performed in eight patients 
on Automated Peritoneal Dialysis during a period of 8.5 h at night. Six exchanges 
either with AA plus G or G dialysate were carried out automatically using a cycler. 
In the daytime, there were one or two exchanges with G (Dianeal 1.36% to 3.86% 
or Physioneal; Baxter BV) and/or polyglucose-containing dialysate (Extraneal, 
Baxter BV). Before the study, all Automated Peritoneal Dialysis patients used 
glucose-based dialysis fluid (Dianeal© or Physioneal©).
In the fed-state study, the dialysis procedure was carried out during a 
period of 9 h at daytime. Six exchanges either with AA plus G or G dialysate 
were performed automatically using a cycler to obtain steady-state condition 
during the WBPT study, liquid food was given in equal hourly aliquots. All 
patients used Extraneal in the night before the study. Before the study, all 
patients had a dialysis scheme of four exchanges of glucose-based dialysis 
fluid (Physioneal© 1.36% to 3.86%) during the day and a dwell of Physioneal© 
1.36% to 3.86% or Extraneal during the night. The composition of the AA 1.1% 
dialysis solution (g/L) was: histidine 0.714, isoleucine 0.850, leucine 1.020, 
lysine-HCl 0.955, methionine 0.850, phenylalanine 0.570, threonine 0.646, 
tryptophane 0.270, valine 1.393, arginine 1.071, alanine 0.951, proline 0.595, 
glycine 0.510, serine 0.510, and tyrosine 0.300. The electrolyte and buffer 
concentrations (mmol/L) were Na 132, Cl 105, Ca 1.25, Mg 0.25, and lactate 
40. The electrolyte and buffer composition (mmol/L) of the 1.36%, 2.27%, or 
3.86% G was: Na 132, Cl 95, Ca 1.25, Mg 0.25, bicarbonate 25 mmol/L, and 
lactate 15 mmol/L.
Figure 1. Schematic diagram of  the study-day protocol of the FSR-albumin in the fed state. 
 denotes portions of the liquid food,  denotes time points of blood sampling.
AA plus G  or G dialysis
13C Leucine infusion
  -60       0      60     240      300      360      420    180     120      540 min     480
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Experimental Procedures
FSR-albumin and WBPS were determined with a stable isotope technique using 
a primed continuous intravenous infusion of 13C-leucine. Priming doses of L-
[1-13C]leucine (3.8 µmol/kg) and of NaH13CO
3 
(1.7 μmol/kg) were given to label 
the leucine and CO
2
 pools, followed by a continuous infusion of L-[1-13C]leucine 
(infusion rate 0.063 µmol/kg/min). In the fasting-state study the 8.5 h dialysis 
started at 2030 hours (T
0 
). Continuous leucine infusion was given between 0230 and 
0500 hours. Blood samples and expiratory breath samples were collected at 0230 
hours (6 h
 
from the start of the dialysis, T
360
) and 30, 60, 90, 105, 120, 135, and 150 
min after priming and starting the tracer infusion at T
390
, T
420
, T
450
, T
465
, T
480, 
T
495
, and 
T
510
 min. The patients were not allowed to eat during the study. In the fed-state study, 
baseline blood samples and expiratory breath samples were collected at 0800 hours 
before starting the oral feeding. At 0830 hours oral feeding, consisting of 11 identical 
portions of a liquid complete nutritional product (Nutridrink Nutricia, Zoetermeer, 
the Netherlands) was started and was given at regular hourly intervals to meet a 
steady-state condition, except for the first three portions that were given at half hourly 
intervals to induce a fed state-steady state. Other food was not allowed. The dialysis 
started at 0930 hours. (T
0
). The constant leucine infusion was administrated during 
the last 3 h of the 9 h dialysis period, started at 1530 hours and was continued for 180 
minutes until the end of the dialysis period at 1830 hours (T
540
). Blood and expired 
air samples were simultaneously collected in duplicate at T
420,
 T
450,
 T
480,
 T
510
, T
525
 and 
T
540
 min, that is at 60, 90, 120, 150, 165, and 180 min after priming and starting the 
tracer infusion. In both part of the study noncaloric beverages were permitted.
Analytical Procedures
The plasma-free 13C leucine enrichment was calculated from the 13C enrichment of 
KIC as described previously.12,13  In brief, the 13C enrichment was determined by gas 
chromatography-mass spectrometry by measuring the fragments 259 and 260 of the 
butyldimethylsilylquinoxalinol derivatives of natural KIC and 13C KIC, respectively. 
In plasma, the measurement of 13C KIC is representative for free 13C leucine.
The enrichment of 13C leucine incorporated in albumin was analyzed as follows:
Heparinized plasma was deproteinized with TCA 20% and centrifugated. 
Ethanol absolute was then added to dissolve selectively the albumin, leaving other 
proteins as precipitate. After centrifugation of this solution, the supernatant 
containing albumin was dried and the residue was taken up in 0.3 mol/l NaOH at 37 
°C. Albumin was precipitated again from this solution with 2 mol/l HCLO
4
 and the 
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pellet was hydrolyzed in 6 mol/l HCL for 24 h at 110° C. After drying, the hydrolysate 
was purified using a cation-exchanger AG 50W-X8, 200-400 mesh, H+ form. The AA 
were eluted with 6 mol/l ammonia and converted into the ethoxycarbonyl-ethylester 
derivate (using ECF ethylchloroformate). The analysis of 13C leucine enrichment in 
the isolated albumin took place with gas chromatography-combustion interface-
isotope ratio mass spectrometry. The AA derivates were converted into the GC 
(Thermo Electron, Breda, the Netherlands) using PTV splitless injection. The 
GC contains a CP-Sil-24 CB lowbleed/MS (Varian, Middelburg, the Netherlands) 
capillary column (30m x 0.25 mm, df = 0.5 um) and subsequently column FACTOR-
four (VF-1701MS, 30m x 0.25 mm, df = 1.00 µm, Varian).
The AA derivates leaving the column were combusted online at 940° C and the 
CO
2 
was online introduced into the Delta-XP IRMS (Thermo Finnigan, Bremen, 
Germany). We measured at masses 44 and 45 for 12CO
2 
and 13CO
2
, respectively.
Blood Chemistries
In the fasting-state study, blood samples for estimation of insulin were taken 
in the fasting state before the morning exchange before the study protocol. In the 
daytime study, blood samples were collected after an overnight fast and drainage of 
dialysate (before starting with oral nutrition) and at the end of the study days. Blood 
samples were taken during the AA plus G and G only dialysis at the end of the WBPT 
study to determine plasma AA levels, both in the fasting- and fed- state study. 
Insulin was measured by a chemiluminescent immunometric assay 
(Immulite 2000 Insulin; DPC, Los Angeles, CA, USA). The AA were measured 
by ion-exchange chromatography on a Biochrome 20 amino acid analyser with 
ninhydrin detection (Biochrome, Cambridge, UK). Other determinations were 
performed according to routine laboratory procedures. 
Calculations 
WBPS was calculated from 13C KIC enrichment, 13C leucine infusion rate 
and the rate of expired 13CO
2
, as described previously.12,13  FSR-albumin is the 
fraction of the intravascular albumin pool, expressed as percentage, synthesized 
per day and was calculated as shown in the formula: FSR-albumin (%/day) = (13C 
Leucinealb) x (13C KICave)-1 x 60 x 24 x100.
13C Leucinealb is expressed as mole percent excess (MPE) change per minute of 
13C leucine incorporated in albumin. The change in albumin enrichment per min was 
calculated from the regression line using data between the start and the end of the 
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time period selected for measurements (t = 390-540 min). The plasma 13C enrichment 
of free lucine, represented by (13C KICave) was found by determining the average 13C 
KIC enrichment from the period of measurement and is expressed as MPE. 
MPE stands for mole percent excess of the isotopic-labeled molecule that 
was measured. The other numbers convert the data into percentage fractional 
synthetic rate per day.
Statistical Analyses
Data were analyzed using the statistical program SPSS, version 11.0, for 
Windows (SPSS Inc., Chicago, IL, USA). Data are expressed as mean ± SD, or 
indicated otherwise. The paired t-test was used to compare differences between 
the two treatment regimens (AA plus G versus G only dialysis) in the cross-over 
experiment. The unpaired t-test was used to compare differences regarding FSR-
albumin between the fasting- and fed-state study. Differences were considered 
statistically significant when the two-sided P-value was < 0.05.
Results
The liquid food contained on average 0.96 ± 0.2 g protein/kg/day and 22 ± 5.0 kcal/
kg/day, that was consumed completely and was well tolerated in all patients. 
In the night-time fasting and daytime-fed study, baseline serum C-reactive 
protein levels ranged from 1 to 33 mg/l (median 9.5 mg/l) and from 1 to 40 mg/l 
(median 6.0 mg/l), respectively. Baseline serum albumin was 38 ± 3.0 and 38 ± 
2.0 g/l, respectively. Baseline levels of serum bicarbonate in the fasting- and fed-
state study were 22.8 ± 2.2 and 23.7 ± 3.3 mmol/l, respectively.
As shown in Table 2 in the night-time fasting-state study, FSR-albumin 
with AA plus G dialysate was not significantly increased as compared with G 
only dialysate (mean difference: 1.0 ± S.E. 0.7%/day, P = 0.18). In the daytime-
fed state study, FSR-albumin was higher using AA plus G dialysate than with G 
only dialysate, but again, not statistically significant (mean difference: 0.6 ± S.E. 
0.4%/day, P = 0.17). FSR-albumin during G dialysis in the fed state was also not 
significantly higher than that in the fasting state (12.0 ± S.E. 0.5 versus 10.3 ± S.E. 
0.9%/day, respectively, mean difference 1.7 ± S.E. 0.9, P = 0.07).
WBPS was significantly higher in the fed state compared with the fasting 
state, both for AA plus G and G only containing solutions (Figure 2). Baseline 
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serum insulin in the fasting-state study was 32.1 ± 9.9 mU/l. In the fed-state study, 
serum insulin levels increased significantly with AA plus G dialysate (22 ± 13 mU/l 
versus 73 ± 45 mU/l, P < 0.001) or G dialysate (18 ± 11 mU/l versus 62 ± 35 mU/l, P = 
0.001) when compared with baseline values. There were no significant differences 
in insulin levels between the AA plus G and G only dialysis as reported previously.13 
As shown in Table 3, plasma AA levels and in particular the essential AA increased 
significantly during AA plus G dialysis compared with G only dialysis.
Table 2. Albumin kinetics
AAG dialysate G dialysate
FSR- albumin %/day FSR- albumin %/day
Fasting patients (N = 8)
1 11.43 10.40
2 8.11 9.71
3 16.22 13.21
4 12.46 10.23
5 9.64 7.33
6 9.34 7.44
7 11.31 9.99
8 12.00 14.18
Mean ± SD 11.37 ± 2.51 10.25 ± 2.53
Fed patients (N = 12)
1 11.46 12.26
2 13.40 12.41
3 12.91 12.19
4 9.52 9.92
5 11.83 12.28
6 11.58 12.14
7 9.32 9.74
8 14.21 14.82
9 16.41 14.25
10 12.53 10.08
11 15.43 12.11
12 12.89 12.11
Mean ± SD 12.62 ± 2.11 12.03 ± 1.55
 AAG, amino acid plus glucose; G, glucose; FSR, fractional synthesis rate of albumin.
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Table 3. Plasma AA during AAG and G dialysis in the fasting- and fed state-studya
Overnight fasting state Daytime-fed state
AAG dialysis G dialysis AAG dialysis G dialysis
Essential
Threonine 177 ± 38** 121± 28 194 ± 30** 167 ± 28
Valine 240 ± 41** 125 ± 22 357 ± 72** 260  ± 55
Methionine 18 ± 8* 9 ± 8 60 ± 15** 37 ± 14
Isoleucine 85 ± 19** 56 ± 13 110 ± 24** 90 ± 21
Leucine 132 ± 23** 110 ± 23 198 ± 41** 172 ± 37
Phenylalanine 76 ± 12** 66 ± 10 113 ± 24** 93 ± 24
Lysine 174 ± 31** 155 ± 37 197 ± 27 184 ± 33
Histidine 94 ± 10** 72 ± 10 85 ± 15** 77 ± 15
Total essentialb 995 ± 141** 715 ± 129 1314 ± 144** 1080 ± 152
Semiessential 
Tyrosine 41 ± 9 39 ± 9 96 ± 22* 89 ± 22
Cystine ND ND 14 ± 11 11 ± 7
Nonessential 
Taurine 43 ±13 45±20 30 ± 12 35 ± 27
Aspartic acid ND ND 37 ± 7 31 ± 14
Asparagine 39 ± 10 36 ± 9 70 ± 13 75 ± 15
Serine 107 ± 48 76  ± 15 90 ± 18 89 ± 19
Glutamic acid 286 ± 112 284 ± 116 93 ± 55 90 ± 48
Glutamine 260 ± 107 224 ± 95 475 ± 57 481 ± 64
Glycine 382 ± 116* 328 ± 104 254 ± 70 260 ± 66
Alanine 413 ± 95* 354 ± 93 542 ± 91* 500 ± 107
Citrulline 105 ± 28** 90 ± 30 90 ± 27 90 ± 22
Ornithine 61 ± 13** 49  ± 15 70 ± 11** 60 ± 12
Arginine 127 ± 29** 101 ± 29 94 ± 16* 84 ± 14
Proline 290 ± 43** 240 ± 42 622 ± 117* 574 ± 112
Total non 
essentialc
2111 ± 233** 1827 ± 239 2465 ± 243* 2369 ± 254
Total AAd 3148 ± 344** 2581 ± 356 3890 ± 349** 3550 ± 381
AA, amino acid; AAG, amino acid and glucose; G, glucose; ND, not determined.
aData are expressed as mean ± SD in µmol/L. 
bCalculated as the sum of threonine, valine, methionine, isoleucine, leucine, phenylalanine, lysine, and 
histidine. cCalculated as the sum of taurine, aspartic acid, asparagine, serine, glutamic acid, glutamine, 
glycine, alanine, citrulline, ornithine, arginine,and proline. dCalculated as the sum of total essential AA 
and total nonessential AA with tyrosine (overnight fasting- state study) and with cystine and tyrosine 
(daytime fed state study). *P < 0.05 versus G dialysis; **P < 0.01 versus G dialysis.
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Figure 2. Whole-body protein synthesis during fasting and fed state.  glucose (G) dialysate 
and  amino acid (AA) plus glucose dialysate.
Discussion
Recently, we showed an acute anabolic effect of AA plus G-based dialysis solutions 
in PD patients in the fasting and fed state12,13  In this study, we investigated the 
influence of such dialysis solutions on the FSR-albumin in PD patients. We 
found that FSR-albumin values were similar to those obtained in one previous 
study in Continuous Ambulatory Peritoneal Dialysis patients.8  We did not find 
a statistically significant increase in FSR-albumin with combined AA plus G 
dialysate compared to G only dialysate in either the fasting or in the fed state. In 
contrast, in several reported experimental and human studies it was found that 
albumin synthesis increased in response to proteins or AA supplementation.14,15. 
In a recent study in seven hemodialysis patients, FSR-albumin increased in 
response to Intra Dialytic Parenteral Nutrition.16  In this study, 11 g of AA were 
given per hour of dialysis time. In our studies, about 3 g of AA per hour of dialysis 
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were administered. Taking into account that about 40-50% of the supplied AA 
was absorbed, 1.6 g AA per hour of dialysis was given. In our study, the failure to 
demonstrate a significant effect on FSR-albumin may be due to the low amount of 
AA given. However, even an oral protein intake of 8 g per hour on average did not 
bring about a statistically significant increase in FSR-albumin, as shown when 
the corresponding results of the fasting- and the fed-state study are compared. 
When comparing fasting and fed state in PD patients, it is important to realize 
that a moderate hyperinsulinemia is present even in fasting PD patients through 
the continuous flow of glucose via dialysis solutions.17  Various experimental and 
human studies provide ample evidence that in addition to substrate availability, 
insulin has a stimulating effect on hepatic albumin synthesis.18-20  In previously 
reported studies, the effects of nutrition were assessed by comparison with a 
true fasting state.14,15  This suggests that the increase in albumin synthesis as 
found in those studies after a meal containing both protein and carbohydrates 
could, in part be due to increased insulin secretion. One may speculate that in 
our studies in fasting PD patients using G only dialysate, albumin synthesis was 
already stimulated via insulin, so that supply of intraperitoneal or oral AA did 
not induce a significantly further increase of FSR-albumin. 
It is certainly possible that an even higher protein intake could have resulted 
in a significant increase of FSR-albumin. Yet the effects on FSR-albumin contrast 
markedly with the substantially increase in WBPS, demonstrating a differential 
effect of food on the synthesis rates of albumin and whole-body proteins. WBPS 
reflects the sum of protein synthesis rates of all tissues and, in particular, of 
muscle and liver, which together account for the major part of WBPS. Using the 
forearm perfusion method it has been shown in PD patients that availability of 
AA promotes skeletal muscle protein synthesis, whereas insulin has an inhibitory 
effect on muscle protein breakdown.17  As muscle protein synthesis contributes 
substantially to WBPS, the stimulating effect of AA on WBPS may be attributed 
to a large extent to increased muscle protein synthesis. Protein has also been 
shown to stimulate hepatic albumin synthesis. In malnutrition and protein-
depleted conditions in humans and animals, albumin synthesis was found to be 
depressed, whereas protein repletion resulted in a prompt recovery.21- 23  In these 
studies, energy intake was kept constant in the protein-depleted and protein-
replenished conditions clearly indicating that proteins and AA modulate 
albumin synthesis. In postoperative patients, intravenous administration 
of AA and energy each was found to stimulate albumin synthesis.24  In many 
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studies, however, it is not possible to distinguish the effects of insulin and AA. 
Moreover, the comparison of studies is complicated by marked differences 
in patient characteristics, such as the presence or absence of inflammatory 
conditions,1,25  and in design including the composition and the route of nutrient 
administration, time frame, and measurement of albumin synthesis rate. In an 
animal study for example, it was found that the stimulating effect of insulin on 
albumin synthesis was blunted because of an inhibitory effect on whole-body 
protein breakdown and AA availability.26  There is some evidence that protein 
depletion make albumin synthesis responsive to protein intake, which suggests 
that the nutritional state may play an important role in the effects of proteins 
and calories on albumin synthesis.25,27  On the other and, in healthy subjects with 
a good nutritional status, albumin synthesis was also found to be stimulated 
after a meal.14,15  In another study in healthy humans, albumin synthesis rates 
were not found to be responsive to short-term intravenous nutrients, suggesting 
that the route of administration may also play a role.28
In this study, albumin synthesis was assessed by estimation of the FSR-
albumin using stable isotope infusion technique. With this method, enrichment 
of α-ketoisocaproic acid (KIC) in plasma is measured after infusion with labeled 
leucine. Other methods include determination of mRNA or the enrichment of 
liver aminoacyl-tRNA, the direct precursor of albumin synthesis.26  For these 
techniques and for the determination of total liver protein synthesis as well, 
hepatic tissue samples are required. Plasma KIC enrichment has been proven 
to be a reliable surrogate measure of leucyl-tRNA in liver.26  The contribution of 
albumin synthesis to total liver protein synthesis is estimated at about 15%.29 
Different effects of insulin on the fractional synthesis rates of albumin and 
another liver protein fibrinogen have been found in several studies.15,18  
This is the first study in PD patients to compare the effects of supplementation 
of intraperitoneal AA or food on albumin synthesis with those on whole-body 
protein metabolism. We found that the significant improvements in WBPS were 
not accompanied by a parallel increase of albumin synthesis. Such a discrepancy 
is consistent with the finding that the regulation of albumin synthesis is 
different from that of skeletal muscles and various other hepatic proteins such 
as fibrinogen. It is worth mentioning that plasma AA, mainly the essential 
AA, increased significantly with both intraperitoneal and oral AA supply. It 
has been reported that essential AA, in particular, the branched chain AA, are 
responsible for the stimulation of muscle protein anabolism by AA.30-32  Our 
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study was conducted in a small, relatively stable and well-nourished population 
free of liver diseases33  or acidosis,34  and without clinical signs of inflammation. 
In addition, the fact that the fasting patients were not in a true fasting state may 
have complicated the interpretation of the results. Further work including PD 
patients in a true fasting state are needed to evaluate the effects of AA plus G 
containing dialysis solutions in various clinical conditions such as inflammation 
and malnutrition.
Acknowledgements
This study was supported by grants from Baxter Benelux. The authors thank the 
patients for their participation and van Dijk LJ and Kahriman D, PD nurses, van 
Egmond AM, van der Wiel AM, and van der Steen J, dieticians, and Belder M, 
nurse, for their cooperation in the studies. We appreciate the assistance from W. 
Cairo-Rowling for amino acid measurements.
 
22321_tjong_V6.indd   103 17-12-2007   10:50:28
104 Chapter 5
References
1.  Kaysen GA. Biological basis of hypoalbuminemia in ESRD. J Am Soc Nephrol 1998; 9: 2368-
2376.
2.  Blake PG, Flowerdew G, Blake RM, Oreopoulos DG. Serum albumin in patients on continuous 
ambulatory peritoneal dialysis-predictors and correlations with outcomes. J Am Soc Nephrol 
1993; 3: 1501-1507.
3.  Spiegel DM, Breyer JA. Serum albumin: a predictor of long-term outcome in peritoneal dialysis 
patients. Am J Kidney Dis 1994; 23: 283-285.
4.  Kopple JD. Effect of nutrition on morbidity and mortality in maintenance dialysis patients. 
Am J Kidney Dis 1994; 24: 1002-1009.
5. Yeun JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 
1998; 32(Suppl 4): S118-S125.
6.  Kaysen GA, Schoenfeld PY. Albumin homeostasis in patients undergoing continuous 
ambulatory peritoneal dialysis. Kidney Int 1984; 25: 107-114.
7.  Blumenkrantz MJ, Gahl GM, Kopple JD, Kamdar AV, Jones MR, Kessel M, Coburn JW. Protein 
losses during peritoneal dialysis. Kidney Int 1981; 19: 593-602.
8.  Prinsen BHCMT, Rabelink TJ, Beutler JJ, Kaysen GA, De Boer J, Boer WH, Hagen EC, Berger R, 
De Sain-Van der Velden MG. Increased albumin and fibrinogen synthesis rate in patients with 
chronic renal failure. Kidney Int 2003; 64: 1495-1504.
9. Kalantar-Zadeh K, Block G, McAllister CJ, Humphreys MH, Kopple D. Appetite and 
inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin 
Nutr 2004; 80: 299-307.
10.  Jones CH, Newstead CG, Will EJ, Smye SW, Davison AM. Assessment of nutritional status 
in CAPD patients: serum albumin is not a useful measure. Nephrol Dial Transplant 1997; 12: 
1406-1413.
11.  Karlawish J, Craiq RM, Koretz R. The effect of total parenteral nutrition on serum albumin. 
J Clin Gastroenterol 1994; 19: 300-302.
12.  Tjiong HL, van den Berg JW, Wattimena JL, Rietveld T, van Dijk LJ, van der Wiel AM, van 
Egmond AM, Fieren MW, Swart R. Dialysate as Food: combined amino acid and glucose 
dialysate improves protein anabolism in renal failure patients on automated peritoneal 
dialysis. J Am Soc Nephrol 2005; 16: 1486-1493.
13  Tjiong HL, Rietveld T, Wattimena JL , van den Berg JW, Kahriman D, van der Steen J, Hop 
WC, Swart R, and Fieren MW. Peritoneal dialysis with solutions containing amino acids plus 
glucose promotes protein synthesis during oral feeding. Clin J Am Soc Nephrol 2007; 2: 74-80.
14.  Hunter KA, Ballmer PE, Anderson SE, Broom J, Garlick PJ, McNurlan MA. Acute stimulation 
of albumin synthesis rate with oral meal feeding in healthy subjects measured with [ring- 
2H
5
]phenylalanine. Clin Sci 1995; 88: 235-242.
15.  De Feo P, Horber FF, Haymond MW. Meal stimulation of albumin synthesis: a significant 
contributor to whole body protein synthesis in humans. Am J Physiol 1992; 263: E794-E799.
16.  Pupim LB, Flakoll PJ, Ikizler TA. Nutritional supplementation acutely increases albumin 
fractional synthetic rate in chronic hemodialysis patients. J Am Soc Nephrol 2004; 15: 1920-
1926.
17.  Garibotto G, Sofia A, Canepa A, Saffioti S, Sacco P, Sala MR, Dertenois L, Pastorino N, Defferrari 
G, Russo R. Acute effects of peritoneal dialysis with dialysates containing dextrose or dextrose 
and amino acids on muscle protein turnover in patients with chronic renal failure. J Am Soc 
Nephrol 2001; 12: 557-567.
22321_tjong_V6.indd   104 17-12-2007   10:50:29
105Amino acids on albumin and protein synthesis
18.  De Feo P, Gaisano MG, Haymond MW. Differential effects of insulin deficiency on albumin 
and fibrinogen synthesis in humans. J Clin Invest 1991; 88: 833-840.
19.  Flaim KE, Hutson SM, Lloyd CE, Taylor JM, Shiman R, Jefferson LS. Direct effect of insulin on 
albumin gene expression in primary cultures of rat hepatocytes.  Am J Physiol 1985; 249: E447-
E453.
20.  Volpi E, Lucidi P, Cruciani G, Monacchia F, Rebold G, Brunetti P, Bolli GB, De Feo P. 
Contribution of amino acids and insulin to protein anabolism during meal absorption. 
Diabetes 1996; 45: 1245-1252.
21.  Kirsch R, Frith L, Black E, Hoffenberg R. Regulation of albumin synthesis and catabolism 
alteration of dietary protein. Nature 1968; 217: 578-579.
22.  James WPT, Hay AM. Albumin metabolism: effect of the nutritional state and the dietary 
protein intake. J Clin Inves 1968; 47: 1958-1972.
23.  Morgan EH, Peters T. The biosynthesis of rat serum albumin. J Biol Chem 1971; 246: 3500-
3507.
24.  Skillman JJ, Rosenoer VM, Smith PC, Fang MS. Improved albumin synthesis in postoperative 
patients by amino acid infusion. New Engl J Med 1976; 295: 1037-1040.
25.  Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales LM, Levin NW. Relationships 
among inflammation nutrition and physiologic mechanism establishing albumin levels in 
hemodialysis patients. Kidney Int 2002; 61: 2240-2249.
26.  Ahlman B, Charlton M, Fu A, Berg C, O’Brien P, Nair KS. Insulin’s effect on synthesis rates of 
liver proteins. A swine model comparing various precursors of protein synthesis. Diabetes 
2001; 50: 947-954.
27.  Gersovitz M, Munro HN, Udall J, Young VR. Albumin synthesis in young and elderly subjects 
using a new stable isotope methodology: response to level of protein intake. Metabolism 1980; 
29: 1075-1086.
28.  Ballmer PE, McNurlan MA, Essen P, Anderson SE, Garlick PJ. Albumin synthesis rates 
measured with [2H
5
ring]phenylalanine are not responsive to short-term intravenous nutrients 
in healthy humans. J Nutr 1995; 125: 512-519.
 29.  Barle H, Nyberg B, Essen P, Andersson K, McNurlan MA, Wernerman J, Garlick PJ. The 
synthesis rates of total liver protein and plasma albumin determined simultaneously in vivo 
in humans. Hepatology 1997; 25: 154-158.
30.  Raj DSC, Oladipo A, Lim S. Amino acid and protein kinetics in renal failure: an integrated 
approach. Semin Nephrol 2005; 26: 158-166.
 31.  Raj DSC, Adeniyi O, Dominic EA, Boivin MA, McClelland S, Tzamaloukas AH, Morgan N, 
Gonzales L, Wolfe R, Ferrando A. Amino acid repletion does not decrease muscle protein 
catabolism during hemodialysis. Am J Physiol Endocrinol Metab 2007; 292: E1534-E1542.
32.  Volpi E, Kobayashi H, Sheffield-Moore M, Mittendorfer B, Wolfe RR. Essential amino acids are 
primarily responsible for the amino acid stimulation of muscle protein anabolism in healthy 
elderly adults. Am J Clin Nutr 2003; 78: 250-258.
33.  Tessari P, Barazzoni R, Kiwanuka E, Davanzo G, De Pergola G, Orlando R, Vettore M, Zanetti 
M. Impairment of albumin and whole body postprandial protein synthesis in compensated 
liver cirrhosis. Am J Physiol Endocrinol Metab 2002; 282: E304-E311.
34.  Ballmer PE, McNurlan MA, Hulter HN, Anderson SE, Garlick PJ, Krapf R. Chronic metabolic 
acidosis decreases albumin synthesis and induces negative nitrogen balance in humans. J Clin 
Invest 1995; 95: 39-45.
22321_tjong_V6.indd   105 17-12-2007   10:50:30
22321_tjong_V6.indd   106 17-12-2007   10:50:30
Chapter 6
Whole-body protein turnover in peritoneal 
dialysis patients: a comparison of the 
[15N]glycine end-product and the 
L-[1-13C]leucine precursor methods
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Abstract 
Two well-described methods for measuring whole body protein turnover 
(WBPT) are the precursor method using a primed continuous infusion of [1-
13C]leucine and the end-product method with a single oral dose of [15N]glycine. 
We previously measured the effects of amino acid (AA) containing dialysate on 
protein anabolism in patients undergoing continuous ambulatory peritoneal 
dialysis (CAPD) using the [1-13C]leucine technique. Here, we examine whether 
the less invasive [15N]glycine-method could also be appropriate for studying 
nutritional interventions.
We compared the results of WBPT measurements using a single oral dose of 
[15N]glycine with those obtained with the primed continuous infusion of [1-
13C]leucine during AA plus glucose (G) dialysis and glucose-only dialysis in 
twelve CAPD patients in the fed state.
The end-product method showed a wide variation for protein synthesis and 
breakdown measurements. It did not detect a small but significant increase in 
protein synthesis with AA containing dialysate shown by the precursor method. 
However, a significant relation was found between both methods for net protein 
synthesis (i.e., protein synthesis minus breakdown) during AA plus G (r = 0.75, 
P = 0.005) or during G only dialysis (r = 0.86, P < 0.001). The agreement between 
the two methods for the net protein balance was good (Intracclass correlation 
coefficient (ICC) = 0.88) with G-only dialysate and moderate (ICC 0.70) with AA 
plus G dialysate. In conclusion, while the precursor method shows less variation, 
the more convenient end-product method may be useful in larger groups of 
selected patients including those on peritoneal dialysis.
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Introduction
Stable isotope-labeled tracers have been used extensively to study whole-body 
protein turnover (WBPT) in humans.1 Both [1-13C]leucine as primed continuous 
infusion and [15N]glycine as single oral dose are validated and commonly used 
techniques for measuring WBPT in humans.2-6  In recent years, leucine is the most 
frequently used amino acid (AA). [1-13C]leucine given as a primed continuous 
infusion has been considered the reference tracer method for measuring WBPT.7 
However, this method requires a complex study protocol, the taking of several 
blood and breath samples, and cannot be performed in an outpatient setting.8 
Another method to measure WBPT is the end-product method using a single 
oral dose of [15N]glycine, which was introduced by Waterlow.9,10  Due to its less 
invasive character, studies can be repeated in an outpatient setting without much 
discomfort to the patient, and it has been shown to be suitable for evaluating 
WBPT in a variety of conditions.11-18  The end-product method is an attractive 
method for evaluating the acute and chronic effect of nutritional interventions 
on WBPT. To our knowledge no studies have been reported comparing the end-
product method with the precursor method to measure WBPT in patients on 
peritoneal dialysis (PD). Therefore we studied WBPT in patients on continuous 
ambulatory PD (CAPD) in the fed state using the precursor method with a primed 
continuous infusion of [1-13C]leucine and the end-product method using a single 
oral dose of [15N]glycine. The two methods were simultaneously applied and were 
compared during dialysis with amino acids (AA) plus glucose (G) containing 
solutions (AAG) and during dialysis with G-only solutions. The present report is 
focused on comparing the results obtained with the two isotope methods. In our 
previous publications,19,20  we discussed the clinical implications based on the 
[1- 13C]leucine precursor method, which is considered the ‘gold standard.’
Materials and Methods
Patients
Twelve CAPD patients were recruited from the Peritoneal Dialysis Unit of the 
Erasmus MC. Inclusion criteria called for stable patients, on PD for more than 3 
months and a weekly Kt/V above 1.7. Exclusion criteria were peritonitis, other 
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infectious or inflammatory diseases in the previous 6 weeks, malignancy and a 
life expectancy of less than 6 months. The Medical Ethics Committee approved 
the study and written informed consent was obtained from all patients.
Study Design 
Previously we performed an open-label, randomized, crossover study on 2 d with a 
6 d interval comparing the effect of AAG dialysate (one bag of 2.5 L Nutrineal 1.1%, 
containing 27 g AA, mixed with 4 bags of 2.5 L Physioneal 1.36% to 3.86%, Baxter 
BV, Utrecht, the Netherlands, depending on ultrafiltration targets) with a control 
dialysate containing only G (5 bags of 2.5 L Physioneal 1.36% to 3.86% individualized 
per patient depending on ultrafiltration targets). WBPT was measured using the 
precursor method with a primed continuous infusion of [1-13C]leucine.
In the present publication we compared the end-product method using an oral 
single dose of [15N]glycine with the precursor method to measure WBPT during 
a 9h dialysis with AAG versus G-only dialysis in CAPD patients in the fed state 
(Figure 1). Frequent exchanges were carried out with an automated cycler, because 
metabolic steady-state conditions are required for WBPT using [1-13C]leucine, and 
these are not achieved with a conventional CAPD scheme. The dialysis took place 
during the day while the patients consumed a liquid complete diet, isonitrogeneous 
and isocaloric to their habitual diet, based on food records and a dietary interview. 
The total food intake was divided into 11 identical portions. The first two portions 
AAG  or G dialysis
13
C leucine infusion
 -60       0    60 240      300      360      420180     120 540 min  480
Collection of dialysate and urine
oral 
13
N- glycine
Figure 1. Schematic diagram of the study-day protocol.  denotes portions of the liquid food, 
the first two portions given half hourly and thereafter hourly.  denotes time points of blood 
sampling and  breath sampling.     
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were given at half hourly intervals and the remaining nine portions at hourly 
intervals to provide metabolic steady state conditions. Patients were randomized 
to start with AAG or G on the first day by drawing one of twelve sealed envelopes. 
On the 2 study days the patients stayed in the Department of Nephrology of the 
Erasmus MC during the 9 h study period entering at 8.00 a.m. and leaving at the 
end of the study and after filling the abdomen with their usual nightly dialysate. 
Patients were not allowed to eat anything except their liquid diet during the whole 
study, but non-caloric fluids were permitted.
WBPT using a primed continuous infusion of  [1-13C]leucine
On the two study days, rates of WBPT during 9 h daytime dialysis and oral 
feeding were determined with a primed continuous intravenous infusion of 
[1-13C]leucine, which was carried out during the last three hours of the dialysis 
period. To measure plateau plasma keto-isocaproic acid (KIC)21 and CO
2 
13C 
enrichment, blood and expired air samples were simultaneously collected at 
appropriate time points. Indirect calorimetry (Deltatrac metabolic monitor, 
Datex, Finland) was performed to measure CO
2
 production (VCO
2
). 
WBPT using a single oral dose of [15N]glycine
On the two study days, rates of WBPT were studied with a single oral dose of 
[15N]glycine. At 08.00 a.m. the overnight dialysis fluid was drained and ‘dry’ body 
weight was measured using a chair wheel weight (Seca Corp. Scale, USA). At 8.30 
a.m. a catheter was inserted into a superficial vein. Blood samples were collected 
for baseline 15N-urea values. Oral liquid nutrition was then started. After emptying 
the bladder all voided urine was collected and blood samples were taken. At 9.30 
a.m. (T
0
) 200 mg 15N of glycine dissolved in 50 ml water was given orally and dialysis 
was started, which ended at 6.30 p.m. 15N urea was determined in collected drained 
dialysate, plasma and all voided urine during the 9 h study period.
Analytical Determinations and Calculations
The WBPT based on [15N]glycine as a single oral dose was calculated according 
to Waterlow.10 Because of the very low amount of ammonia in the dialysate, only 
the end-product 15N urea was used for the analysis. Any traces of free ammonia 
were previously removed. Urea in plasma, dialysate and urine was converted 
by urease to ammonia and the formed ammonia was trapped in KHSO
4 
by 
the Conway diffusion method. Collected ammoniumsulphate was combusted 
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in an elemental analyzer (Carlo Erba NC1500, Interscience BV, Breda, the 
Netherlands), and the effluent was led to an Isotope Ratio Mass Spectrometer 
(ABCA, Sercon LMTD, Crewe, United Kingdom) for 15N determination. Changes 
in the body urea pool were calculated from blood urea nitrogen measurements 
before (T
0
),
 
and 9 h after the start of the experiment (T
540 min
) and calculated 
using total body water as distribution volume. Flux (Q), Synthesis (S), and 
Breakdown (B) were calculated on the basis of 15N urea excretion disregarding 
the very low amount of 15N ammonia present in dialysate and the data are 
expressed as g protein /kg/9 h. The flux (Q) is the rate of nitrogen flux (grams 
of nitrogen over 9 h) and was calculated using the equation Q = d (E
d
+E
 u
+E
p  
)/
(e
d
 + e
u
+e
p
); E
d
, E
u 
and E
p 
are the amount N-urea in the dialysate, urine and the 
corrected ureapool, respectively. e
d 
, e
u 
and e
p 
are the amount
 
15N-urea in the 
dialysate, urine and the corrected ureapool, respectively; d is the amount of 
isotope administered (grams of 15N). Using calculated nitrogen (N) intake (I) 
and measured total N loss (E), the Synthesis by urea (Su), the Breakdown to urea 
(Bu) was calculated using the equation Q = I + B = S + E. 
In the precursor method the leucine carbon flux was calculated from the 
13C enrichment of ∝-ketoisocaproic acid (KIC), oxidation of L-[1-13C]leucine was 
determined by measuring breath CO
2 
13C- enrichment, and Flux (Q), Synthesis 
(S), and Breakdown (B) were calculated as previously reported.8,21  To convert 
the results of the 15Nglycine-WBPT (g of N/9 h) to its protein equivalent, it was 
assumed that 1g of N corresponds to 6.25 g of protein. The results of WBPT using 
[1-13C]leucine (μmol leucine.kg-1.min-1) are converted to its protein equivalent (g 
of protein/9 h), assuming a leucine content of 590 umol/gram protein.
Statistical Analyses
Data were analyzed using the statistical program SPSS, version 11.0, for 
Windows (SPSS Inc., Chicago, IL, USA). Data are expressed as mean ± SD, or 
indicated otherwise. The paired t-test was used to compare differences between 
the two treatment regimens (AAG versus G dialysis) with regard to leucine and 
glycine-method. The Pearson’s correlation coefficient was used to assess the 
relations between the two methods for measuring net protein synthesis during 
the two treatment regimens. Intraclass correlation coefficient (ICC) and the 
Bland and Altman method were used to assess the agreement between the two 
methods. Differences were considered statistically significant when the two-
sided P value was < 0.05. 
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Results
The baseline characteristics of the twelve patients are summarized in Table 1. 
Three patients were anuric, whereas the remaining nine patients had a mean 
residual renal function of 4.45 ± 2.16 ml.min/1.73 m2. The study protocol was well 
tolerated by all patients. The liquid diet was consumed completely. None of the 
patients dropped out of the study. The baseline weight and the weight at the end 
of G-only dialysis were 77.1 ± 13 kg and 77.3 ± 13 kg, respectively, P = 0.015. The 
baseline weight and the weight at the end of AAG dialysis were 77.5 ± 13 kg and 
77.6 ± 13 kg, respectively, NS. Serum urea concentration prior to the start and at 
the end of WBPT during G dialysis were 20.5 ± 7.6 mmol/l and 20.0 ± 6.9 mmol/l, 
respectively. Serum urea concentration before the start and at the end of WBPT 
during AAG dialysis were 22.0 ± 7.6 mmol/l and 21.8 ± 6.5 mmol/l, respectively. 
Flux and oxidation (excretion) were significantly higher using AAG compared 
with G only dialysate, both with the precursor method (P < 0.05) and the end-product 
method (P < 0.05) Using AAG protein synthesis rate was significantly higher with the 
precursor method (P < 0.03) but with the end-product method significant difference 
was not attained (P = 0.06) between AAG and G dialysate. There is a larger variation 
coefficient in the results with the [15N]glycine end-product method compared with 
the data found with the [1-13C]leucine method measuring protein synthesis and 
protein breakdown (Table 2). Both methods showed a significant relation for net 
protein synthesis (i.e., protein synthesis minus breakdown) during AA and G (r = 
0.75, P = 0.005) or during G only dialysis (r = 0.86, P = 0.000). Figure 2 shows moderate 
agreement between both methods (ICC = 0.70) during AAG dialysis. Figure 3 shows 
good agreement (ICC = 0.88) during G-only dialysis. The Bland and Altman plots 
show that for individual cases the difference between the two methods can be rather 
large and the limits of agreement are rather wide.
Table 1. Characteristics of the patientsa
Number of patients 12
Sex, m/f 8/4
Age, years 54.8 ± 12.2
BMI, wt/ht2 26.4 ± 3.8
Residual renal function, ml/min/1.73 m2 4.45 ± 2.16
Study dietary intake
protein, g/kg/day
energy, kJ/kg/day
0.96 ± 0.2
89 ± 22
aData are expressed as mean ± SD; m, male; f, female; BMI, wt/ht2, body mass index (weight/height2).
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Discussion
In this study we investigated whether the results of WBPT in patients undergoing 
CAPD, measured with the end-product method using a single oral dose of 
[15N]glycine, were comparable with those obtained with the precursor method 
with a primed continuous infusion of [1-3C]leucine.20 Both methods were applied 
simultaneously in the same patients to measure WBPT during dialysis with AAG 
solutions and during dialysis with G-only solutions. To our knowledge this is the 
first study comparing the two methods in PD patients.
The two isotope methods used in this study are based on models of 
complicated metabolic processes. Each of the models makes use of different 
assumptions and calculations.7 It has been reported that each of these methods 
gives an approximation of the true value for the process in question. These 
methods are, however, suitable for comparative studies and to detect trends in 
relative magnitude and direction of changes that might have clinical relevance.
The objective of the present publication is to compare data found for 
synthesis, breakdown, and net protein synthesis obtained with each of the two 
methods. The data are represented in Table 2. The two methods show a good 
correlation for measuring the net protein balance (i.e. protein synthesis minus 
protein breakdown) during AAG dialysis and G-only dialysis as well (Figures 2 
and 3). There is an acceptable agreement between both methods. The net protein 
synthesis can be regarded as the actual amount of protein changing in whole-body 
protein mass. Therefore these figures are most relevant for clinical practice.
Comparisons of the end-product and precursor method performed in the same 
patients at the same time are scarce and it is difficult to compare our results with 
previously performed studies in non-dialysis patients.22,23  In most of the studies in 
non-dialysis patients, the calculation of WBPT measured with [15N]glycine was based 
on the average of 15N enrichment in urinary ammonia and urea.24  Our calculations 
of WBPT were based on the method of Waterlow et al.7  However, our patients 
were treated with peritoneal dialysis because of end-stage renal failure. Therefore 
we measured 15N enrichment in urea, not in ammonia as end product present in 
dialysate, plasma and, if any, in urine. Complete collection of urine is essential for 
the calculations. The 15N enrichment of ammonia was ignored because ammonia 
was found in minute amounts in dialysate. Some patients produced a small amount 
of urine, and in them, the analysis was also based on 15N urea. In contrast to the 1-
[13C]leucine-precursor method, splanchnic retention is not taken into account in the 
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calculation of the WBPT with the [15N]glycine method. Although the efficiency of 
intestinal absorption of [15N]glycine might be less than 100%, we assumed that the 
absorption was complete because no gastrointestinal problems were present. The 
end-product method with a single oral dose of [15N]glycine gives results in calculated 
data (synthesis, breakdown) with wider variation coefficients than the precursor 
method (Table 2). One of the reasons is that patients with renal failure have a large 
urea pool in which 15N urea enrichment is measured. This might increase the error 
in its measurement. Body water content may also be abnormal in renal patients, 
and indeed more so in patients on dialysis. As body water has to be estimated in 
order to calculate the N-retention, the error in WBPT results might increase further. 
Calculations of the WBPT based on measured 15N enrichment of urea as end 
product, entail a substantial potential error in results for synthesis, breakdown, and 
net synthesis. In addition to difficulties related to renal failure peritoneal dialysis 
interferes with the end-product method in that total N(E) must be corrected for 
N in non-absorbed amino acids left behind in effluent dialysate. This interferes in 
particular with the comparison of AAG and G-only dialysis. Together these factors 
may explain why [15N]glycine method failed to detect the subtle increase of WBPS 
during AAG dialysis as found with the precursor method.
The primed continuous infusion of L-[1-13C]leucine is a widely accepted 
method for measuring WBPT in all population groups including dialysis patients 
and is considered to be the reference method.  It is, however, an invasive method, 
which needs frequent blood sampling and admission to a hospital or a metabolic 
ward. The end-product method using a single oral dose of [15N]glycine is less 
invasive and more convenient. It can be performed in an outpatient setting, and 
it is therefore more suitable for population studies. 
In conclusion, our results demonstrate that in patients treated with CAPD, 
the end-product method shows wider variation than the precursor method. 
Small, but clinically relevant differences may therefore be more difficult to 
detect with the [15N]glycine method as it has been found in this study. The basic 
assumptions differ between the two methods; especially peritoneal dialysis 
complicates the end-product method. It is noteworthy that on average the 
results with both methods were in the same order of magnitude. Furthermore, 
the level of agreement between the two methods regarding net protein synthesis 
is acceptable. While the precursor method is preferable to study whole-body 
protein turnover in small groups, the more practical end-product method is 
useful in larger groups of selected patients, including those undergoing PD. 
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Abstract 
Protein-energy malnutrition as a consequence of a poor appetite occurs frequently 
in peritoneal dialysis (PD) patients. Previously we showed that peritoneal dialysate 
containing a mixture of amino acids (AA) and glucose has anabolic effects. 
However, AA-dialysate has been reported to increase intraperitoneal protein 
and AA losses and the release of proinflammatory cytokines. We investigated 
the effect of AA plus glucose (AAG) solutions on peritoneal protein losses and 
cytokine generation. In six patients on standard automated PD (APD) twelve 
APD sessions of six cycles each were performed during the night using dialysate 
containing 1.1 %  (AA) plus  (glucose) or glucose alone as control. Protein losses 
and TNFα and IL-6 concentrations were measured in dialysates separately 
collected from nightly cycling and daytime dwell. The 24 h protein losses with 
AAG (median 6.7 g, range 4.7 to 9.4 g) were similar to control dialysate (median 
6.0 g, range 4.2 to 9.2 g). Daytime dialysate IL-6 levels were higher after nightly 
AAG dialysis than after control dialysis (142 pg/ml and 82 pg/ml respectively, 
P < 0.05). TNFα concentrations were very low. In conclusion, nightly APD with 
amino acids containing dialysate was associated with an increase in peritoneal 
IL-6 generation during the day. The addition of AA to the standard glucose 
solutions did not induce a significant increase in peritoneal protein losses.
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Introduction
One of the untoward effects of peritoneal dialysis (PD) is the loss of proteins 
and amino acids into the dialysate effluent. Patients undergoing continuous 
ambulatory PD (CAPD) lose amino acids, 2 to 4 grams a day, and a substantial 
amount of proteins, varying between 5 and 15 grams per day. The protein and AA 
losses increase during peritonitis.1-9 The continuous loss of proteins and amino 
acids through peritoneal clearance can be compensated by adequate dietary 
intake, but a poor appetite limits protein intake in many patients.10   Previously 
we showed that the gain in protein provided by supplying amino acids (AA) plus 
glucose (G) intraperitoneally exceeds the usual 24 h protein and AA losses through 
peritoneal clearance.11 However, it has been reported that AA-based dialysate may 
increase intraperitoneal protein losses, as well as stimulating the release of various 
vasoactive substances including several proinflammatory cytokines.12-15
In this study we investigated the protein losses into overnight and daytime 
dialysate effluents and changes in the levels of the cytokines TNFα and IL-6 in 
effluent and in plasma, comparing dialysate containing AA plus G (AAG) with 
glucose (G)-only solutions in patients on APD. Additionally we determined the 
peritoneal AA losses into the overnight and daytime effluents using standard 
glucose-based dialysis solution.
Patients and Methods
Patients
Six patients who had been on APD for more than 3 months and had a weekly Kt/V 
greater than 1.7 were recruited from the Peritoneal Dialysis Unit of the Erasmus 
MC. Patients who had had peritonitis or other infectious or inflammatory 
diseases in the previous 6 weeks, a malignancy or a life expectancy < 6 months 
were excluded. The Medical Ethical Committee of Erasmus MC approved the 
study and written informed consent was obtained from all patients. 
Study Design
This study was a part of our previous open label, randomized, crossover 
single center study of the effects of dialysate containing AA and G (Nutrineal 
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1.1% plus Physioneal 1.36 to 3.86% G (Baxter BV, Utrecht, the Netherlands) 
on whole body protein metabolism, compared with a control solution 
containing G alone (Physioneal 1.36% to 3.86%). Prior to the study all patients 
used standard glucose-based dialysis f luid (Dianeal or Physioneal, Baxter BV, 
Utrecht, the Netherlands). After the patients were randomized to start with 
either AAG or with G (concentration of 1.36% to 3.86% depending on the 
ultrafiltration targets) each f luid was used in two consecutive periods of 7 
d. The APD schedule for each patient before and during the study was kept 
constant.
The dialysis procedure during the study was as follows: six nighttime 
exchanges were performed automatically using a cycler (HomeChoice, Baxter 
BV, Utrecht, the Netherlands). In the daytime, all patients, except for one 
patient, used polyglucose-containing dialysate (Extraneal, Baxter BV). Two 
patients had an additional exchange with glucose dialysate (Physioneal). The 
APD schedule for each patient was similar to that used before the study in 
order to meet adequacy and ultrafiltration targets. The cycler regulated the 
mixing procedure. The composition of AA 1.1% dialysis solution has been 
described previously.11   The AA 1.1% solution contained as buffer 40 mmol/L 
lactate and the 1.36%, 2.27%, or 3.86% G-solutions 25 mmol/L bicarbonate, 
plus 15 mmol/L lactate.
 At the end of each study week after an overnight fast using either AAG or 
G-only dialysate and before the morning exchange, venous blood samples were 
taken for determination of the levels of C-reactive protein and the cytokines, 
interleukine-6 (IL-6) and tumor necrosis factor alpha (TNFα). In all six patients 
overnight and daytime dialysates were collected separately during the last 
three days of each week to determine cytokine and protein and amino acid 
concentrations.
Analytical Determinations
Blood Chemistry
Concentrations of C-reactive protein and dialysate protein were determined by 
particle-enhanced immunoturbidimetric assay in the central clinical chemistry 
laboratory of our hospital. The dialysate amino acids were analysed by ion 
exchange chromatography on a Biochrome 20 aminoacid analyser (Biochrom, 
Cambridge, UK.) with UV-Vis detection using ninhydrin. 
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Cytokines
For measurement of TNFα and IL-6, plasma and dialysis fluid samples were 
diluted 1:1 in appropriate calibrator diluent assay buffer. Cytokine assays were 
performed following the manufacturers protocol (Pelikine™ human ELISA 
compact kits for IL-6 (cat. no. M1906) and TNFα (cat. no. M1920), Sanquin, 
Amsterdam, the Netherlands). The standard curve ranges and mean calculated 
zero signal plus 3 SD for IL-6 were 0-450 pg/ml and 0.2 pg/ml, respectively; and 
for TNFα 0-1000 pg/ml and 0.5 pg/ml, respectively. The requested solutions 
were provided with the ELISA compact kits and additional toolkits (Pelikine-
ToolTM set (cat. no. M1980), Sanquin, Amsterdam, the Netherlands). Following 
the manufacturers assay instruction step-by-step, at the end of the procedure 
the absorbance per well was measured at 450 nm with a Medgenix ELISA 
reader. Sample concentrations were calculated using the appropriate standard 
calibration lines and the Softmax software of the reader.
Statistical Analyses
Data were analyzed using the statistical program SPSS, version 14.0, for Windows 
(SPSS Inc., Chicago, IL, USA). Data are expressed as median with range, or 
indicated otherwise. Comparisons of outcomes were made using the Wilcoxon 
Signed Rank test. All tests of significance were two-sided, and differences were 
considered statistically significant when the P value was < 0.05.
Results
Table 1 shows the baseline characteristics of the patients. Three patients were 
anuric. Apart from the use of medication regularly taken by PD patients, two 
patients used prednisone in a maintenance dose. Peritoneal ultrafiltration after 
administration of AAG based dialysis fluid did not differ from that with G only 
dialysate (data not shown). Serum C-reactive protein levels ranged from 6 to 
65 mg/L (median 7.5 mg/L) with AAG based dialysate and from 1 to 33 mg/L 
(median 9.5 mg/L) using G only dialysate. The protein losses per 24 h, i.e. the 
sum of daytime dwell and nightly APD with standard G solution ranged from 
4.2 to 9.2 g (median 6.0 g) were not significantly different from that occurring 
with AAG, which ranged from 4.7 to 9.4 g (median 6.7 g). No difference was 
found between the protein losses in daytime and overnight dwells with both 
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type of dialysis schemes. The appearance rate of protein losses in the overnight 
effluent was significantly higher than that in the daytime (Table 2). The mean 
total AA losses, i.e. essential AA (EAA) and non-essential AA (NEAA) per 24 h, 
i.e. the sum of daytime dwell and nightly APD with standard G solution varied 
between 1.7 and 3.2 g (median 2.2 g), and 26 ± 1.7% of effluent AA were essential 
AA. Using standard G only dialysis solution, the total AA losses in the 8.5 h 
overnight effluents were higher than in the 15.5 h daytime effluents. Likewise, 
the appearance rate of total AA losses into overnight dwells was significantly 
Table 1. Baseline characteristics of the patientsa
Patient Primary diagnose of renal disease Time on PD Gender Age BMI Kt/V PET
 (months) (years) (wt/ht2) (weekly)
1 Nephrosclerosis 14 M 57 23.9 1.95 HA
2 Reflux nephropathy 8 M 43 25.1 1.85 HA
3 Alport disease 63 M 35 25.9 1.82 H
4 Rapidly progressive 
glomerulonephitis
45 M 56 22.8 2.04 H
5 Periarteritis nodosa 5 M 47 22.1 1.76 HA
6 Polycystic disease 36 F 45 30.1 1.98 HA
Mean 29 47 25 2
SD 23 8 3 0.1
aM, male; F, female; BMI (wt/ht2), body mass index (weight/height2); PD, peritoneal dialysis; PET, 
peritoneal equilibrium test; H, high; HA, high average.
Table 2. Protein and amino acid losses in dialysis effluent in APD patientsa
Overnight Daytime
AAG dialysis(1) G dialysis(2) After AAG 
dialysis(3)
After G dialysis(4)
Protein (g/8.5h) 3.06 (2.28-3.51) 3.0 (1.84-3.99) 3.48 (2.44-6.16) 3.03 (2.17-5.54)
Protein (g/h) 0.36 (0.27-0.41) 0.35 (0.22-0.47)b 0.22 (0.16-0.40) 0.20 (0.14-0.36)
Total AA (g/8.5h) 1.47 (1.02-1.94)c 0.70 (0.62-1.25)
EAA (g/8.5 h) 0.37 (0.25-0.55)d 0.18 (0.17-0.37)
a Data are expressed as median and range; AAG, amino acid and glucose; G, glucose.
Comparisons were made for columns (2) vs (4). These resulted in significant differences for: b,c and d (P < 
0.05 versus daytime after G). No significant differences were found for columns (1) vs (2) and ((3) vs (4). 
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higher than that into daytime dwells (data not shown). The total EAA losses in 
the overnight dwell were also higher than that in daytime dwell (Table 2). The 
IL-6 levels in plasma were lower than in the effluents with both AAG and G-only 
dialysis, in particular as compared with the daytime effluent (Table 3). Dialysate 
IL-6 concentrations at daytime dwell differed significantly from overnight dwell 
during both type of dialysis schemes. The IL-6 levels in the daytime effluents 
after nightly cycling with AAG were significantly higher that that after G. Plasma 
and both overnight and daytime effluent levels of tumor necrosis factor (TNF)α 
were low using both AAG and G-only dialysis solutions.
Table 3. IL-6 and TNF-α levels in plasma and dialysatea
Overnight Daytime
Plasma
AAG (1)
Plasma
G (2)
Dialysate
AAG (3)
Dialysate
G (4)
After dialysate
AAG (5)
After dialysate
G (6)
IL-6 ( pg/ml) 13 (4-26) 13 (3-48) 21 (16-59) 17 (13-40) 142 (71-599)b,d,f 82 (51-338)c,e
IL-6 (ng) 247 (206-784) 197 (168-536) 343 (240-1613) 178 (133-872)
TNFα (pg/ml) 2 (1-52) 2 (1-49) 1 (1-1) 1(0-2) 2 (1-39) 2 (1- 5)
TNFα (ng) 15 (9-18) 14 (5-21) 5 (2-93) 5 (2-12)
aData are expressed as median and range. AAG, amino acid and glucose; G, glucose; IL-6, interleukine-6; 
TNFα, tumor necrosis factor α. Comparisons for IL-6 (pg/ml) were made for columns (1) vs (5), (2) vs (6), 
(3) vs (4), (5) vs (6), (3) vs (5), (4) vs (6) and (5) vs (6).These resulted in significant differences for b (P < 0.05 
versus plasma AAG); c (P < 0.05 versus plasma G); d (P < 0.05 versus overnight dialysate AAG); e (P < 0.05 
versus overnight dialysate G); f (P < 0.05 versus daytime after dialysate G). No significant differences were 
found for columns (1) vs (3) and (2) vs (4).
Discussion
As part of previous work on the effects of amino acids containing dialysate 
on whole body protein metabolism, we investigated in this study the loss 
of proteins in dialysate in APD patients using either the standard dialysate 
containing only glucose or a mixture of amino acids plus glucose. In addition 
we studied the effects of these dialysis fluids on the peritoneal  release of the 
cytokines IL-6 and TNFα and we investigated the losses of amino acids with 
the use of glucose-based (standard) dialysis solution. Although APD is widely 
used, the peritoneal protein losses have been studied only occasionally in adult 
patients undergoing APD.
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We found that the mean protein losses per 24 h, i.e. the sum of daytime dwell 
and nightly APD with standard glucose dialysate was on average about 6 grams, 
which is in the same order of magnitude as previously reported for CAPD patients 
by various authors.3,4  The peritoneal protein losses during 8.5 h nightly APD and 
in the daytime dwell of 15.5 h were similar. By comparison, in a recent study, 
protein losses during nightly cycling were found to be rather high, exceeding 
protein losses during the daytime dwell.16 Yet, also in our patients protein losses 
per time were higher during cycling with standard glucose solution. This may 
seem surprising as it is generally accepted that peritoneal protein losses, in 
contrast to small molecular weight solutes, are linear with time irrespective of 
the number of dialysate exchanges. It has, however, been shown in patients on 
intermittent peritoneal dialysis (IPD) that protein loss is greater during the first 
dwell after a ‘dry’ period and stabilizes at lower levels after a few exchanges. 
This finding could be explained by wash out of proteins from the previous dry 
period.17,18  Assuming a residual volume of 400-500 ml in our patients, wash out of 
proteins from the long daytime dwell could account for the difference of protein 
losses per time between day time dwell and nighttime cycling. 
In previous studies we showed that the amino acids plus glucose-containing 
dialysis fluid has anabolic effects on protein metabolism.11,19  The current study 
shows that the presence of amino acids in the dialysate did not increase protein 
loss in the overnight dialysate effluent as compared with G-only dialysis solutions 
in APD patients. Others have reported that a 2.6% amino acid peritoneal dialysis 
solution induced an increased loss of macromolecules including albumin and 
IgG and the small molecular weight amino acids, which was accompanied by 
an increased prostanoid generation in the peritoneal cavity.12 One percent  AA 
solutions were also found to stimulate  protein losses and release of prostanoids 
and several proinflammatory cytokines consistent with an increase in peritoneal 
blood flow and effective peritoneal surface area.13,14 In some studies, however, no 
significant effect on protein losses or release of prostanoids was found.20,21 
Reports on the peritoneal losses of AA in APD are scarce. In our present 
study the mean 24 h AA losses, i.e., daytime dwell and nightly APD was similar 
as earlier reported in patients who are on CAPD and somewhat higher compared 
with a previous report in APD patients, using standard G dialysis solution.1,2,16 
We found that total AA losses were greater during nightly APD than during the 
long daytime dwell with standard G-based dialysis solution. This finding is in line 
with the fact that transperitoneal transport of small molecular weight solutes 
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is dependent on the dialysate flow rate, i.e., number of dialysate exchanges. 
Approximately 26% of the effluent AA were essential AA in agreement with 
previous findings in patients on CAPD.1 
We also studied the influence of amino acid-based dialysate on cytokines 
both during the night and during the day. The levels of TNFα and IL-6 as found 
in the present study in daytime dialysate are on the whole comparable to those 
described in several studies in CAPD patients with standard glucose dialysis 
solutions during an infection-free period.13,22-24  Daytime dialysate IL-6 levels 
were significantly higher, when during the preceding nightly APD dialysate was 
used that contained amino acids instead of only glucose. This finding may be 
somewhat puzzling as during nightly cycling no statistically significant difference 
in IL-6 levels was found. It cannot be ruled out, however, that any effect of AA 
on IL-6 during cycling was diluted by rather low IL-6 concentrations as a result 
of the high dialysate flow rate. It has been shown in several studies in CAPD 
that amino acid dialysate was accompanied with increased levels of various 
cytokines including IL-6 and TNFα.13,25 There is ample evidence that even in the 
absence of peritonitis IL-6 is produced locally within the peritoneal cavity rather 
than transported across the peritoneal membrane. Our finding that IL-6 levels in 
dialysate was higher than in plasma, especially during the long daytime dwell, are 
consistent with local production and release.22,23  The main source of peritoneal 
TNF-α is thought to be the mononuclear phagocyte, whereas both mesothelial 
cells and macrophages are able to produce and release substantial amounts of 
IL-6.23,26 The release of IL-6 from mesothelial cells occurs constitutively and can 
be stimulated by macrophage-derived TNFα and IL-1β.13,23,26  In the dialysate of 
patients with PD-related peritonitis and in ascites of liver cirrhosis patients with 
spontaneous bacterial peritonitis, high levels of various cytokines including 
TNFα and IL-6 are found due to increased local production.23,26-28  In the present 
study the patients were clinically free of infection, and C-reactive protein levels 
in most of the  patients were normal or only slightly increased. Dialysate TNFα 
was very low both with the standard glucose and the amino acid and glucose 
mixture. The clinical implications of increased intraperitoneal IL-6 levels are far 
from straightforward. Any increases in levels of cytokines in dialysate in vivo may 
be interpreted as a sign of a local inflammatory stimulus or as an improvement 
of the capacity to synthesize inflammatory factors. It is therefore a matter of 
debate as to whether any changes in cytokine release should be considered as 
harmful or as a marker of improved tissue responsiveness. 
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In conclusion, our study suggests that in APD the use of dialysis fluid 
containing a mixture of amino acids and glucose induces an increase in 
peritoneal production of IL-6 without increasing protein losses as compared to 
dialysate containing only glucose. In contrast, no appreciable amounts of TNFα 
were found in peritoneal dialysate. This is the first controlled study to investigate 
the effects of amino acids containing dialysate on cytokines and protein losses. 
A limitation of this study is the small number of patients. Further studies are 
required to elucidate the relationship between amino acids containing dialysate 
and the cytokine network of the peritoneal cavity. 
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139Discussion and conclusions
This thesis was aimed at studying the concept that the nutritional state of 
patients undergoing peritoneal dialysis can be improved by dialysis with 
solutions containing amino acids as well as glucose instead of glucose only.
Assessment of the nutritional status of peritoneal dialysis patients 
It is crucial to identify peritoneal dialysis (PD) patients who are at risk of or 
suffering from malnutrition, and to treat these patients in time in order to 
prevent malnutrition-related complications. At present there is no universally 
accepted standard method available. The original three-point subjective global 
assessment (SGA) scale is a simple, reproducible method that can be carried out 
in daily practice.1  We assessed the nutritional state of thirty PD patients treated 
in our center using the SGA as originally described to identify malnourished 
surgical patients.2  We found malnutrition in 37% of our patients, and 10% of 
them were severely malnourished, which is in agreement with the literature. 
We also compared the SGA with the results of body composition measurements 
using the body mass index (BMI), four-site skinfold anthropometry (FSA), 
bioelectrical impedance analysis (BIA), and dual energy x-ray absorptiometry 
(DEXA). There is no consensus in the literature which method is the best to 
assess body composition in PD patients and each method has its own limitations. 
In particular, FSA does not work well in routine clinical practice as this method 
is not only subject to a high intra-observer and inter-observer variability, but is 
difficult to perform in obese patients.3  We found a high intraclass correlation 
coefficient (ICC) between the different methods in our study (0.90-0.94), in 
line with what has been reported previously by others.4  In males we showed a 
strong correlation between SGA and all measured objective parameters that 
discriminate the malnourished from the well-nourished patients. In female 
patients there were no significant correlations between SGA and FFM index 
measured with all three methods. The reason for this discrepancy is not 
clear, it may due to the small number of patients. SGA differs from the other 
methods in that it takes clinical findings into account and reflects changes in 
the nutritional state as developed in the preceding months, and also includes 
functional components. We also found that a cut-off value for BMI of < 23 kg/m2 
was suitable for defining malnutrition. This indicates that a normal BMI does 
not exclude malnutrition in PD patients. In part, this may be due to the higher 
visceral fat content of PD patients at a given BMI when compared with the 
normal population.5  Interestingly, we observed a strong correlation between the 
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SGA and the residual renal function. This may indicate that a decline in residual 
renal clearance plays a role in the development of malnutrition in PD patients.6,7 
In conclusion, there is a high prevalence of malnutrition in our PD population. 
SGA is a practical screening tool to assess malnutrition in PD patients.
Rational use of dialysis solution containing both amino acids and glucose
Protein deficiency is often observed in PD patients and is to a greater or lesser 
extent due to the combination of reduced intake of nutrients and loss of amino 
acids and proteins through the peritoneal membrane. Dialysis solutions 
containing amino acids (AA) have been introduced in an attempt to prevent 
and treat protein deficiency. Others have shown that simultaneous ingestion 
of calories is crucial to achieving an optimal utilization of intraperitoneal AA 
in PD patients.8  A substantial group of PD patients, however, have not only an 
inadequate intake of proteins but also of calories due to a poor appetite. The 
reduced calorie intake is partly compensated by absorption of glucose from 
the dialysate. Therefore supplying both AA and glucose (calories) in dialysate 
is a possible way to guarantee adequate nutritional intake in malnourished PD 
patients and in PD patients with inadequate food intake: a concept we have 
called ‘dialysate as food.’ To determine whether a mixture of AA plus glucose 
does indeed promote protein anabolism, we have studied the effects of this 
type of dialysate on protein turnover in both fasting and fed conditions in PD 
patients. 
Anabolic effect of combined amino acid and glucose dialysate
In eight patients on automated PD (APD) we examined the metabolic effects 
of a dialysate containing AA plus glucose by performing whole-body protein 
turnover (WBPT) studies with a primed continuous infusion of L-[1-13C]leucine 
according to the precursor. These patients dialyzed with an automated device 
(HomeChoice) during the night; therefore they were in the fasting state. The 
dialysis solutions containing both AA plus glucose (AAG) were administered 
using an automated cycler, as part of their regular dialysis schedule. Although 
neither the increase in protein synthesis nor the inhibition of protein breakdown 
attained statistical significance, the net protein synthesis (i.e. protein synthesis 
minus protein breakdown) improved significantly during dialysis with combined 
AA plus glucose solutions as compared with glucose-only solutions. This 
improvement in protein anabolism during nocturnal APD is an acute effect in 
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the fasting state. The results of the nitrogen balance (NB) studies, which reflect 
the effects of the mixture on a 24 h period, indicate an improvement in nitrogen 
retention, although this was not statistically significant. The turnover studies 
with L-[1-3C]leucine showed that virtually all AA absorbed from dialysate were 
utilized for protein synthesis, and that gain in protein exceeded the daily AA and 
protein losses into the dialysate. Our results support the concept that giving AA 
simultaneously with glucose intraperitoneally inhibits protein breakdown and 
stimulates protein synthesis. Splanchnic tissues may account for a significant 
fraction of body protein synthesis and degradation,9  but splanchnic extraction 
cannot be measured reliably. Little is known about splanchnic retention of 
peritoneally absorbed AA and a value up to 40% has been reported.8-11  In this 
study splanchnic retention of peritoneally absorbed AA was not taken into 
account. This may have resulted in overestimation of the entry rate of absorbed 
leucine in the plasma pool and thereby in underestimation of protein breakdown. 
However, even if a value as high as 40% for splanchnic retention had been used 
in calculations with AA plus G dialysis, the net protein balance found in this 
study would still have improved in all patients. The conclusion of this study is 
that APD with a dialysate composed of a mixture of AA plus glucose increases 
protein anabolism. This procedure when applied over a long-term could improve 
the nutritional status of peritoneal dialysis patients whose dietary protein and 
calorie intake is inadequate.
Considering that a substantial portion of patients undergoing continuous 
ambulatory PD (CAPD) have insufficient protein and calories intake due to 
anorexia, and that combined AA plus glucose dialysis fluids could serve as a useful 
extra supply of nutrients in CAPD patients, we evaluated the metabolic effects of 
this solution in twelve CAPD patients. In contrast to APD patients, CAPD patients 
dialyze without an automated cycler, but change their dialysate bags manually 
during the day, while they consume their regular daily meals. Since a steady-state 
metabolic condition is required for the WBPT-study with the precursor method, 
the exchanges of dialysis solutions were carried out using an automated cycler 
instead of manual exchanges, and a defined liquid complete diet comparable in 
nitrogen and energy content to their habitual diet was given at regular intervals. 
Although the amount of AA absorbed from the peritoneal cavity was small in 
comparison with oral AA intake, there were significant anabolic effects. We found 
a statistically increased protein synthesis during dialysis with combined AA 
plus glucose dialysate as compared with glucose-only dialysate. These metabolic 
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responses are in line with other studies reporting a stimulation of both flux and 
protein oxidation by an increase in protein supply.12,13  Supplying combined AA plus 
glucose intraperitoneally caused a significant increase in protein synthesis, despite 
increased protein oxidation. Protein breakdown and net protein synthesis were not 
different between AA plus glucose dialysis and glucose-only dialysis. Some of the 
absorbed AA derived from the oral feeding is sequestered in the splanchnic tissues. 
In this study splanchnic retention was taken into account. We assumed a value of 
25% for both orally and peritoneally absorbed AA.10  In contrast to the negative net 
protein synthesis during fasting in our APD study, the net protein synthesis was 
found positive in all patients who were taking oral food, a finding in agreement 
with reported studies in healthy subjects and in hemodialysis patients.12-14  When 
we compared the results of our study in the fed state with the results of our APD 
study in the fasting state, we found a significantly higher protein synthesis rate and 
net protein synthesis in the fed state as compared with the fasting state, during 
both combined AA plus glucose and glucose-only dialysis. In both studies protein 
breakdown did not significantly change in response to feeding, and this was true 
for both the combined AA plus glucose and glucose-only dialysis schedules. This 
shows that ingested protein was used mainly for increased protein synthesis. It 
has been reported that in fasting patients glucose-containing dialysis solutions 
inhibit protein breakdown as a consequence of moderate hyperinsulinemia.15  This 
may explain why, in our study, feeding did not lead to further reduction of protein 
breakdown. It should also be noted that four out of the twelve CAPD patients 
in the fed state study were clinically malnourished according to the subjective 
global assessment (SGA). When we compared the results of the WBPT in these 
four malnourished patients (SGA-B) with the eight well-nourished subjects (SGA-
A), we found a statistically significant increase in net protein synthesis with the 
combined AA plus glucose dialysate as compared to glucose-only dialysate in 
the malnourished patients. This finding suggests that the nutritional state plays 
a role in the metabolic effects of combined AA plus glucose dialysis. It lends 
further support to the proposition that the use of a dialysis solution containing 
a mixture of AA plus glucose is capable of supplying both protein and calories, 
when oral intake of proteins and calories is deficient in CAPD patients with poor 
appetite. We conclude, that even in a fed state, dialysis solutions that contain AA 
plus glucose improve protein synthesis in CAPD patients. Such solutions could 
function as a nutritional supplement and may help to improve the nutritional state 
in these patients.
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Effect of combined amino acid and glucose dialysate on the fractional 
synthesis rate of albumin and whole-body protein synthesis in PD 
patients in fasting and fed state
Several previous studies reported an increased albumin synthesis in response 
to proteins or AA supplementation.16-18  In contrast, we did not find that the 
fractional synthesis rate of albumin (FSR-albumin) increased with combined 
AA plus glucose dialysate as compared to glucose only in twelve CAPD patients 
either in the fasting or in the fed state, in spite of the significant improvements 
in whole-body protein synthesis (WBPS). Our FSR-albumin values were similar 
to those achieved in a previous study in patients on CAPD.19  When comparing 
fasting and fed state in PD patients, it should be realized that, due to the 
continuous glucose absorption from the dialysate, a moderate hyperinsulinemia 
is present even in the ‘fasting’ PD patients. Thus they are not truly in the fasting 
state. Insulin is known to have a stimulating effect on hepatic albumin synthesis 
additional to that of an increase in substrate availability.20-22  In previously 
published studies the effects of nutrition were assessed by comparison with the 
true fasting state. This implies that the increased albumin synthesis observed 
in those studies might be induced, at least in part, by an increase in insulin 
secretion. It is conceivable that, in our study of fasting PD patients, albumin 
synthesis was already stimulated by insulin, so that supplying intraperitoneal or 
oral AA could not induce a further increase in FSR-albumin. By conducting our 
studies both during the night while the patients were in the fasting state (APD) 
and during the day with the patients in the fed state (CAPD), we were able to 
examine the effects of oral food. It appeared that even the larger amount of oral 
protein intake in the fed state as compared to the fasting state, did not lead to 
a statistically significant increase in FSR-albumin. Thus neither intraperitoneal 
amino acids nor oral food induced an increase in fractional synthesis rate of 
albumin, in spite of a substantial increase of WBPS. Whole-body protein 
synthesis and FSR-albumin apparently respond differently to intraperitoneal 
and oral amino acids. This difference may well be related to region-or organ-
specific kinetics; measured whole-body protein turnover is a composite of all of 
the visceral and somatic compartments taken together.23  Others have shown in 
PD patients that availability of AA promotes skeletal muscle protein synthesis, 
whereas insulin has an inhibitory effect on muscle protein breakdown.15  As 
muscle protein synthesis contributes substantially to WBPS, the stimulating 
effect of AA on WBPS may to a large extent be attributed to increased muscle 
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protein synthesis. Our findings are therefore consistent with the notion that 
the regulation of skeletal muscle protein synthesis is different from that of the 
synthesis of albumin. It has also been reported that essential AA are mainly 
responsible for the AA-induced stimulation of muscle protein anabolism.24  We 
found that plasma AA, and in particular the essential AA, increased significantly 
with both intraperitoneal and oral AA supply. We would like to emphasize that 
our studies were conducted in a small, relatively stable population without liver 
diseases or acidosis, and without clinical signs of inflammation. The fact that PD 
patients were not in a true fasting state due to the continuous glucose absorption 
from the dialysate complicates the interpretation of the results. We conclude 
that the supply of AA has different effect on whole-body protein synthesis and 
the fractional synthesis rate of albumin in clinically stable PD patients.
Comparison between end-product and precursor methods for 
measuring whole-body protein turnover in peritoneal dialysis patients
The precursor method with a primed constant infusion of L-[1-13C]leucine is 
considered to be the reference standard for protein turnover, but is laborious to 
perform.25  There is a need for a validated, less invasive method to evaluate the 
effect of nutritional intervention on protein metabolism, which can be applied 
repeatedly in various patient populations, in different situations, and outside 
the hospital or metabolic ward. The end-product method using a single oral 
dose of [15N]glycine26  is less invasive than the L-[1-13C]leucine technique,27  is 
more convenient, and is suited to population studies in different circumstances. 
We compared both methods by applying them simultaneously to measuring 
WBPT during combined AA plus glucose dialysis and during glucose-only 
dialysis in twelve CAPD patients in the fed state. In the end-product method we 
measured the 15N enrichment of urea in dialysate as the end product of nitrogen 
(N) metabolism. In the precursor method, WBPT was calculated from the 13C 
enrichment of α-ketoisocaproic acid in plasma and the 13C enrichment in expired 
CO
2.
27,28 
  
Both methods are based on different assumptions and calculations.25  
We found that the absolute values for rates of protein synthesis and breakdown 
measured with the two methods were different. However, the calculation 
of the final outcome, i.e. the net protein synthesis (protein synthesis minus 
breakdown) during both dialysis schemes showed a good correlation between 
the two methods. In agreement with the literature, the variability within the 
group is lower with the precursor method, probably due to the more rigidly 
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standardized protocol of this method.29  We therefore conclude that the results of 
the two methods are in agreement but that for studies of relatively small groups 
of patients, the precursor method with a primed continuous infusion of L-[1-
13C]leucine is superior. The precursor method remains the reference method. 
The choice between the precursor and the end-product method will ultimately 
depend on the purpose of the study and on practical considerations. 
Effect of combined amino acids and glucose-containing dialysate 
on protein loss and cytokines generation, and amino acid loss with 
standard glucose solution in APD.
Although APD is commonly used nowadays, peritoneal protein losses have been 
studied only occasionally in adult patients undergoing APD. We reported that the 
mean protein loss per 24 h, i.e. the sum of daytime dwell and nightly APD with 
standard G was in the same order of magnitude as previously reported for CAPD 
patients by other authors.30,31  No difference was found between the peritoneal 
protein losses during 8.5 h nightly APD and 15.5 h daytime dwell. In our study 
all patients had six cycles during APD, and protein losses per time were higher 
during cycling with standard glucose solutions. Washout of proteins from the 
long daytime dwell could well account for the difference of protein losses per time 
between daytime dwell and nighttime cycling as previously suggested in patients 
on intermittent peritoneal dialysis (IPD).32,33  Studies of the effects of AA-based 
dialysis solutions on peritoneal protein losses reported inconsistent results.34-37 
The low amino acid concentrations (0.22%) we used may account for the absence 
of an effect of AA on protein losses in our study. We found that the mean AA 
loss per 24 h was similar to those reported in patients who are on CAPD and 
somewhat higher than found in a previous study in APD patients, using standard 
G dialysis solution.38-40  The total AA losses per time were greater during nightly 
APD than during the long daytime dwell with standard glucose-based dialysis 
solution in line with the transperitoneal transport of small molecular weight 
solutes. The levels of TNFα and IL-6 we found in the daytime dialysate with 
standard glucose dialysis solutions are comparable to those described in other 
studies in CAPD patients during an infection-free period.34,41,42  We also found a 
significant effect of amino acids on the intraperitoneal appearance of IL-6, in 
particular in the daytime effluent compared to standard glucose-only dialysate. 
The higher IL-6 levels in dialysate than in plasma indicate local production of 
IL-6 as previously reported by other studies in CAPD.34,43  There is evidence that 
22321_tjong_V6.indd   145 17-12-2007   10:50:51
146 Chapter 8
even in the absence of peritonitis, IL-6 is produced locally within the peritoneal 
cavity.41,42,44  Both mesothelial cells and macrophages are able to produce and 
release substantial amounts of IL-6. The release of IL-6 from mesothelial cells 
occurs constitutively and can be stimulated by macrophage-derived TNFα 
and IL-1β.34,41,44  We found very low levels plasma and dialysate levels of TNFα. 
As IL-6 is involved in immune and inflammatory responses and also has anti-
inflammatory properties, the clinical implications of increased intraperitoneal 
IL-6 levels are far from straightforward. It is a matter of debate whether any 
changes in cytokine release should be considered as harmful or as a marker of 
improved tissue responsiveness. In conclusion, in this study with a small number 
of patients, nightly APD with amino acids containing dialysate was associated 
with an increase in peritoneal  IL-6 generation during the day. Combined AA 
plus glucose dialysate did not induce a significant increase in peritoneal protein 
losses compared to dialysate containing only glucose. Peritoneal losses of amino 
acids per 24 h with standard glucose solutions were similar to those previously 
reported in CAPD.
Perspectives for future research
A larger randomized controlled (multi-center) study is warranted to evaluate 
the long-term effects of dialysis solutions containing AA plus glucose on the 
nutritional state of PD patients, and to determine whether an improvement 
in the nutritional status of PD patients is associated with a decrease in their 
mortality and morbidity and improved quality of life. 
The optimal proportions of AA plus glucose in combined diaysate have not 
yet been determined. As the amount of AA given in the studies of this thesis 
is relatively modest, the question arises whether higher doses could be given if 
dietary protein intake is far below target levels. The fact that plasma urea levels 
did not increase and bicarbonate levels only slightly decreased in our studies 
suggests that higher amounts of amino acids may be given without the risk of 
uraemic adverse effects and acidosis. Further studies are needed to investigate 
how much amino acid can be given safely. 
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Summary 
Up to 50% of uremic patients, including those treated with peritoneal dialysis 
(PD), suffer from protein and energy malnutrition (PEM). Malnutrition is 
strongly associated with an increased morbidity and mortality, in particular from 
cardiovascular diseases. Inflammation, low nutrient intake due to anorexia, and 
peritoneal losses of amino acids and proteins are important factors contributing 
to malnutrition. 
In the Introduction to the thesis, the peritoneal dialysis procedures and the 
pathogenesis of malnutrition in peritoneal dialysis (PD) patients are described. 
Methods to assess the nutritional state are mentioned. Protein and amino acid 
(AA) metabolism and the methods to measure nitrogen balance and whole-body 
protein turnover (WBPT) are outlined. The composition, the characteristics and 
the previously conducted studies of AA-based PD fluids are described and the 
aim of the thesis is put forward. The main theme is to determine whether the 
nutritional state of PD patients can be improved by modulating conventional 
PD fluid.
In chapter 2 we report a high prevalence of malnutrition in PD patients 
treated in the Erasmus MC using a clinical screening tool, the subjective global 
assessment (SGA). A good correlation was demonstrated between the original 
SGA and body composition measurements. SGA proved to be a practical 
screening tool to assess malnutrition in PD patients, BIA and DEXA, however, 
provide additional information on body composition and may be used to follow 
up changes in lean body mass or fat mass.
In chapter 3 we investigate the metabolic effects of solutions containing 
combined AA plus glucose in 8 patients on APD, given as part of their regular 
overnight dialysis scheme, as compared with glucose-only dialysate. These 
effects of the AA plus glucose containing dialysis solutions were evaluated by 
measuring WBPT with L-[1-13C]leucine. Dialysis solutions containing AA plus 
glucose improved protein anabolism in the fasting state. A prolonged anabolic 
effect of the mixture on protein metabolism could not definitely be shown by 
classical nitrogen balance studies. No intolerance of the solutions was observed. 
Administering a dialysate composed of a mixture of AA and glucose for a longer 
period might improve the nutritional status of patients treated with APD, 
whose dietary protein intake is inadequate, but this needs to be confirmed by 
prospective studies.
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In chapter 4 we studied the acute effects on the protein metabolism of 
combined AA plus glucose dialysate compared with glucose-only dialysate by 
performing WBPT study in CAPD patients in the fed state. Although the amount 
of AA absorbed from the peritoneal cavity was small in comparison with oral 
AA intake, there was a significant increase in protein synthesis with AA plus 
glucose dialysate compared with glucose only. The ingested protein was used 
mainly for stimulation of protein synthesis, while feeding did not further reduce 
protein breakdown, which was already inhibited, probably by the moderate 
hyperinsulinemia induced by glucose-containing dialysis solutions in the fasting 
state. Thus, AA administered intraperitoneally have similar anabolic effects to oral 
feeding, which lead us to call this concept ‘dialysate as food.’ In addition we showed 
that the anabolic effects of AAG dialysate are more pronounced in malnourished 
patients. Giving a dialysis solution that contains a mixture of AA plus glucose in 
addition to their daily food intake might therefore be of benefit to CAPD patients 
who are unable to meet their requirements due to a poor appetite.
In chapter 5 we showed that neither intraperitoneal amino acids nor oral 
feeding induced a significant increase in the fractional synthetis rate of albumin 
(FSR-albumin), despite of a substantial increase of WBPT. These findings indicate 
that whole-body protein synthesis (WBPS) and the FSR-albumin respond differently 
to intraperitoneal and oral AA. As suggested by previous studies, the supplied 
essential AA are probably mainly used for muscle protein synthesis rather than for 
hepatic protein synthesis in clinically stable and well-nourished PD patients. 
In chapter 6 we present the results of a comparison of the WBPT data 
measured with the end-product method with [15N]glycine with those derived 
from measurements using the precursor method with a primed constant infusion 
of L-[1-13C]leucine. Although the absolute values of the components of WBPT are 
different, the calculation of the final outcome, i.e. the net protein balance, showed a 
good correlation between both measurements. As the more strict and standardized 
protocol, the variability within the group is lower with the precursor method. At 
present the choice between the precursor and the end-product method will ultimately 
depend on the purpose of the study and on practical considerations.
In chapter 7 we reported that APD dialysis fluid containing a mixture of 
amino acids plus glucose increased intraperitoneal appearance of proinflammatory 
cytokine, IL-6, as compared with dialysate containing only glucose, but the mixture 
did not affect peritoneal protein losses. The loss of amino acids into the 24 h dialysate 
with standard glucose solutions was similar as previously reported in CAPD.
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Chapter 8 provides a discussion and the conclusions of our results in a 
broader context. The assessment of the nutrition state in our PD population and 
the significance of the tools applied in the nutritional assessment are described. 
The effects of dialysate containing AA plus glucose on whole-body protein 
metabolism in PD patients in the fasting as well as in the fed state are outlined. 
The different response of intraperitoneal and oral AA supply on the albumin 
synthesis are also discussed. The applicability of the less invasive method to 
measure WBPT in PD making use of a single oral dose of 15N glycine is discussed. 
Peritoneal protein losses and cytokines generation during APD with AA plus 
glucose-containing dialysis solutions, and the peritoneal amino acids losses 
with standard glucose solution are described.
The addition of AA to glucose-containing dialysis solutions is a promising 
approach to the long-term prevention and treatment of malnutrition in uremic 
patients undergoing peritoneal dialysis. Whether such an approach using 
dialysate as food will indeed have a beneficial effect on morbidity and mortality 
remains to be seen. Suggestions are given for future research.
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Samenvating
Tot 50% van de patiënten met chronische nierinsufficiëntie, inclusief de 
patiënten die behandeld worden met chronische peritoneale dialyse (PD), is 
ondervoed. Ondervoeding is sterk geassocieerd met een verhoogd risico op ziekte 
en overlijden, met name aan hart- en vaatziekten. Verminderde voedselinname 
als gevolg van een slechte eetlust en het verlies van eiwitten en aminozuren via 
de dialysevloeistof zijn belangrijke factoren die bijdragen aan het ontstaan van 
ondervoeding bij PD patiënten. 
In de Introductie van dit proefschrift worden de vormen van en de procedures 
bij PD beschreven, alsmede de oorzaken van ondervoeding bij PD patiënten. De 
toegepaste onderzoeksmethoden om de voedingstoestand te bepalen worden 
vermeld. De eiwit- en aminozuur stofwisseling en de methodieken om de stikstof- 
en eiwitbalans te meten worden besproken. De samenstelling en eigenschappen 
van de aminozuren (AZ)-bevattende PD vloeistoffen worden beschreven, 
alsmede eerder verrichte studies met deze oplossingen. De doelstellingen 
van dit onderzoek worden uiteengezet. Hierbij staat het verbeteren van de 
voedingstoestand van PD patiënten door middel van toevoeging van AZ aan de 
gebruikelijke glucose-bevattende PD vloeistof centraal.
In hoofdstuk 2 worden de resultaten van het onderzoek naar de prevalentie 
van ondervoeding beschreven bij patiënten die in het Erasmus MC met PD 
worden behandeld. De originele 3-puntsschaal SGA werd gebruikt om de 
voedingstoestand te beoordelen. Ook in onze PD populatie komt ondervoeding 
veelvuldig voor namelijk in 37%. Daarnaast werd gebruikgemaakt van de body 
mass index (BMI), de 4-punts huidplooimeting en van meer geavanceerde 
onderzoeksmethoden zoals de bioelectrical impedance analysis (BIA) en de 
dual energy x-ray absorptiometry (DEXA). De resultaten van deze methoden 
blijken ook in ons onderzoek goed onderling overeen te komen. De SGA 
is een betrouwbare, snelle en goedkope methode voor de beoordeling van 
de voedingstoestand van PD patiënten in de klinische praktijk. De overige 
methoden kunnen als aanvulling dienen om de voedingstoestand nader in kaart 
te brengen en zijn zinvol voor het vervolgen van de veranderingen in de spier en 
de vetmassa. 
In hoofdstuk 3 beschrijven wij de resultaten van het onderzoek naar  de 
anabole effecten van een AZ- en glucose bevattend PD-vloeistofmengsel in 8 
patienten die behandeld werden door middel van automatische PD (APD). Deze 
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patiënten werden gedialyseerd met behulp van een geautomatiseerd apparaat 
voor toediening en drainage van dialysaat. Het AZ-en glucose bevattende PD-
vloeistofmengsel werd toegediend tijdens de gebruikelijke peritoneale dialyse 
procedure ’s nachts thuis. De acute effecten op de eiwitstofwisseling werden 
bestudeerd met eiwitomzetonderzoek middels het met het stabiele isotoop 13C 
gelabelde aminozuur leucine (L-[1-13C]leucine). Om het effect over een langere 
periode te kunnen beoordelen hebben we gebruik gemaakt van de  klassieke 
stikstofbalans. Uit de resultaten blijkt dat bij het AZ- en glucose bevattende 
PD-vloeistofmengsel de netto eiwitbalans (snelheid van eiwit synthese minus 
snelheid van eiwitafbraak) significant verbetert. Een langer bestaand anabool 
effect kon op grond van de resultaten van de stikstofbalans niet met zekerheid 
worden aangetoond. Geconcludeerd wordt dat gebruik van PD-vloeistof 
bestaande uit een mengsel van AZ en glucose de voedingstoestand van PD 
patiënten, die ondervoed zijn of slecht eten, zou kunnen verbeteren. 
Een aanzienlijk deel van de PD patiënten wordt behandeld met continue 
ambulante peritoneale dialyse (CAPD). In tegenstelling tot APD-patiënten 
infunderen deze patiënten de PD-vloeistof zelf via een permanente CAPD 
katheter in de buik en ze dialyseren overdag. Om te kunnen beoordelen of 
ook CAPD patiënten baat zouden kunnen hebben van dialyse met AZ- en 
glucose bevattende PD-vloeistoffen wanneer zij tijdens de dialyse overdag hun 
maaltijden gebruiken, werd vergelijkbaar onderzoek ook bij deze patiënten 
verricht. Teneinde een evenwichtssituatie te verkrijgen hetgeen vereist is voor 
een eiwitomzetstudie, vond de dialyse tijdens deze studie plaats met behulp 
van een automatisch dialyse apparaat (cycler). Om de gevoede toestand na te 
bootsen en een evenwichtstoestand daarin te creëren, werden op gezette tijden, 
identieke porties vloeibare voeding toegediend. De resultaten zijn in hoofdstuk 4 
beschreven. Hieruit blijkt, dat de AZ- en glucose bevattende PD-vloeistof de 
eiwitsynthese stimuleert ondanks de - in vergelijking met de uit de orale voeding 
verkregen hoeveelheid - relatief geringe hoeveelheid uit dialysaat geabsorbeerde 
AZ. De geabsorbeerde AZ werden voornamelijk gebruikt voor de eiwitsynthese. 
De conclusie is dat de via de dialysevloeistof toegediende AZ een soortgelijk 
anabool effect hebben op de stofwisseling als normaal voedsel, vandaar de titel 
van de thesis ‘dialysaat als voeding.’ De eiwitafbraak werd bij de CAPD-groep 
niet geremd, dit in tegenstelling tot de APD-patiënten in de nachtelijke gevaste 
toestand, waarbij de eiwitafbraak werd geremd waarschijnlijk door stimulatie 
van de insulinesecretie als gevolg van het vanuit het dialysaat geabsorbeerde 
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glucose. Aangezien de effecten het meest uitgesproken waren bij de ondervoede 
CAPD patiënten, is de voedingstoestand vermoedelijk van belang voor het 
verkrijgen van de anabole effecten. Dialyseren met een mengsel bestaande uit 
AZ- en glucose naast het gebruik van de dagelijkse maaltijden, lijkt zinvol bij 
ondervoede danwel slecht etende CAPD patiënten. 
In hoofdstuk 5 beschrijven wij, dat noch orale voeding noch de aminozuren 
die via de dialysevloeistof werden toegediend noch de snelheid van de 
albuminesynthese stimuleerden, terwijl de totale eiwitsynthese toch duidelijk 
toenam. Dit wijst er op dat de snelheid van de albumine synthese en die van 
de totale eiwitsynthese verschillend reageren op toegediende aminozuren. 
In de literatuur wordt gesuggereerd dat bij klinisch stabiele niet ondervoede 
PD patiënten de toegediende essentiële AZ veel meer gebruikt worden voor 
de eiwitsynthese in de spier dan voor de synthese van eiwitten in de lever. 
Misschien verklaart dit waarom wij geen toename van de albumine-synthese 
hebben kunnen aantonen. 
Hoofdstuk 6 beschrijft de vergelijking tussen de eindproduktmethode met 
behulp van [15N]glycine en de voorloperproduct-methode met [L- 1-13C]leucine 
voor het meten van de eiwitomzet. De laatste methode wordt beschouwd als de 
‘gouden standaard.’ Uit de resultaten blijkt dat de [L- 1-13C]leucine gemiddeld 
nauwkeuriger- dat wil zeggen met minder spreiding binnen de patiëntengroep- 
de eiwitomzet meet dan de [15N]glycinemethode, vermoedelijk door het 
strakkere protocol. Echter beide methoden komen goed overeen in de meting 
van de netto eiwitbalans, waar het uiteindelijk omgaat bij de eiwitomzet studies. 
Onze resultaten wijzen er op, dat men voor een meer nauwkeurige analyse beter 
de [L-1-13C]leucine methode kan gebruiken voor het meten van eiwitomzet bij 
PD patiënten, als men de studie in het ziekenhuis kan uitvoeren, maar dat voor 
poliklinisch danwel veldonderzoek de glycine-methode valt te overwegen. 
In hoofdstuk 7 beschrijven wij dat tijdens dialyse met de standaard 
glucosevloeistof het eiwitverlies in het dialysaat per tijdseenheid ’s nachts (APD) 
groter is dan overdag (CAPD). Dit verschil lijkt te wijten aan de uitwas van 
eiwitten in het overgebleven dialysaat van overdag. Wij hebben geen verschil 
kunnen aantonen in het eiwitverlies in het dialysaat tijdens het gebruik van 
het AZ-en glucose bevattende PD-vloeistofmegsel in vergelijking met alleen de 
glucose bevattende PD-vloeistof. Tijdens dialyse met het AZ bevattende PD-
vloeistofmengsel zijn de concentraties van het cytokine IL-6 in het dialysaat 
hoger dan tijdens dialyse met alleen de glucose bevattende PD-vloeistof, terwijl 
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de concentraties van het cytokine tumor necrosis factor α (TNFα) laag zijn. De 
IL-6 spiegels in het dialysaat, met name overdag, zijn hoger dan in het plasma 
tijdens het gebruik van zowel het PD-vloeistofmengsel als alleen de glucose PD-
vloeistof. Dit wijst op lokale productie van IL-6. Echter de klinische betekenis 
van deze verhoogde IL-6 spiegels in het dialysaat is vooralsnog onduidelijk. In 
ieder geval heeft de toename in de IL-6 concentraties in het dialysaat niet geleid 
tot een toegenomen verlies van eiwitten in het dialysaat tijdens dialyse met de 
AZ-bevattende PD-vloeistof. Het verlies van aminozuren in het dialysaat tijdens 
APD met standaard glucose PD-vloeistof is in dezelfde orde van groottte zoals 
beschreven bij CAPD patiënten.
De discussie en de conclusies die uit de onderzoeksresultaten voortvloeien 
zijn beschreven in hoofdstuk 8. Onderzoek naar ondervoeding bij PD 
patiënten in het Erasmus MC verricht met behulp van de originele subjective 
global assessment (SGA) wordt beschreven. Verschillende methoden voor 
het meten van lichaamssamenstelling worden besproken en gerelateeerd 
aan de SGA-classificatie. Fysiologische mechanismen die betrokken zijn bij 
de eiwitomzetting in de gevaste en gevoede toestand bij PD patiënten tijdens 
dialyse met AZ en glucose bevattende PD vloeistofmengsel worden besproken. 
Op de invloed van de intraperitoneaal en via de voeding toegediende aminozuren 
op de albuminesynthese en de totale lichaamseiwitsynthese wordt uitgebreid 
ingegaan. Twee gerenommeerde methoden om met behulp van met stabiele 
isotopen gemerkte aminozuren de eiwitomzet te meten worden besproken, 
met name ook de toepasbaarheid van de minder ingrijpende methode met 15N 
glycine bij PD patiënten. Een plausibele verklaring voor het verschil tussen het 
nacht (APD) en de dag (CAPD) eiwitverlies per tijdseenheid via het dialysaat 
tijdens dialyse met de standaard glucose PD-vloeistof wordt gegeven, alsmede 
voor de produktie van cytokines in het dialysaat. Tevens wordt het verlies van 
aminozuren in het dialysaat tijdens APD met de standaard glucose beschreven. 
Tenslotte worden enkele aanbevelingen gedaan voor toekomstig onderzoek, 
dat de huidige bevindingen klinische toepasbaarheid zou kunnen geven.
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Abbreviations
AA : Amino acids
AAG : Amino acids and glucose
AZ : Aminozuren
APD : Automated peritoneal dialysis
BIA : Bioelectrical impedance analysis
BMI : Body mass index
CAPD : Continuous ambulatory peritoneal dialysis
CRF : Chronic renal failure
DEXA : Dual energy x-ray absorptiometry 
FMI : Fat mass index
FFMI : Fat free mass index
FSA : Four skin-fold anthropometry
FSR-alb : Fractional synthesis rate of albumin
G : Glucose
GFR : Glomerular filtration rate
ICC : Intraclass correlation coefficient
MIA : Malnutrition inflammation, and atheroslerosis
N : Nitrogen
PD : Peritoneal dialysis
PEM : Protein energy malnutrition
SGA : Subjective global assessment
WBPT : Whole-body protein turnover
WBPS  : Whole-body protein synthesis
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Thank you for being such a gifted educator. I learned a great deal and worked 
with much pleasure under your guidance. Thank you in particular for your faith 
in me. Though it was a long time in the making, my doctoral thesis is finally 
complete. I have never forgotten one of your sayings: ‘Hard work is the best 
method of birth control.’ I look forward to having you here on this special day. 
Prof. M.A.D.H. Schalekamp: Dear Maarten, your enthusiasm in so many 
fields, and science in particular, has always impressed me. Indeed, it has been 
contagious. As you know, I still needed your help. I continue to learn from you, 
and regret that I did not finish my research in your field of interest. You gave me 
the freedom to develop myself and to do what I wanted to do both in the area 
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of science and in the area of patient care. I thank you for everything, and am 
pleased you will be sitting in front of me when I defend my thesis. 
Dr. F. Mulder, my supervisor: Dear Fred, thank you for supervising me 
during the first and most important period of my training to be an internist. It 
was you who specifically advised me to do research. I have learned a great deal 
from you.
Colleagues of the former hypertension group (Dr. F.H.M. Derkx, Dr. G.J. 
Wenting, Dr. A.J. Man in ‘t Veld, Dr. F. Boomsma, Dr. A.H. van den Meiracker, 
and Dr. J. Deinum): Dear all, and Frans Derkx in particular, I enjoyed working 
with you all in the past. Ton and I still work together. Dear Frans, thanks you for 
all your help during my first attempts to do research. You were always willing to 
help me also in other fields – you are a real friend. Thanks for everything. 
I would also thanks to the nurses (C. Zeelenberg, J. Ouborg, E. van Vliet, 
L. Otten, L. Gantevoort, J. Kees, and Piet de Vries, among others), medical 
assistants (Inge Norbruis and Annelies v.d. Meer), chemical analysts (Adrie van 
Westen and Thea van Dam), nutritionist’s assistants (Anneke Moor and Natalie 
Gomes De Pina), and the secretaries (Rita Meyer, Denise Hennep, Edith Padberg, 
Karin van der Zwaan, Muriel Peiter, Gertrude Geilvoet, among others) during 
my training and my time as supervisor in the 3 M-unit. 
E. Maurik: Dear Ellen, thanks for all your help with taking care of my 
outpatient clinic patients and your support in many areas. 
Clinical geriatricians Dr. T. van der Cammen, K. Verschoor, Dr. J. Krulder and 
Dr. F. Mattace Raso: Dear Tischa, Kees, Jaap and Francesco, I enjoyed working 
with you all in the past in the 3 M-unit, our kingdom.
Residents in the consultative internal medicine training program: I regret I 
have had too little time to teach you all. Thank you for your kindness, support, 
understanding and all your help.
The patients, the residents in internal medicine, and the medical students 
have all played a very important in my career, that is why I dedicate my PD thesis 
to them.
Colleagues, nurses, and others, thank you all for the pleasant working 
relationship we had during my time as supervisor of consultative internal 
medicine training.
My parents: I am deeply sorry you could not be here with me today. I am 
grateful to you for the loving, carefree, and protected childhood and youth I had. 
I cannot imagine having had any parents better than you were. You gave me 
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every possibility to educate myself further and never prevented me from making 
my own choices in life. Father, I know you were passionate about knowledge and 
study, and that you wanted me to obtain my doctoral degree. Unfortunately, the 
spirit was willing but the flesh was weak. Nevertheless, I have finally fulfilled 
your desire. Above all, I dedicate this dissertation to your memory, my beloved 
parents.
My brothers and sisters: Dear Swie, Boen, Boe, and Non, you never criticized 
what I was doing. In contrast to others – who found it ridiculous that I wanted 
to obtain my PhD before I retired – you all thought it was a tremendous idea to 
complete my medical career with a doctoral thesis, just as you did, Boen and 
Boe. I am grateful for your understanding and for your emotional and moral 
support.
Dear Tik Ho, you could not be here - thanks for everything. 
My family-in-law have also been a source of comfort, and I am sorry that 
Papa could not be here on this occasion. Mama, thank you for your kindness 
and understanding. My deepest thanks to all of you. I regret I have not been as 
readily available in the past year. 
Finally, I want to acknowledge the most important person in all of this: my 
Huub. You have had the most to put up with over the past three years, in particular 
during this last one. Even though you had the pressure of settling into your new 
position, you were always prepared to help me with all kinds of problems, from 
computers to statistics. I know I have neglected my social commitments, but I 
hope I will have more time to enjoy life together with you now. 
With this doctoral thesis as my symbol of farewell, I will be leaving Dijkzigt 
Hospital (Erasmus MC), where I have worked with so much pleasure for thirty-
seven years. My best wishes to you all.
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